Associations Between Statin Use and Negative Affective Bias During COVID-19: An Observational, Longitudinal UK Study Investigating Depression Vulnerability

Supplementary Information

Supplementary Figures



Supplementary Figure S1: Visual summary of data collection throughout the COSIE study



Supplementary Figure S2: Description and screenshots of cognitive tasks included in the COSIE study



Figure 5: Working memory task performance - N-back - by medication group.

Supplementary Figure S3: Working memory task performance - N-back - by medication group. A) Mean proportion of hits on N-back, by condition (0 = control condition, 3 = most challenging). B) Mean proportion of false alarms on N-back, by condition. C) Mean proportion of correct rejections on N-back, by condition. D) Mean proportion of misses on N-back, by condition.

Detailed statistical analysis approach

<table>
<tr><td colspan="3">Medication groups
In order to investigate the specific effect of statins, independent of blood pressure medication, participants were classified into four groups: those taking 1) statins only, 2) blood pressure medication only, 3) both medications, or 4) neither.</td></tr>
<tr><td colspan="3">Group differences in demographic and self-report measures</td></tr>
<tr><td colspan="3">Due to the low frequency of specific non-white ethnicities in the medication groups (n<6, see Table 1), ethnicity was categorised as white or non-white.

Covariate selection: Variables found to significantly differ between groups were included as covariates in below task analysis. See Supplementary File C for results.

Where multiple potential covariates assessed overlapping constructs, final covariates were chosen based on either greater sensitivity (i.e. continuous variables), greater theoretical/mechanistic plausibility (e.g. antidepressant use) or greater associations/significance after controlling for other covariates.</td></tr>
<tr><td>Continuous variables</td><td colspan="2">Linear regression, controlling for age and gender
e.g. lm(outcome ~ group + Age + Gender, data = df)</td></tr>
<tr><td>Categorical variables</td><td colspan="2">Logistic regression, controlling for age and gender
e.g. glm(outcome ~ group + Age + Gender, data = df, family = binomial)</td></tr>
<tr><td colspan="3">Task analysis</td></tr>
<tr><td colspan="3">For all tasks, participants with a total percentage accuracy (across conditions) of more than 3sds above or below the mean, or with a total mean reaction time (across conditions) of more than 3sds above or below the mean were excluded.</td></tr>
<tr><td>FERT</td><td>Outcomes:
Unbiased hit rate, as described by Wagner (1993) – a measure of emotion identification accuracy which accounts for response bias i.e. any general tendency to identify the emotion when it is not present. Calculated as proportion of hits * (number of hits/all hits and misses).
Misclassifications: For emotions with a significant group differences in unbiased hit rate, we assessed misclassifications (the number of times a participant made a specific misclassification, e.g. identifying a fearful face as surprised) to determine which emotion they were incorrectly identifying these faces as.
Reaction time (ms) for trials with correct responses was also assessed.

ANCOVAs were chosen as the primary analysis approach due to the lack of natural reference condition for the FERT, our primary emotional processing task.

Mixed model ANCOVAs
• Between subject factor – medication group
• Within-subject factor - emotion of the facial expression
• Interaction between group and task condition on task performance
• Covariates - identified as above</td><td>Outlier removal:
Trials where participants responded in under 200ms or over 6000ms were excluded (across all time-points, 0.05% and 1.01% of trials respectively).

Participants with a total percentage accuracy below 20% were excluded (Baseline, n=1; Phase 2, n=4; Phase 3, n=7).

Exclusion for summary variables being 3sds above or below the mean (Baseline, n = 29; Phase 2, n=28; Phase 3, n=30).</td></tr>
</table>

	e.g. *anova(lmer(Task outcome ~ Emotion * Group + covariates + (1|Participant.Public.ID), data=df))* ***Post-hoc analysis for significant interactions**:* One-way ANCOVAs for specific task conditions and/or specific medication groups • If significant, an equivalent linear regression model was used to confirm analytical robustness *e.g. lmer(Task outcome ~ Group + covariates + (1|Participant.Public.ID), data=df_restricted_by_condition/groups)* Data from all three time-points was included, with time-point added as a covariate.	
PILT	*Outcome:* **Proportion of trials for which the participant chose the most advantageous symbol** (%) i.e. whether participants correctly chose the stimuli with the 0.7 probability of gaining points in the gain trials, and whether participants correctly chose the stimuli with the 0.3 probability of losing points in the loss trials. Performance was primarily assessed over the final 20 trials for each condition, as – similar to previous studies (e.g. Walsh 2017), this is where learning plateaued. Models were re-run including all trials to ensure robustness. One-way ANCOVAs for gain trials and loss trials • Between subject factor – medication group • Covariates - identified as above e.g. *anova(lmer(Task outcome ~ Group + covariates + (1|Participant.Public.ID), data=df))* ***Post-hoc analysis for significant interactions**:* One-way ANCOVAs for specific medication groups • If significant, an equivalent linear regression model was used to confirm analytical robustness *e.g. lmer(Task outcome ~ Group + covariates + (1|Participant.Public.ID), data=df_restricted_by_groups)*	*Outlier removal:* Trials where participants responded in under 200ms or over 5000ms were excluded (0.44% and 0.64% of trials respectively). Participants who chose the high probability stimulus less than 60% of the time in the gain trials or more than 40% of the time in loss trials were excluded, as they were presumed to not adequately understand the task (n=295). Exclusion for summary variables being 3sds above or below the mean (n=27).
N-back	*Outcomes:* **Hit rate** (%) i.e. the proportion of trials in which a letter matched the n-back requirement and the participant correctly identified this. **Misses** (%) i.e. the proportion of trials in which a letter matched the n-back requirement and the participant incorrectly identified that it did not. **Correct rejections** (%) i.e. the proportion of trials in which a letter did not meet the n-back requirement and the participant correctly identified that it did not. **False alarms** (%) i.e. the proportion of trials in which a letter did not meet the n-back requirement and the participant incorrectly identified that it did.	*Outlier removal:* Trials where participants responded in under 200ms or over 6000ms were excluded (1.79%, and 0.0065% of trials respectively) Participants with a total percentage accuracy below 20% were excluded (n=44). Exclusion for summary variables being 3sds above or below the mean (n=11).

	***d'* (*d* prime)** measures sensitivity i.e. the normalised distance between the two distributions: signal, and signal + noise. The d' is calculated from the Z value of the hit rate minus that of the false alarm (FA) rate i.e. *d'* = ZHit – ZFA. A positive d' indicates better than chance performance. **beta** an index of accuracy that accounts for response bias. **Reaction time** (ms) for trials with correct responses were also assessed. Mixed model ANCOVAs • Between subject factor – medication group • Within-subject factor – n-back condition (0-back, 1-back, 2-back, 3-back) • Interaction between group and task condition on task performance • Covariates - identified as above e.g. *anova(lmer(Task outcome ~ n-back condition * Group + covariates + (1|Participant.Public.ID), data=df))* ***Post-hoc analysis for significant interactions**:* One-way ANCOVAs for specific task conditions and/or specific medication groups • If significant, an equivalent linear regression model was used to confirm analytical robustness *e.g. lmer(Task outcome ~ Group + covariates + (1|Participant.Public.ID), data=df_restricted_by_condition/groups)*	

Sensitivity Checks

To confirm the robustness of our models, all analyses were repeated controlling only for demographic covariates, as well as uncorrected.
Sensitivity checks for analyses included:
a) excluding participants on a non-lipophilic statin, to confirm results were associated with statins able to cross the blood-brain barrier (*all analyses*);
b) excluding participants who reported a non-binary or other gender (due to the small group size, n<10) (*all analyses*);
c) excluding all participants who failed understanding checks on the PILT (*PILT analyses*);
d) excluding all participants who scored below 90% on the ECAT (*ECAT and EREC analyses*);
e) excluding all participants who recalled zero words on the EREC (*ECAT and EREC analyses*).

Additional Analyses

To explore effects of age and gender, all core analyses were repeated including these as interaction terms e.g. *lmer(Task outcome ~ Group * Age/Gender + covariates + (1|Participant.Public.ID), data=df))*

To explore effects of anti-hypertensive medication type, all core analyses were repeated in four separate ways:

1) Including anti-hypertensive medication type as a covariate e.g. *lmer(Task Outcome ~ Group + covariates + BPmed_group + (1|Participant.Public.ID), data=df)*
2) Including use of L-type calcium channel blockers as a covariate e.g. *lmer(Task Outcome ~ Group + covariates + Calcium_channel + (1|Participant.Public.ID), data=df)*
3) Anti-hypertensive medication type as predictor e.g. *lmer(Task Outcome ~ BPmed_group + covariates + (1|Participant.Public.ID), data=df)*

4) L-type calcium channel blockers as predictor *e.g. lmer(Task Outcome ~ Calcium_channel + covariates + (1|Participant.Public.ID), data=df)*

Post-hocs were conducted as appropriate.

Predicting long term outcomes

Linear regression models were used e.g. *lm(outcome ~ predictor + covariates, data = df)*

Predictors: Baseline medication group and baseline task performance measures that significantly differed between medication groups

Outcomes: Self-reported depression (CESD) and anxiety (GAD-7) at all timepoints, absolute and change from baseline (score at timepoint - baseline score)

Covariates: Identified as above.

Pathway analysis:

Self-report outcome ~ Negative affective bias measure + Statin use + covariates

Negative affective bias measure + Statin use

Growth curve models:

*i =~ 1*outcome_BL+ 1*outcome_T2 + 1*outcome_T3 + 1*outcome _T4*

*s =~ 0*outcome_BL + 1*outcome_T2 + 2*outcome_T3 + 3*outcome _T4*

i ~ predictor + covariates

s ~ predictor + covariates

Additional methods

Participants were paid £7.50 for completion of Phase One, £7.50 for completion of Phase Two, £10 for completion of Phase Three and £2.50 for completion of Phase Four.

The fixed order of the emotional processing tasks was ECAT, FERT, EREC.

During the ECAT, participants were asked to decide whether they would 'like' or 'dislike' to be described with positive and negative personality characteristic words presented briefly (500ms) on screen, in the context of imagining that they have overheard a third party discuss them. The ECAT includes 40 words in a single block, presented with a new randomisation for each participant. Words are matched for word length and ratings of frequency and meaningfulness. The EREC is a free recall task during which participants are given three minutes to type as many words from the ECAT as possible. Participants were aware that they would be asked to recall words from the ECAT. The words recalled were rated as correct or incorrect and as positive, negative or ambiguous/neutral by at least two independent researchers, with a third senior researcher making a final decision on any discrepancies, all blind to group allocation.

For ECAT, the task condition was the valence of the word. The primary outcome was percentage of correctly categorised words. Reaction time (ms) for trials with correct categorisation was also assessed. Trials where participants responded in under 200ms or over 3000ms were excluded, and participants with a total percentage accuracy below 50% were excluded.

For EREC, the task condition was the valence of the word. The primary outcome was the number of correct words recalled. The number of incorrect words (intrusions) was also assessed.

For all emotional processing tasks, task performance across Phases 1, 2 and 3 were included in the models with time-point as a covariate.

Engagement checks

At Phase One, successful completion of FERT and ECAT understanding checks was mandatory for inclusion. At subsequent time-points, if participants answered incorrectly they were prompted to re-read the instructions and answer the questions again.

Text given to participants is below:

FERT

Faces Task - Instructions

In this task faces will be presented in the centre of the screen and they will appear for about half a second only. For each face you need to decide whether the emotional expression on the face is one of anger, disgust, fear, happiness, sadness, surprise or is neutral. You will have options along the bottom of the screen with these emotions:

ANG = anger

DISG = disgust

FEAR = fear

HAP = happy

SAD = sadness

SURP = surprise

NEUT = neutral

You will need to respond by using your mouse to select the appropriate option on screen, as quickly and accurately as possible. You must press just one option for every face. If you are unsure, please still make your best guess to choose an emotion. On the next page, there will be some simple questions to check you understand these instructions.

To check your understanding of the task, please answer the below questions. If you are unsure of any and give an incorrect answer, you will see the instructions again and have the chance to complete these questions again.

1.) What should you do when presented with a face on screen?

- use your cursor to select the response at the bottom of the screen which matches how you are currently feeling
- **use your cursor to select the response at the bottom of the screen which matches the expression of the face [correct answer]**
- type the name of the emotional expression of the face
- do nothing but try to remember the face

2.) ANG =

- angle
- **anger [correct answer]**
- angel

3.) NEUT =

- **neutral [correct answer]**
- neutron
- neuter

4.) If you're not sure which option to choose, what should you do?

- do nothing and wait for the next face
- **still choose your best guess [correct answer]**

ECAT

Words Task - Instructions

In this task, you will be presented with personality characteristic words. Please imagine overhearing someone describing you in this way. Press the "D" key on your keyboard if you would dislike to be described in this way and "L" button if you would like to be described in this way. For example, you might see the word "helpful" which you would like to be described as, so you would press "L", or the word "boring" which you would dislike to be described as, so you would press "D". Please use your index fingers, and keep them on the two keyboard keys throughout the task. Please respond as quickly and accurately as possible. Later in the session you will be asked to recall as many of the words from this task as you can and type them into a free text box.

The next page will ask you some simple questions about these instructions, to check you understand them.

To check your understanding of the task, please answer the below questions. If you are unsure of any and give an incorrect answer, you will see the instructions again and have the chance to complete these questions again.

1.) What should you do if you would dislike to be described as the word which appears on screen?

- do nothing and wait for the next word
- press ENTER
- **press D on the keyboard [correct answer]**
- press the right arrow key

2.) What should you do if you would like to be described as the word which appears on screen?

- press the space bar
- **press L on the keyboard [correct answer]**
- press the left arrow key
- do nothing and wait for the next word

PILT

Learning Task - Instructions

In this task you will presented with a series of symbol pairs. On each trial you will be asked to choose between the two symbols displayed on screen. You can select a symbol by clicking on it with your mouse or trackpad. In this task, the aim is to win as many points as possible. You will begin the task with 100 points. Some symbols, if you choose them, will result in winning 20 points. Some symbols, if you choose them, will result in losing 20 points. Some symbols, if you choose them, will result in no change. After you make your choice the screen will immediately tell you if you've won or lost any points. It's your job to choose the symbol you believe is most likely to win points or least likely to lose points. The best symbol won't always result in winning (or not losing) points- it will just result in winning (or not losing) points more frequently than the other symbol.

On the next page, there will be some simple questions to check you understand these instructions.

To check your understanding of the task, please answer the below questions. If you are unsure of any and give an incorrect answer, you will see the instructions again and have the chance to complete these questions again.

1.) What is the aim of the task, and how do you select symbols?

- to pick the most appealing symbol (using arrow keys)
- to win as many points as possible (using arrow keys)
- **to win as many points as possible (using your mouse/trackpad) [correct answer]**
- to pick the most appealing symbol (using your mouse/trackpad)

2.) Will a symbol always result in the same outcome?

- Yes - the best symbol always wins points/avoids losing points
- **No - the best symbol will win points/avoid losing points more frequently than other symbols [correct answer]**
- No - the symbols have random outcomes

3.) How many points do you start with?

- 0
- **100 [correct answer]**
- 3000

Statistical packages used

- Alboukadel Kassambara (2021). rstatix: Pipe-Friendly Framework for Basic Statistical Tests. R package version 0.7.0. https://CRAN.R-project.org/package=rstatix
- Daniel D. Sjoberg, Michael Curry, Margie Hannum, Joseph Larmarange, Karissa Whiting and Emily C. Zabor (2021). gtsummary: Presentation-Ready Data Summary and Analytic Result Tables. R package version 1.4.1. https://CRAN.R-project.org/package=gtsummary
- Douglas Bates and Martin Maechler (2019). Matrix: Sparse and Dense Matrix Classes and Methods. R package version 1.2-17. https://CRAN.R-project.org/package=Matrix
- Douglas Bates, Martin Maechler, Ben Bolker, Steve Walker (2015). Fitting Linear Mixed-Effects Models Using lme4. Journal of Statistical Software, 67(1), 1-48. doi:10.18637/jss.v067.i01.
- H. Wickham. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York, 2016.
- Hadley Wickham (2019). stringr: Simple, Consistent Wrappers for Common String Operations. R package version 1.4.0. https://CRAN.R-project.org/package=stringr
- Hadley Wickham (2021). forcats: Tools for Working with Categorical Variables (Factors). R package version 0.5.1. https://CRAN.R-project.org/package=forcats
- Hadley Wickham (2021). tidyr: Tidy Messy Data. R package version 1.1.3. https://CRAN.R-project.org/package=tidyr
- Hadley Wickham and Jim Hester (2020). readr: Read Rectangular Text Data. R package version 1.4.0. https://CRAN.R-project.org/package=readr
- Hadley Wickham, Romain François, Lionel Henry and Kirill Müller (2021). dplyr: A Grammar of Data Manipulation. R package version 1.0.6. https://CRAN.R-project.org/package=dplyr
- Jacob Kaplan (2020). fastDummies: Fast Creation of Dummy (Binary) Columns and Rows from Categorical Variables. R package version 1.6.3. https://CRAN.R-project.org/package=fastDummies
- Kirill Müller and Hadley Wickham (2021). tibble: Simple Data Frames. R package version 3.1.2. https://CRAN.R-project.org/package=tibble
- Kuznetsova A, Brockhoff PB, Christensen RHB (2017). "lmerTest Package:Tests in Linear Mixed Effects Models." Journal of StatisticalSoftware, 82(13), 1-26. doi: 10.18637/jss.v082.i13 (URL:https://doi.org/10.18637/jss.v082.i13).
- Lemon, J. (2006) Plotrix: a package in the red light district of R. R-News, 6(4): 8-12.
- Lionel Henry and Hadley Wickham (2020). purrr: Functional Programming Tools. R package version 0.3.4. https://CRAN.R-project.org/package=purrr
- Long JA (2020). jtools: Analysis and Presentation of Social ScientificData. R package version 2.1.0, <URL:https://cran.r-project.org/package=jtools>.
- Makowski, D. (2018). The Psycho Package: An Efficient and Publishing-Oriented Workflow for Psychological Science. Journal of Open Source Software, 3(22), 470. Available from https://github.com/neuropsychology/psycho.R
- Makowski, D., Ben-Shachar, M.S., Patil, I. & Lüdecke, D. (2020). Automated Results Reporting as a Practical Tool to Improve Reproducibility and Methodological Best Practices Adoption. CRAN. Available from https://github.com/easystats/report. doi: .

- R Core Team (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.
- Richard Iannone, Joe Cheng and Barret Schloerke (2021). gt: Easily Create Presentation-Ready Display Tables. R package version 0.3.0. https://CRAN.R-project.org/package=gt
- Thomas Lin Pedersen (2020). patchwork: The Composer of Plots. R package version 1.1.1. https://CRAN.R-project.org/package=patchwork
- Wickham et al., (2019). Welcome to the tidyverse. Journal of Open Source Software, 4(43), 1686, https://doi.org/10.21105/joss.01686
- Yihui Xie (2021). knitr: A General-Purpose Package for Dynamic Report Generation in R. R package version 1.33.
- Yves Rosseel (2012). lavaan: An R Package for Structural Equation Modeling. Journal of Statistical Software, 48(2), 1-36. https://doi.org/10.18637/jss.v048.i02

Supplementary Table S1

Characteristics of participants by medication group

	Overall, N = 2,043	**Neither**, N = 1,725	**Statin**, N = 81	**Both**, N = 111	**BP**, N = 126
Age	45.09 (14.49)	42.87 (13.94)	58.16 (11.03)	60.59 (7.69)	53.52 (12.44)
Gender					
Female	1,216 (60%)	1,066 (62%)	31 (38%)	46 (41%)	73 (58%)
Male	821 (40%)	654 (38%)	50 (62%)	65 (59%)	52 (41%)
Non-binary or other	6 (0.2%)	5 (0.2%)	0 (0%)	0 (0%)	1 (0.8%)
Ethnicity					
White	1,802 (89%)	1,512 (88%)	73 (90%)	105 (95%)	112 (90%)
Asian	99 (4.9%)	91 (5.3%)	5 (6.2%)	1 (0.9%)	2 (1.6%)
Black	54 (2.7%)	44 (2.6%)	2 (2.5%)	3 (2.7%)	5 (4.0%)
Chinese	19 (0.9%)	17 (1.0%)	0 (0%)	1 (0.9%)	1 (0.8%)
Middle-eastern	5 (0.2%)	5 (0.3%)	0 (0%)	0 (0%)	0 (0%)
Mixed (black)	10 (0.5%)	8 (0.5%)	0 (0%)	0 (0%)	2 (1.6%)
Mixed (other)	32 (1.6%)	31 (1.8%)	0 (0%)	0 (0%)	1 (0.8%)
Not reported	11 (0.5%)	8 (0.5%)	1 (1.2%)	0 (0%)	2 (1.6%)
English as first language					
Yes	1,845 (90%)	1,542 (89%)	76 (94%)	109 (98%)	118 (94%)
No	198 (10%)	183 (11%)	5 (6%)	2 (2%)	8 (6%)
Education					
No qualifications	20 (1.0%)	12 (0.7%)	3 (3.7%)	5 (4.5%)	0 (0%)
Completed GCSE/CSE/O-levels or equivalent (at school till aged 16)	287 (14%)	227 (13%)	16 (20%)	19 (17%)	25 (20%)
Completed post-16 vocational course	113 (5.5%)	89 (5.2%)	4 (4.9%)	13 (12%)	7 (5.6%)
A-levels or equivalent (at school till aged 18)	419 (21%)	362 (21%)	16 (20%)	16 (14%)	25 (20%)
Undergraduate degree or professional qualification	844 (41%)	726 (42%)	26 (32%)	41 (37%)	51 (40%)
Postgraduate degree	360 (18%)	309 (18%)	16 (20%)	17 (15%)	18 (14%)
Annual household income					
Under £16, 000	326 (16%)	286 (17%)	12 (15%)	15 (14%)	13 (10%)
£16,000 - £29,999	535 (26%)	439 (25%)	26 (32%)	40 (36%)	30 (24%)
£30,000 - £59,999	712 (35%)	589 (34%)	30 (37%)	36 (32%)	57 (45%)
Over £60,000	355 (17%)	310 (18%)	11 (14%)	15 (14%)	19 (15%)
Not reported	115 (5.6%)	101 (5.9%)	2 (2.5%)	5 (4.5%)	7 (5.6%)
Workhours					
Full-time	540 (26%)	469 (27%)	15 (19%)	23 (21%)	33 (26%)
Part-time	391 (19%)	345 (20%)	13 (16%)	11 (9.9%)	22 (17%)
Not at all	1,112 (54%)	911 (53%)	53 (65%)	77 (69%)	71 (56%)
Current MDD diagnosis	203 (9.9%)	167 (9.7%)	8 (9.9%)	10 (9.0%)	18 (14%)

Current GAD diagnosis	189 (9.3%)	156 (9.0%)	4 (4.9%)	14 (13%)	15 (12%)
No past psychiatric history	1,371 (67%)	1,177 (68%)	52 (64%)	58 (52%)	84 (67%)
Current psychological therapy	317 (16%)	270 (16%)	13 (16%)	13 (12%)	21 (17%)
Current antidepressant use	271 (13%)	216 (13%)	16 (20%)	18 (16%)	21 (17%)
Social Distancing due to COVID-19 (Phase One)					
Leaving the house as normal	20 (1.0%)	16 (0.9%)	2 (2.5%)	0 (0%)	2 (1.6%)
Leaving the house as normal but practising social distancing where possible	460 (23%)	399 (23%)	18 (22%)	19 (17%)	24 (19%)
Leaving the house for essentials supplies and exercise only	1,222 (60%)	1,028 (60%)	48 (59%)	69 (62%)	77 (61%)
Shielding with access to outside space	300 (15%)	244 (14%)	12 (15%)	22 (20%)	22 (17%)
Shielding with no access to outside space	41 (2.0%)	38 (2.2%)	1 (1.2%)	1 (0.9%)	1 (0.8%)
Social Distancing due to COVID-19 (Phase Two)					
Leaving the house as normal	47 (2.4%)	42 (2.6%)	0 (0%)	2 (1.7%)	3 (3.9%)
Leaving the house as normal but practising social distancing where possible	677 (35%)	594 (37%)	26 (24%)	35 (30%)	22 (29%)
Leaving the house for essentials supplies and exercise only	955 (50%)	792 (49%)	58 (54%)	64 (54%)	41 (54%)
Shielding with access to outside space	218 (11%)	171 (11%)	21 (20%)	17 (14%)	9 (12%)
Shielding with no access to outside space	26 (1.4%)	23 (1.4%)	2 (1.9%)	0 (0%)	1 (1.3%)
Social Distancing due to COVID-19 (Phase Three)					
Leaving the house as normal	129 (7.0%)	113 (7.4%)	4 (3.8%)	8 (6.7%)	4 (5.3%)
Leaving the house to socialise, but practising social distancing where possible	538 (29%)	469 (31%)	19 (18%)	33 (28%)	17 (23%)
Leaving the house for essential responsibilities but practising social distancing where possible	625 (34%)	512 (33%)	38 (36%)	47 (39%)	28 (37%)
Leaving the house for essentials supplies and exercise only	424 (23%)	344 (22%)	33 (31%)	24 (20%)	23 (31%)
Shielding with access to outside space	105 (5.7%)	84 (5.5%)	10 (9.4%)	8 (6.7%)	3 (4.0%)
Shielding with no access to outside space	10 (0.5%)	8 (0.5%)	2 (1.9%)	0 (0%)	0 (0%)
Social Distancing due to COVID-19 (Phase Four)					
Leaving the house as normal	59 (3.5%)	50 (3.5%)	3 (3.0%)	4 (3.4%)	2 (2.7%)
Leaving the house to socialise, but practising social distancing where possible	58 (3.4%)	53 (3.7%)	0 (0%)	3 (2.6%)	2 (2.7%)
Leaving the house for essential responsibilities but practising social distancing where possible	508 (30%)	456 (32%)	15 (15%)	19 (16%)	18 (25%)
Leaving the house for essentials supplies and exercise only	928 (54%)	739 (52%)	67 (67%)	74 (64%)	48 (66%)
Shielding with access to outside space	133 (7.8%)	101 (7.1%)	13 (13%)	16 (14%)	3 (4.1%)
Shielding with no access to outside space	19 (1.1%)	17 (1.2%)	2 (2.0%)	0 (0%)	0 (0%)
Depressive symptoms (CESD)					
Phase One	17.65 (12.34)	18.02 (12.36)	13.96 (10.46)	15.18 (12.88)	17.01 (12.20)
Phase Two	16.76 (12.27)	17.14 (12.32)	13.18 (10.23)	15.09 (12.86)	15.43 (11.79)
Phase Three	16.83 (12.62)	17.10 (12.66)	14.20 (11.87)	15.27 (12.94)	16.41 (12.16)
Phase Four	18.51 (12.80)	18.91 (12.90)	16.59 (11.87)	15.68 (12.16)	17.17 (12.28)
Anxiety symptoms (GAD7)					
Phase One	5.65 (5.49)	5.88 (5.53)	3.57 (4.17)	3.97 (4.98)	5.36 (5.50)
Phase Two	5.01 (5.11)	5.18 (5.16)	2.92 (3.39)	4.01 (4.87)	5.00 (5.18)

Phase Three	4.97 (5.21)	5.10 (5.25)	3.31 (4.04)	3.92 (5.16)	5.27 (5.21)
Phase Four	5.51 (5.55)	5.70 (5.59)	3.95 (4.86)	3.85 (4.67)	5.64 (5.72)
Loneliness (UCLA)					
Phase One	5.12 (1.93)	5.17 (1.93)	5.01 (1.69)	4.80 (1.98)	4.67 (1.92)
Phase Two	5.11 (1.89)	5.17 (1.89)	4.84 (1.83)	4.79 (1.92)	4.75 (1.86)
Phase Three	4.98 (1.92)	5.03 (1.93)	4.92 (1.91)	4.65 (1.86)	4.68 (1.82)
Phase Four	5.34 (2.00)	5.38 (2.01)	5.08 (1.98)	5.03 (1.91)	5.38 (2.07)
Social Interaction (adapted ESLA)					
Phase One	17.02 (5.45)	17.14 (5.46)	16.06 (5.57)	16.12 (4.67)	16.77 (5.75)
Phase Two	18.73 (5.21)	18.81 (5.26)	17.75 (4.89)	18.40 (4.82)	18.49 (5.07)
Phase Three	18.18 (5.16)	18.20 (5.09)	17.57 (5.33)	18.08 (5.44)	18.38 (5.64)
Phase Four	17.17 (5.08)	17.20 (5.07)	17.22 (5.36)	16.98 (4.78)	16.82 (5.25)
Anhedonia (SHAPS)					
Phase Two	1.69 (2.56)	1.70 (2.60)	1.63 (2.26)	1.69 (2.28)	1.53 (2.41)
Phase Three	1.71 (2.75)	1.74 (2.78)	1.33 (2.19)	1.59 (2.74)	1.75 (2.76)
Phase Four	2.02 (2.90)	2.04 (2.94)	1.79 (2.36)	2.15 (3.19)	1.73 (2.29)
Trait Anxiety	42.58 (12.85)	43.05 (12.89)	37.90 (11.14)	39.41 (12.05)	41.98 (13.13)

Unless otherwise stated, all measures are from Phase One of data collection.

Supplementary Table S2

Results for covariate identification analysis

Where multiple potential covariates assessed overlapping constructs, final covariates were chosen based on either greater sensitivity (i.e. continuous variables), greater theoretical/mechanistic plausibility (e.g. antidepressant use) or greater associations/significance after controlling for other covariates. Covariates included in fully corrected models are in bold.

		B	SE	Z value	p
Household Income	**Neither vs Statin**	**0.30458**	**0.32857**	**0.93**	**0.354**
	Neither vs BP	**0.67773**	**0.30480**	**2.22**	**0.026 ***
	Neither vs Both	**0.44321**	**0.29665**	**1.49**	**0.135**
Work hours	Neither vs Statin	0.40118	0.30076	1.33	0.1822
	Neither vs BP	-0.10970	0.21710	-0.51	0.6134
	Neither vs Both	0.19250	0.25331	0.76	0.4473
English as first language	Neither vs Statin	0.04650	0.48823	0.10	0.92412
	Neither vs BP	-0.19600	0.38572	-0.51	0.61136
	Neither vs Both	-1.07942	0.73128	-1.48	0.13993
Education	Neither vs Statin	-0.36308	0.29748	-1.22	0.222
	Neither vs BP	-0.23631	0.24001	-0.98	0.325
	Neither vs Both	-0.05182	0.29056	-0.18	0.858
Current antidepressant use	**Neither vs Statin**	**0.8631**	**0.3046**	**2.83**	**0.00461 ****
	Neither vs BP	**0.4808**	**0.2588**	**1.86**	**0.06320 .**
	Neither vs Both	**0.5990**	**0.2866**	**2.09**	**0.03664 ***
Current psychological therapy	Neither vs Statin	0.48560	0.32286	1.50	0.1326
	Neither vs BP	0.31181	0.25921	1.20	0.2290
	Neither vs Both	0.15639	0.31794	0.49	0.6228
Current MDD diagnosis	Neither vs Statin	0.77082	0.40148	1.92	0.0549 .
	Neither vs BP	0.90778	0.28566	3.18	0.0015 **
	Neither vs Both	0.76416	0.36718	2.08	0.0374*
Current GAD diagnosis	Neither vs Statin	-0.00326	0.53296	-0.01	0.99512
	Neither vs BP	0.65780	0.30249	2.17	0.02966 *
	Neither vs Both	1.10199	0.32708	3.37	0.00075 ***
History of mental health diagnosis	**Neither vs Statin**	**0.51806**	**0.24831**	**2.09**	**0.037 ***
	Neither vs BP	**0.23436**	**0.20348**	**1.15**	**0.249**
	Neither vs Both	**1.01697**	**0.21104**	**4.82**	**1.4e-06 *****
Isolation level	Neither vs Statin	0.02644	0.23929	0.11	0.91201
	Neither vs BP	-0.09158	0.19376	-0.47	0.63647
	Neither vs Both	-0.08777	0.21207	-0.41	0.67896
CESD	**Neither vs Statin**	**0.8599**	**1.3648**	**0.63**	**0.529**
	Neither vs BP	**1.8006**	**1.1009**	**1.64**	**0.102**
	Neither vs Both	**2.4547**	**1.2011**	**2.04**	**0.041 ***
GAD7	Neither vs Statin	-0.1583	0.6061	-0.26	0.79
	Neither vs BP	0.7275	0.4889	1.49	0.14
	Neither vs Both	0.4150	0.5334	0.78	0.44
ESLA	Neither vs Statin	0.62317	0.61355	1.02	0.3099
	Neither vs BP	0.59627	0.49492	1.20	0.2284
	Neither vs Both	0.86872	0.53993	1.61	0.1078
UCLA	Neither vs Statin	0.33023	0.22093	1.49	0.135
	Neither vs BP	-0.18239	0.17821	-1.02	0.306
	Neither vs Both	0.17958	0.19377	0.93	0.354
SHAPS (Timepoint 2 – first measurement)	Neither vs Statin	0.34013	0.30707	1.11	0.268
	Neither vs BP	0.14283	0.24827	0.58	0.565
	Neither vs Both	0.49892	0.26751	1.87	0.062 .
STAIT	Neither vs Statin	-0.3293	1.4276	-0.23	0.82
	Neither vs BP	1.8301	1.1515	1.59	0.11
	Neither vs Both	1.6814	1.2569	1.34	0.18
History of mental health diagnosis – controlling for antidepressant use and CESD score	Neither vs Statin	0.31024	0.28834	1.08	0.2819
	Neither vs BP	0.04614	0.23764	0.19	0.8460
	Neither vs Both	1.02052	0.23827	4.28	1.8e-05 ***
Current MDD diagnosis – controlling for antidepressant use and CESD score and past history of mental health diagnosis	Neither vs Statin	0.36567	0.50970	0.72	0.473
	Neither vs BP	0.91603	0.40799	2.25	0.025 *
	Neither vs Both	0.05082	0.48467	0.10	0.916
	Neither vs Statin	-0.63898	0.58813	-1.09	0.2773

Current GAD diagnosis – controlling for antidepressant use and CESD score and past history of mental health diagnosis	Neither vs BP	0.43955	0.35960	1.22	0.2216
	Neither vs Both	0.64593	0.38665	1.67	0.0948 .
Tobacco Use	Neither vs Statin	0.34441	0.24329	1.42	0.15688
	Neither vs BP	-0.15077	0.20499	-0.74	0.46203
	Neither vs Both	0.31948	0.21215	1.51	0.13209
Alcohol Use	**Neither vs Statin**	**-0.53869**	**0.24192**	**-2.23**	**0.02597 ***
	Neither vs BP	**-0.36024**	**0.19440**	**-1.85**	**0.06387 .**
	Neither vs Both	**-0.19113**	**0.21789**	**-0.88**	**0.38037**
Weekly Physical Activity	**Neither vs Statin**	**-0.14966**	**0.27199**	**-0.55**	**0.582**
	Neither vs BP	**-0.35644**	**0.20776**	**-1.72**	**0.086 .**
	Neither vs Both	**-0.57081**	**0.22163**	**-2.58**	**0.010 ***

Supplementary Table S3

Results for all analyses and sensitivity checks

Notes

- Corrected for demographics (minimally adjusted) = Age, gender, ethnicity, and household income
- Corrected for all covariates (maximally adjusted) = Age, gender, ethnicity, household income, current antidepressant use, current depression scores, presence of past psychiatric history, weekly units of alcohol and weekly hours of physical activity
- Cells with significant results ($p<0.05$) are shaded blue
- Primary corrected analyses (reported within the main manuscript, as appropriate) are within - - - - bordered cells

FERT

Outcome	Groups	Full dataset (n=2033)						Sensitivity Checks			
								Excluding non-lipophilic (n=2011)		Excluding small gender groups (n=2027)	
		Uncorrected		Corrected for demographics		Corrected for all covariates		Corrected for all covariates			
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
All emotions - UBHR	All	Group: F(3) = 7.78, p < .001; Eta2 (partial) = 0.01, 90% CI [4.29e-03, 0.02] Interaction: F(18) = 6.08, p < .001; Eta2 (partial) = 2.88e-03, 90% CI [1.64e-03, 3.38e-03]	N/A	Group: F(3) = 4.44, p = 0.004; Eta2 (partial) = 6.74e-03, 90% CI [1.28e-03, 0.01] Interaction: F(18) = 6.08, p < .001; Eta2 (partial) = 2.88e-03, 90% CI [1.64e-03, 3.38e-03])	N/A	Group: F(3) = 3.44, p = 0.016; Eta2 (partial) = 5.57e-03, 90% CI [5.67e-04, 0.01] Interaction: F(18) = 5.41, p < .001; Eta2 (partial) = 2.64e-03, 90% CI [1.41e-03, 3.09e-03]	N/A	Group: F(3) = 3.18, p = 0.023; Eta2 (partial) = 5.21e-03, 90% CI [3.85e-04, 0.01] Interaction: F(18) = 4.77, p < .001; Eta2 (partial) = 2.36e-03, 90% CI [1.17e-03, 2.76e-03]	N/A	Group: F(3) = 3.41, p = 0.017; Eta2 (partial) = 5.53e-03, 90% CI [5.43e-04, 0.01] Interaction: F(18) = 5.40, p < .001; Eta2 (partial) = 2.64e-03, 90% CI [1.41e-03, 3.10e-03]	N/A
Angry - UBHR	All	F(3) = 10.36, p < .001; Eta2 (partial) = 0.02, 90% CI [6.85e-03, 0.02]	N/A	F(3) = 5.17, p = 0.001; Eta2 (partial) = 7.77e-03, 90% CI [1.87e-03, 0.01]	N/A	F(3) = 4.52, p = 0.004; Eta2 (partial) = 7.23e-03, 90% CI [1.42e-03, 0.01]	N/A	F(3) = 4.21, p = 0.006; Eta2 (partial) = 6.80e-03, 90% CI [1.17e-03, 0.01]	N/A	F(3) = 4.45, p = 0.004; Eta2 (partial) = 7.12e-03, 90% CI [1.36e-03, 0.01]	N/A
	Statins vs Neither	F(1) = 18.64, p < .001; Eta2 (partial) = 0.01, 90% CI [4.04e-03, 0.02]	Beta = -0.06, 95% CI [-0.09, -0.03], t(5691) = -4.29, p < .001; Std. beta = -0.40, 95% CI [-0.58, -0.21]	F(1) = 11.66, p < .001; Eta2 (partial) = 6.64e-03, 90% CI [1.78e-03, 0.01]	beta = -0.05, 95% CI [-0.08, -0.02], t(5682) = -3.28, p < .01; Std. beta = -0.31, 95% CI [-0.49, -0.12]	F(1) = 9.19, p = 0.002; Eta2 (partial) = 5.55e-03, 90% CI [1.16e-03, 0.01]	beta = -0.05, 95% CI [-0.08, -0.02], t(5505) = -3.00, p < .01; Std. beta = -0.29, 95% CI [-0.48, -0.10]	F(1) = 7.07, p = 0.008; Eta2 (partial) = 4.30e-03, 90% CI [6.23e-04, 0.01]	beta = -0.05, 95% CI [-0.08, -0.01], t(5439) = -2.67, p < .01; Std. beta = -0.29, 95% CI [-0.50, -0.08]	F(1) = 9.19, p = 0.002; Eta2 (partial) = 5.55e-03, 90% CI [1.16e-03, 0.01]	beta = -0.05, 95% CI [-0.08, -0.02], t(5492) = -2.99, p < .01; Std. beta = -0.29, 95% CI [-0.48, -0.10]
	BP vs neither	F(1) = 2.26, p = 0.133; Eta2 (partial) = 1.25e-03, 90% CI [0.00, 5.47e-03]	beta = -0.02, 95% CI [-0.04, 5.51e-03], t(5691) = -1.49, p = 0.135; Std. beta = -0.11, 95% CI [-0.26, 0.04])	(F(1) = 1.09, p = 0.297; Eta2 (partial) = 6.06e-04, 90% CI [0.00, 4.01e-03])	beta = -0.01, 95% CI [-0.04, 0.01], t(5682) = -0.97, p = 0.332; Std. beta = -0.07, 95% CI [-0.22, 0.08]	F(1) = 1.37, p = 0.242; Eta2 (partial) = 8.14e-04, 90% CI [0.00, 4.69e-03]	beta = -0.01, 95% CI [-0.04, 0.01], t(5505) = -1.09, p = 0.276; Std. beta = -0.09, 95% CI [-0.24, 0.07]	F(1) = 1.37, p = 0.242; Eta2 (partial) = 8.15e-04, 90% CI [0.00, 4.69e-03]	beta = -0.01, 95% CI [-0.04, 0.01], t(5439) = -1.12, p = 0.264; Std. beta = -0.09, 95% CI [-0.24, 0.07]	F(1) = 1.14, p = 0.286; Eta2 (partial) = 6.76e-04, 90% CI [0.00, 4.35e-03]	beta = -0.01, 95% CI [-0.04, 0.01], t(5492) = -0.99, p = 0.323; Std. beta = -0.08, 95% CI [-0.23, 0.08]
	Both vs neither	F(1) = 13.22, p < .001; Eta2 (partial) = 7.39e-03, 90% CI [2.22e-03, 0.02])	(beta = -0.05, 95% CI [-0.07, -0.02], t(5691) = -3.63, p < .001; Std. beta = -0.29, 95% CI [-0.44, -0.13]	(F(1) = 7.44, p = 0.006; Eta2 (partial) = 4.19e-03, 90% CI [6.59e-04, 0.01])	beta = -0.03, 95% CI [-0.06, -7.22e-03], t(5682) = -2.52, p < .05; Std. beta = -0.21, 95% CI [-0.37, -0.05]	F(1) = 6.48, p = 0.011; Eta2 (partial) = 3.87e-03, 90% CI [4.82e-04, 0.01]	beta = -0.03, 95% CI [-0.06, -6.21e-03], t(5505) = -2.42, p < .05; Std. beta = -0.21, 95% CI [-0.37, -0.04]	F(1) = 7.18, p = 0.007; Eta2 (partial) = 4.30e-03, 90% CI [6.40e-04, 0.01]	beta = -0.03, 95% CI [-0.06, -8.06e-03], t(5439) = -2.55, p < .05; Std. beta = -0.22, 95% CI [-0.39, -0.05]	F(1) = 6.50, p = 0.011; Eta2 (partial) = 3.89e-03, 90% CI [4.86e-04, 0.01]	beta = -0.03, 95% CI [-0.06, -6.07e-03], t(5492) = -2.41, p < .05; Std. beta = -0.21, 95% CI [-0.37, -0.04]

Outcome	Groups	Full dataset (n=2033)						Sensitivity Checks			
								Excluding non-lipophilic (n=2011)		Excluding small gender groups (n=2027)	
		Uncorrected		Corrected for demographics		Corrected for all covariates		Corrected for all covariates			
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
Disgust - UBHR	**All**	F(3) = 0.38, p = 0.768; Eta2 (partial) = 5.76e-04, 90% CI [0.00, 1.95e-03]	N/A	(F(3) = 0.35, p = 0.792; Eta2 (partial) = 5.31e-04, 90% CI [0.00, 1.79e-03])	N/A	F(3) = 0.48, p = 0.698; Eta2 (partial) = 7.75e-04, 90% CI [0.00, 2.57e-03]	N/A	F(3) = 0.31, p = 0.817; Eta2 (partial) = 5.11e-04, 90% CI [0.00, 1.71e-03]	N/A	F(3) = 0.49, p = 0.691; Eta2 (partial) = 7.94e-04, 90% CI [0.00, 2.63e-03]	N/A
Fear - UBHR	**All**	F(3) = 8.09, p < .001; Eta2 (partial) = 0.01, 90% CI [4.54e-03, 0.02]	N/A	(F(3) = 5.03, p = 0.002; Eta2 (partial) = 7.55e-03, 90% CI [1.75e-03, 0.01])	N/A	F(3) = 3.76, p = 0.010; Eta2 (partial) = 6.00e-03, 90% CI [8.01e-04, 0.01]	N/A	F(3) = 2.94, p = 0.032; Eta2 (partial) = 4.74e-03, 90% CI [2.12e-04, 0.01]	N/A	F(3) = 3.77, p = 0.010; Eta2 (partial) = 6.03e-03, 90% CI [8.10e-04, 0.01]	N/A
	Statin vs neither	F(1) = 13.84, p < .001; Eta2 (partial) = 7.78e-03, 90% CI [2.43e-03, 0.02]	beta = -0.05, 95% CI [-0.08, -0.02], t(5687) = -3.76, p < .001; Std. beta = -0.36, 95% CI [-0.54, -0.17]	(F(1) = 9.94, p = 0.002; Eta2 (partial) = 5.64e-03, 90% CI [1.29e-03, 0.01])	beta = -0.04, 95% CI [-0.07, -0.02], t(5678) = -3.17, p < .01; Std. beta = -0.31, 95% CI [-0.50, -0.12])	F(1) = 6.90, p = 0.009; Eta2 (partial) = 4.16e-03, 90% CI [5.79e-04, 0.01]	beta = -0.04, 95% CI [-0.07, -9.59e-03], t(5501) = -2.62, p < .01; Std. beta = -0.26, 95% CI [-0.46, -0.07]	F(1) = 4.37, p = 0.037; Eta2 (partial) = 2.65e-03, 90% CI [8.42e-05, 8.42e-03]	beta = -0.03, 95% CI [-0.07, -2.23e-03], t(5435) = -2.10, p < .05; Std. beta = -0.23, 95% CI [-0.45, -0.02]	F(1) = 6.93, p = 0.009; Eta2 (partial) = 4.18e-03, 90% CI [5.87e-04, 0.01]	beta = -0.04, 95% CI [-0.07, -9.67e-03], t(5488) = -2.63, p < .01; Std. beta = -0.26, 95% CI [-0.46, -0.07]
	BP vs neither	(F(1) = 2.35, p = 0.125; Eta2 (partial) = 1.30e-03, 90% CI [0.00, 5.56e-03]	beta = -0.02, 95% CI [-0.04, 4.71e-03], t(5687) = -1.54, p = 0.125; Std. beta = -0.12, 95% CI [-0.27, 0.03]	(F(1) = 1.76, p = 0.184; Eta2 (partial) = 9.79e-04, 90% CI [0.00, 4.89e-03])	beta = -0.01, 95% CI [-0.04, 7.68e-03], t(5678) = -1.28, p = 0.200; Std. beta = -0.10, 95% CI [-0.25, 0.05]	F(1) = 1.69, p = 0.194; Eta2 (partial) = 1.00e-03, 90% CI [0.00, 5.11e-03]	beta = -0.01, 95% CI [-0.04, 8.75e-03], t(5501) = -1.21, p = 0.225; Std. beta = -0.10, 95% CI [-0.26, 0.06]	F(1) = 1.62, p = 0.203; Eta2 (partial) = 9.62e-04, 90% CI [0.00, 5.03e-03]	beta = -0.01, 95% CI [-0.04, 8.95e-03], t(5435) = -1.20, p = 0.231; Std. beta = -0.10, 95% CI [-0.26, 0.06]	F(1) = 1.67, p = 0.196; Eta2 (partial) = 9.91e-04, 90% CI [0.00, 5.10e-03]	beta = -0.01, 95% CI [-0.04, 8.85e-03], t(5488) = -1.21, p = 0.227; Std. beta = -0.10, 95% CI [-0.26, 0.06]
	Both vs neither	F(1) = 9.97, p = 0.002; Eta2 (partial) = 5.55e-03, 90% CI [1.28e-03, 0.01]	beta = -0.04, 95% CI [-0.06, -0.01], t(5687) = -3.16, p < .01; Std. beta = -0.26, 95% CI [-0.42, -0.10]	(F(1) = 6.88, p = 0.009; Eta2 (partial) = 3.86e-03, 90% CI [5.35e-04, 0.01])	beta = -0.03, 95% CI [-0.05, -6.47e-03], t(5678) = -2.49, p < .05; Std. beta = -0.21, 95% CI [-0.38, -0.04]	F(1) = 5.66, p = 0.017; Eta2 (partial) = 3.37e-03, 90% CI [3.13e-04, 9.59e-03]	beta = -0.03, 95% CI [-0.05, -4.04e-03], t(5501) = -2.28, p < .05; Std. beta = -0.20, 95% CI [-0.37, -0.03]	F(1) = 5.28, p = 0.022; Eta2 (partial) = 3.16e-03, 90% CI [2.42e-04, 9.24e-03]	beta = -0.03, 95% CI [-0.05, -2.75e-03], t(5435) = -2.17, p < .05; Std. beta = -0.20, 95% CI [-0.37, -0.02]	F(1) = 5.69, p = 0.017; Eta2 (partial) = 3.39e-03, 90% CI [3.18e-04, 9.63e-03]	beta = -0.03, 95% CI [-0.05, -4.10e-03], t(5488) = -2.28, p < .05; Std. beta = -0.20, 95% CI [-0.37, -0.03]
Happiness - UBHR	**All**	F(3) = 1.10, p = 0.350; Eta2 (partial) = 1.68e-03, 90% CI [0.00, 4.65e-03]	N/A	(F(3) = 2.07, p = 0.103; Eta2 (partial) = 3.16e-03, 90% CI [0.00, 7.37e-03])	N/A	F(3) = 2.05, p = 0.104; Eta2 (partial) = 3.35e-03, 90% CI [0.00, 7.80e-03]	N/A	F(3) = 2.20, p = 0.086; Eta2 (partial) = 3.63e-03, 90% CI [0.00, 8.30e-03]	N/A	F(3) = 2.05, p = 0.105; Eta2 (partial) = 3.34e-03, 90% CI [0.00, 7.79e-03]	N/A
Sadness - UBHR	**All**	F(3) = 0.55, p = 0.650; Eta2 (partial) = 8.28e-04, 90% CI [0.00, 2.69e-03])	N/A	(F(3) = 1.83, p = 0.140; Eta2 (partial) = 2.77e-03, 90% CI [0.00, 6.20e-03])	N/A	F(3) = 1.75, p = 0.154; Eta2 (partial) = 2.83e-03, 90% CI [0.00, 6.88e-03]	N/A	F(3) = 1.83, p = 0.140; Eta2 (partial) = 2.98e-03, 90% CI [0.00, 7.17e-03]	N/A	F(3) = 1.75, p = 0.155; Eta2 (partial) = 2.83e-03, 90% CI [0.00, 6.89e-03]	N/A

Outcome	Groups	Full dataset (n=2033)						Sensitivity Checks			
								Excluding non-lipophilic (n=2011)		Excluding small gender groups (n=2027)	
		Uncorrected		Corrected for demographics		Corrected for all covariates		Corrected for all covariates			
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
Surprise - UBHR	**All**	F(3) = 3.11, p = 0.025; Eta2 (partial) = 4.74e-03, 90% CI [3.12e-04, 9.90e-03]	N/A	(F(3) = 0.44, p = 0.724; Eta2 (partial) = 6.79e-04, 90% CI [0.00, 2.25e-03])	N/A	(F(3) = 0.67, p = 0.572; Eta2 (partial) = 1.09e-03, 90% CI [0.00, 3.40e-03]	N/A	F(3) = 0.80, p = 0.494; Eta2 (partial) = 1.32e-03, 90% CI [0.00, 3.95e-03]	N/A	F(3) = 0.68, p = 0.566; Eta2 (partial) = 1.11e-03, 90% CI [0.00, 3.45e-03]	N/A
Neutral - UBHR	**All**	F(3) = 1.98, p = 0.115; Eta2 (partial) = 3.00e-03, 90% CI [0.00, 7.08e-03]	N/A	(F(3) = 0.48, p = 0.693; Eta2 (partial) = 7.41e-04, 90% CI [0.00, 2.45e-03])	N/A	F(3) = 0.67, p = 0.570; Eta2 (partial) = 1.09e-03, 90% CI [0.00, 3.39e-03]	N/A	F(3) = 0.74, p = 0.527; Eta2 (partial) = 1.21e-03, 90% CI [0.00, 3.70e-03]	N/A	F(3) = 0.70, p = 0.553; Eta2 (partial) = 1.13e-03, 90% CI [0.00, 3.50e-03]	N/A
Anger – misclassifications (all)	**All**	Group: F(3) = 8.47, p < .001; Eta2 (partial) = 0.01, 90% CI [4.93e-03, 0.02] Interaction: F(15) = 3.57, p < .001; Eta2 (partial) = 1.66e-03, 90% CI [6.18e-04, 2.01e-03])	N/A	Group: F(3) = 3.96, p = 0.008; Eta2 (partial) = 5.97e-03, 90% CI [9.03e-04, 0.01] Interaction: (F(15) = 3.57, p < .001; Eta2 (partial) = 1.66e-03, 90% CI [6.18e-04, 2.01e-03])	N/A	Group: F(3) = 3.47, p = 0.016; Eta2 (partial) = 5.58e-03, 90% CI [5.86e-04, 0.01] Interaction: F(15) = 3.31, p < .001; Eta2 (partial) = 1.58e-03, 90% CI [5.41e-04, 1.91e-03]	N/A	Group: F(3) = 3.15, p = 0.024; Eta2 (partial) = 5.12e-03, 90% CI [3.61e-04, 0.01] Interaction: F(15) = 3.36, p < .001; Eta2 (partial) = 1.63e-03, 90% CI [5.68e-04, 1.97e-03]	N/A	Group: F(3) = 3.37, p = 0.018; Eta2 (partial) = 5.42e-03, 90% CI [5.10e-04, 0.01] Interaction: F(15) = 3.47, p < .001; Eta2 (partial) = 1.66e-03, 90% CI [6.00e-04, 2.01e-03]	N/A
Anger – misclassifications (disgust)	**Statin vs neither**	(F(1) = 3.89, p = 0.049; Eta2 (partial) = 2.23e-03, 90% CI [6.23e-06, 7.46e-03])	beta = 0.56, 95% CI [3.41e-03, 1.12], t(5019) = 1.97, p < .05; Std. beta = 0.17, 95% CI [1.04e-03, 0.34]	F(1) = 3.33, p = 0.068; Eta2 (partial) = 1.92e-03, 90% CI [0.00, 6.90e-03])	beta = 0.54, 95% CI [-0.04, 1.11], t(5010) = 1.82, p = 0.068; Std. beta = 0.16, 95% CI [-0.01, 0.34]	F(1) = 2.62, p = 0.105; Eta2 (partial) = 1.59e-03, 90% CI [0.00, 6.43e-03]	beta = 0.49, 95% CI [-0.10, 1.08], t(4851) = 1.62, p = 0.105; Std. beta = 0.15, 95% CI [-0.03, 0.33]	F(1) = 0.70, p = 0.403; Eta2 (partial) = 4.27e-04, 90% CI [0.00, 3.73e-03]	beta = 0.28, 95% CI [-0.38, 0.94], t(4800) = 0.84, p = 0.403; Std. beta = 0.09, 95% CI [-0.12, 0.29]	F(1) = 2.62, p = 0.106; Eta2 (partial) = 1.59e-03, 90% CI [0.00, 6.44e-03]	beta = 0.49, 95% CI [-0.10, 1.08], t(4841) = 1.62, p = 0.105; Std. beta = 0.15, 95% CI [-0.03, 0.33]
Anger – misclassifications (fear)	**Statin vs neither**	F(1) = 8.20, p = 0.004; Eta2 (partial) = 4.72e-03, 90% CI [8.56e-04, 0.01])	beta = 0.43, 95% CI [0.14, 0.73], t(5019) = 2.86, p < .01; Std. beta = 0.27, 95% CI [0.08, 0.45]	F(1) = 2.11, p = 0.146; Eta2 (partial) = 1.23e-03, 90% CI [0.00, 5.56e-03]	beta = 0.22, 95% CI [-0.08, 0.52], t(5010) = 1.45, p = 0.146; Std. beta = 0.14, 95% CI [-0.05, 0.32]	F(1) = 1.75, p = 0.187; Eta2 (partial) = 1.08e-03, 90% CI [0.00, 5.41e-03]	beta = 0.21, 95% CI [-0.10, 0.52], t(4851) = 1.32, p = 0.186; Std. beta = 0.13, 95% CI [-0.06, 0.32]	F(1) = 4.10, p = 0.043; Eta2 (partial) = 2.55e-03, 90% CI [4.19e-05, 8.32e-03]	beta = 0.36, 95% CI [0.01, 0.70], t(4800) = 2.03, p < .05; Std. beta = 0.22, 95% CI [7.10e-03, 0.43]	F(1) = 1.74, p = 0.187; Eta2 (partial) = 1.08e-03, 90% CI [0.00, 5.42e-03]	beta = 0.21, 95% CI [-0.10, 0.52], t(4841) = 1.32, p = 0.187; Std. beta = 0.13, 95% CI [-0.06, 0.32]
Anger – misclassifications (happy)	**Statin vs neither**	(F(1) = 0.53, p = 0.466; Eta2 (partial) = 3.19e-04, 90% CI [0.00, 3.35e-03])	beta = -0.03, 95% CI [-0.11, 0.05], t(5019) = -0.73, p = 0.466; Std. beta = -0.06, 95% CI [-0.21, 0.10]	F(1) = 0.36, p = 0.547; Eta2 (partial) = 2.19e-04, 90% CI [0.00, 2.98e-03]	beta = -0.02, 95% CI [-0.10, 0.06], t(5010) = -0.60, p = 0.547; Std. beta = -0.05, 95% CI [-0.21, 0.11	F(1) = 0.49, p = 0.486; Eta2 (partial) = 3.05e-04, 90% CI [0.00, 3.39e-03]	beta = -0.03, 95% CI [-0.11, 0.05], t(4851) = -0.70, p = 0.486; Std. beta = -0.06, 95% CI [-0.22, 0.10]	F(1) = 0.43, p = 0.511; Eta2 (partial) = 2.73e-04, 90% CI [0.00, 3.28e-03]	beta = -0.03, 95% CI [-0.12, 0.06], t(4800) = -0.66, p = 0.511; Std. beta = -0.06, 95% CI [-0.24, 0.12]	F(1) = 0.48, p = 0.487; Eta2 (partial) = 3.04e-04, 90% CI [0.00, 3.39e-03]	beta = -0.03, 95% CI [-0.11, 0.05], t(4841) = -0.70, p = 0.487; Std. beta = -0.06, 95% CI [-0.22, 0.10]

Outcome	Groups	Full dataset (n=2033)						Sensitivity Checks			
								Excluding non-lipophilic (n=2011)		Excluding small gender groups (n=2027)	
		Uncorrected		Corrected for demographics		Corrected for all covariates		Corrected for all covariates			
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
Anger – misclassifications (sad)	**Statin vs neither**	(F(1) = 3.09, p = 0.079; Eta2 (partial) = 1.77e-03, 90% CI [0.00, 6.59e-03])	beta = 0.52, 95% CI [-0.06, 1.11], t(5019) = 1.76, p = 0.079; Std. beta = 0.17, 95% CI [-0.02, 0.35]	(F(1) = 0.21, p = 0.646; Eta2 (partial) = 1.21e-04, 90% CI [0.00, 2.41e-03]	beta = 0.14, 95% CI [-0.46, 0.74], t(5010) = 0.46, p = 0.646; Std. beta = 0.04, 95% CI [-0.15, 0.24]	F(1) = 4.44e-03, p = 0.947; Eta2 (partial) = 2.71e-06, 90% CI [0.00, 7.07e-05]	beta = -0.02, 95% CI [-0.63, 0.59], t(4851) = -0.07, p = 0.947; Std. beta = -6.64e-03, 95% CI [-0.20, 0.19]	F(1) = 0.02, p = 0.891; Eta2 (partial) = 1.16e-05, 90% CI [0.00, 9.65e-04]	beta = -0.05, 95% CI [-0.73, 0.63], t(4800) = -0.14, p = 0.891; Std. beta = -0.02, 95% CI [-0.23, 0.20]	F(1) = 4.56e-03, p = 0.946; Eta2 (partial) = 2.78e-06, 90% CI [0.00, 8.99e-05]	beta = -0.02, 95% CI [-0.64, 0.59], t(4841) = -0.07, p = 0.946; Std. beta = -6.73e-03, 95% CI [-0.20, 0.19]
Anger – misclassifications (surprise)	**Statin vs neither**	(F(1) = 7.51, p = 0.006; Eta2 (partial) = 4.28e-03, 90% CI [6.83e-04, 0.01])	beta = 0.12, 95% CI [0.04, 0.21], t(5019) = 2.74, p < .01; Std. beta = 0.22, 95% CI [0.06, 0.38]	F(1) = 10.85, p = 0.001; Eta2 (partial) = 6.22e-03, 90% CI [1.56e-03, 0.01]	beta = 0.15, 95% CI [0.06, 0.24], t(5010) = 3.29, p < .001; Std. beta = 0.27, 95% CI [0.11, 0.43]	F(1) = 11.52, p < .001; Eta2 (partial) = 7.00e-03, 90% CI [1.86e-03, 0.02]	beta = 0.16, 95% CI [0.07, 0.26], t(4851) = 3.39, p < .001; Std. beta = 0.29, 95% CI [0.12, 0.46]	F(1) = 6.87, p = 0.009; Eta2 (partial) = 4.21e-03, 90% CI [5.82e-04, 0.01]	beta = 0.14, 95% CI [0.03, 0.24], t(4800) = 2.62, p < .01; Std. beta = 0.25, 95% CI [0.06, 0.43]	F(1) = 11.52, p < .001; Eta2 (partial) = 7.01e-03, 90% CI [1.86e-03, 0.02]	beta = 0.16, 95% CI [0.07, 0.26], t(4841) = 3.39, p < .001; Std. beta = 0.29, 95% CI [0.12, 0.46]
Anger – misclassifications (neutral)	**Statin vs neither**	(F(1) = 2.28, p = 0.131; Eta2 (partial) = 1.28e-03, 90% CI [0.00, 5.58e-03])	beta = 0.54, 95% CI [-0.16, 1.25], t(5019) = 1.51, p = 0.131; Std. beta = 0.14, 95% CI [-0.04, 0.33]	F(1) = 3.40, p = 0.065; Eta2 (partial) = 1.92e-03, 90% CI [0.00, 6.86e-03]	beta = 0.68, 95% CI [-0.04, 1.40], t(5010) = 1.84, p = 0.065; Std. beta = 0.18, 95% CI [-0.01, 0.37]	F(1) = 3.17, p = 0.075; Eta2 (partial) = 1.91e-03, 90% CI [0.00, 7.05e-03]	beta = 0.68, 95% CI [-0.07, 1.42], t(4851) = 1.78, p = 0.075; Std. beta = 0.18, 95% CI [-0.02, 0.37]	F(1) = 2.31, p = 0.129; Eta2 (partial) = 1.41e-03, 90% CI [0.00, 6.07e-03]	beta = 0.64, 95% CI [-0.18, 1.46], t(4800) = 1.52, p = 0.128; Std. beta = 0.17, 95% CI [-0.05, 0.39]	F(1) = 3.16, p = 0.076; Eta2 (partial) = 1.91e-03, 90% CI [0.00, 7.05e-03]	beta = 0.68, 95% CI [-0.07, 1.42], t(4841) = 1.78, p = 0.075; Std. beta = 0.18, 95% CI [-0.02, 0.37]
Fear – misclassifications (all)	**All**	Group: F(3) = 5.99, p < .001; Eta2 (partial) = 8.95e-03, 90% CI [2.58e-03, 0.02] Interaction: F(15) = 3.49, p < .001; Eta2 (partial) = 1.62e-03, 90% CI [5.90e-04, 1.96e-03])	N/A	Group: F(3) = 3.28, p = 0.020; Eta2 (partial) = 4.95e-03, 90% CI [4.18e-04, 0.01] Interaction: F(15) = 3.49, p < .001; Eta2 (partial) = 1.62e-03, 90% CI [5.90e-04, 1.96e-03]	N/A	Group: F(3) = 2.37, p = 0.069; Eta2 (partial) = 3.80e-03, 90% CI [0.00, 8.52e-03] Interaction: F(15) = 3.47, p < .001; Eta2 (partial) = 1.66e-03, 90% CI [5.99e-04, 2.01e-03]	N/A	Group: F(3) = 1.65, p = 0.175; Eta2 (partial) = 2.68e-03, 90% CI [0.00, 6.63e-03] Interaction: F(15) = 3.06, p < .001; Eta2 (partial) = 1.48e-03, 90% CI [4.58e-04, 1.78e-03]	N/A	Group: F(3) = 2.38, p = 0.068; Eta2 (partial) = 3.81e-03, 90% CI [0.00, 8.55e-03] Interaction: F(15) = 3.43, p < .001; Eta2 (partial) = 1.65e-03, 90% CI [5.88e-04, 1.99e-03]	N/A
Fear – misclassifications (anger)	**Statin vs neither**	F(1) = 4.33, p = 0.038; Eta2 (partial) = 2.43e-03, 90% CI [7.24e-05, 7.75e-03]	(beta = 0.27, 95% CI [0.02, 0.53], t(5019) = 2.08, p < .05; Std. beta = 0.16, 95% CI [9.05e-03, 0.30]	F(1) = 3.46e-03, p = 0.953; Eta2 (partial) = 1.96e-06, 90% CI [0.00, 0.00]	beta = 7.74e-03, 95% CI [-0.25, 0.27], t(5010) = 0.06, p = 0.953; Std. beta = 4.44e-03, 95% CI [-0.14, 0.15]	F(1) = 0.13, p = 0.721; Eta2 (partial) = 7.71e-05, 90% CI [0.00, 2.16e-03]	beta = -0.05, 95% CI [-0.31, 0.22], t(4851) = -0.36, p = 0.721; Std. beta = -0.03, 95% CI [-0.18, 0.12]	F(1) = 8.06e-03, p = 0.928; Eta2 (partial) = 4.89e-06, 90% CI [0.00, 4.36e-04]	beta = -0.01, 95% CI [-0.31, 0.28], t(4800) = -0.09, p = 0.928; Std. beta = -7.74e-03, 95% CI [-0.18, 0.16]	F(1) = 0.13, p = 0.724; Eta2 (partial) = 7.58e-05, 90% CI [0.00, 2.30e-03]	beta = -0.05, 95% CI [-0.31, 0.22], t(4841) = -0.35, p = 0.723; Std. beta = -0.03, 95% CI [-0.18, 0.12]
Fear – misclassifications (disgust)	**Statin vs neither**	F(1) = 2.11, p = 0.146; Eta2 (partial) = 1.25e-03, 90% CI [0.00, 5.67e-03]	beta = 0.32, 95% CI [-0.11, 0.75], t(5019) = 1.45, p = 0.146; Std. beta = 0.12, 95% CI [-0.04, 0.28]	F(1) = 4.21, p = 0.040; Eta2 (partial) = 2.51e-03, 90% CI [5.77e-05, 8.10e-03]	beta = 0.46, 95% CI [0.02, 0.90], t(5010) = 2.05, p < .05; Std. beta = 0.17, 95% CI [7.82e-03, 0.34]	F(1) = 3.12, p = 0.077; Eta2 (partial) = 1.91e-03, 90% CI [0.00, 7.10e-03]	beta = 0.40, 95% CI [-0.04, 0.85], t(4851) = 1.77, p = 0.077; Std. beta = 0.15, 95% CI [-0.02, 0.32]	F(1) = 1.72, p = 0.190; Eta2 (partial) = 1.06e-03, 90% CI [0.00, 5.37e-03]	beta = 0.33, 95% CI [-0.16, 0.82], t(4800) = 1.31, p = 0.189; Std. beta = 0.12, 95% CI [-0.06, 0.31]	F(1) = 3.13, p = 0.077; Eta2 (partial) = 1.92e-03, 90% CI [0.00, 7.12e-03]	beta = 0.40, 95% CI [-0.04, 0.85], t(4841) = 1.77, p = 0.077; Std. beta = 0.15, 95% CI [-0.02, 0.32]

Outcome	Groups	Full dataset (n=2033)						Sensitivity Checks			
								Excluding non-lipophilic (n=2011)		Excluding small gender groups (n=2027)	
		Uncorrected		Corrected for demographics		Corrected for all covariates		Corrected for all covariates			
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
Fear – misclassifications (happy)	**Statin vs neither**	F(1) = 0.24, p = 0.626; Eta2 (partial) = 1.40e-04, 90% CI [0.00, 2.54e-03]	beta = 0.04, 95% CI [-0.11, 0.18], t(5019) = 0.49, p = 0.626; Std. beta = 0.04, 95% CI [-0.12, 0.20]	F(1) = 2.10e-05, p = 0.996; Eta2 (partial) = 1.24e-08, 90% CI [0.00, 0.00]	beta = 3.51e-04, 95% CI [-0.15, 0.15], t(5010) = 4.58e-03, p = 0.996; Std. beta = 3.86e-04, 95% CI [-0.16, 0.17]	F(1) = 0.03, p = 0.866; Eta2 (partial) = 1.79e-05, 90% CI [0.00, 1.24e-03]	beta = -0.01, 95% CI [-0.17, 0.14], t(4851) = -0.17, p = 0.866; Std. beta = -0.01, 95% CI [-0.18, 0.15]	F(1) = 0.38, p = 0.540; Eta2 (partial) = 2.36e-04, 90% CI [0.00, 3.13e-03]	beta = -0.05, 95% CI [-0.22, 0.12], t(4800) = -0.61, p = 0.540; Std. beta = -0.06, 95% CI [-0.25, 0.13]	F(1) = 0.03, p = 0.866; Eta2 (partial) = 1.77e-05, 90% CI [0.00, 1.28e-03]	beta = -0.01, 95% CI [-0.17, 0.14], t(4841) = -0.17, p = 0.866; Std. beta = -0.01, 95% CI [-0.18, 0.15]
Fear – misclassifications (sad)	**Statin vs neither**	(F(1) = 0.74, p = 0.390; Eta2 (partial) = 4.23e-04, 90% CI [0.00, 3.57e-03]	beta = 0.21, 95% CI [-0.27, 0.70], t(5019) = 0.86, p = 0.390; Std. beta = 0.08, 95% CI [-0.10, 0.26]	F(1) = 0.40, p = 0.527; Eta2 (partial) = 2.31e-04, 90% CI [0.00, 2.94e-03]	beta = -0.16, 95% CI [-0.66, 0.34], t(5010) = -0.63, p = 0.527; Std. beta = -0.06, 95% CI [-0.24, 0.12]	F(1) = 2.01, p = 0.157; Eta2 (partial) = 1.22e-03, 90% CI [0.00, 5.65e-03]	beta = -0.37, 95% CI [-0.87, 0.14], t(4851) = -1.42, p = 0.156; Std. beta = -0.13, 95% CI [-0.32, 0.05]	F(1) = 0.74, p = 0.390; Eta2 (partial) = 4.51e-04, 90% CI [0.00, 3.80e-03]	beta = -0.25, 95% CI [-0.81, 0.32], t(4800) = -0.86, p = 0.390; Std. beta = -0.09, 95% CI [-0.30, 0.12]	F(1) = 2.00, p = 0.157; Eta2 (partial) = 1.21e-03, 90% CI [0.00, 5.65e-03]	beta = -0.37, 95% CI [-0.87, 0.14], t(4841) = -1.42, p = 0.157; Std. beta = -0.13, 95% CI [-0.32, 0.05]
Fear – misclassifications (surprise)	**Statin vs neither**	F(1) = 0.44, p = 0.505; Eta2 (partial) = 2.52e-04, 90% CI [0.00, 2.99e-03]	beta = 0.28, 95% CI [-0.54, 1.09], t(5019) = 0.67, p = 0.505; Std. beta = 0.06, 95% CI [-0.12, 0.25]	F(1) = 4.45, p = 0.035; Eta2 (partial) = 2.54e-03, 90% CI [9.21e-05, 7.99e-03]	beta = 0.89, 95% CI [0.06, 1.72], t(5010) = 2.11, p < .05; Std. beta = 0.21, 95% CI [0.01, 0.40]	F(1) = 4.36, p = 0.037; Eta2 (partial) = 2.63e-03, 90% CI [8.27e-05, 8.36e-03]	beta = 0.91, 95% CI [0.06, 1.76], t(4851) = 2.09, p < .05; Std. beta = 0.21, 95% CI [0.01, 0.41]	F(1) = 2.81, p = 0.094; Eta2 (partial) = 1.71e-03, 90% CI [0.00, 6.67e-03]	beta = 0.81, 95% CI [-0.14, 1.75], t(4800) = 1.68, p = 0.094; Std. beta = 0.19, 95% CI [-0.03, 0.40]	F(1) = 4.39, p = 0.036; Eta2 (partial) = 2.65e-03, 90% CI [8.68e-05, 8.39e-03]	beta = 0.91, 95% CI [0.06, 1.76], t(4841) = 2.09, p < .05; Std. beta = 0.21, 95% CI [0.01, 0.41]
Fear – misclassifications (neutral)	**Statin vs neither**	F(1) = 7.93, p = 0.005; Eta2 (partial) = 4.48e-03, 90% CI [7.73e-04, 0.01]	beta = 0.95, 95% CI [0.29, 1.62], t(5019) = 2.82, p < .01; Std. beta = 0.27, 95% CI [0.08, 0.45]	(F(1) = 2.58, p = 0.109; Eta2 (partial) = 1.47e-03, 90% CI [0.00, 5.99e-03]	beta = 0.56, 95% CI [-0.12, 1.24], t(5010) = 1.61, p = 0.108; Std. beta = 0.16, 95% CI [-0.03, 0.35]	F(1) = 2.49, p = 0.115; Eta2 (partial) = 1.51e-03, 90% CI [0.00, 6.26e-03]	beta = 0.57, 95% CI [-0.14, 1.27], t(4851) = 1.58, p = 0.115; Std. beta = 0.16, 95% CI [-0.04, 0.35]	F(1) = 0.86, p = 0.355; Eta2 (partial) = 5.23e-04, 90% CI [0.00, 4.01e-03]	beta = 0.37, 95% CI [-0.41, 1.14], t(4800) = 0.93, p = 0.355; Std. beta = 0.10, 95% CI [-0.11, 0.32]	F(1) = 2.47, p = 0.116; Eta2 (partial) = 1.50e-03, 90% CI [0.00, 6.25e-03]	beta = 0.56, 95% CI [-0.14, 1.27], t(4841) = 1.57, p = 0.116; Std. beta = 0.16, 95% CI [-0.04, 0.35]
All emotions - RT	**All**	Group: F(3) = 14.57, p < .001; Eta2 (partial) = 0.02, 90% CI [0.01, 0.03] Interaction: F(18) = 5.03, p < .001; Eta2 (partial) = 2.39e-03, 90% CI [1.23e-03, 2.80e-03]	N/A	Group: F(3) = 1.13, p = 0.335; Eta2 (partial) = 1.69e-03, 90% CI [0.00, 4.63e-03] Interaction: F(18) = 5.03, p < .001; Eta2 (partial) = 2.39e-03, 90% CI [1.23e-03, 2.80e-03]	N/A	Group: F(3) = 1.49, p = 0.216; Eta2 (partial) = 2.37e-03, 90% CI [0.00, 6.03e-03] Interaction: F(18) = 5.01, p < .001; Eta2 (partial) = 2.45e-03, 90% CI [1.25e-03, 2.87e-03]	N/A	Group: F(3) = 0.83, p = 0.480; Eta2 (partial) = 1.33e-03, 90% CI [0.00, 3.96e-03] Interaction: F(18) = 4.91, p < .001; Eta2 (partial) = 2.43e-03, 90% CI [1.23e-03, 2.84e-03]	N/A	Group: F(3) = 1.49, p = 0.216; Eta2 (partial) = 2.37e-03, 90% CI [0.00, 6.04e-03] Interaction: F(18) = 4.94, p < .001; Eta2 (partial) = 2.42e-03, 90% CI [1.23e-03, 2.84e-03]	N/A
Anger - RT	**Statin vs neither**	F(1) = 33.47, p < .001; Eta2 (partial) = 0.02, 90% CI [9.56e-03, 0.03]	beta = 254.41, 95% CI [168.22, 340.60], t(5017) = 5.79, p < .001; Std. beta = 0.59,	F(1) = 7.05, p = 0.008; Eta2 (partial) = 3.99e-03, 90% CI [5.76e-04, 0.01]	beta = 114.46, 95% CI [29.95, 198.97], t(5008) = 2.65, p < .01; Std. beta = 0.26,	F(1) = 7.93, p = 0.005; Eta2 (partial) = 4.78e-03, 90% CI [8.27e-04, 0.01]	beta = 124.47, 95% CI [37.86, 211.08], t(4849) = 2.82, p < .01; Std. beta = 0.29,	F(1) = 5.43, p = 0.020; Eta2 (partial) = 3.30e-03, 90% CI [2.75e-04, 9.56e-03]	beta = 114.03, 95% CI [18.16, 209.90], t(4798) = 2.33, p < .05; Std. beta = 0.26,	F(1) = 7.93, p = 0.005; Eta2 (partial) = 4.78e-03, 90% CI [8.26e-04, 0.01]	beta = 124.48, 95% CI [37.82, 211.14], t(4839) = 2.82, p < .01; Std. beta = 0.29,

Outcome	Groups	Full dataset (n=2033)						Sensitivity Checks			
								Excluding non-lipophilic (n=2011)		Excluding small gender groups (n=2027)	
		Uncorrected		Corrected for demographics		Corrected for all covariates		Corrected for all covariates			
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
			95% CI [0.39, 0.78]		95% CI [0.07, 0.46]		95% CI [0.09, 0.49]		95% CI [0.04, 0.49]		95% CI [0.09, 0.49]
Disgust - RT	**Statin vs neither**	F(1) = 21.99, p < .001; Eta2 (partial) = 0.01, 90% CI [5.18e-03, 0.02]	(beta = 194.66, 95% CI [113.29, 276.03], t(5017) = 4.69, p < .001; Std. beta = 0.47, 95% CI [0.27, 0.66]	F(1) = 3.37, p = 0.067; Eta2 (partial) = 1.91e-03, 90% CI [0.00, 6.83e-03]	beta = 75.43, 95% CI [-5.11, 155.98], t(5008) = 1.84, p = 0.066; Std. beta = 0.18, 95% CI [-0.01, 0.38]	F(1) = 3.88, p = 0.049; Eta2 (partial) = 2.34e-03, 90% CI [4.51e-06, 7.84e-03]	beta = 83.36, 95% CI [0.37, 166.35], t(4849) = 1.97, p < .05; Std. beta = 0.20, 95% CI [8.88e-04, 0.40]	F(1) = 1.81, p = 0.178; Eta2 (partial) = 1.10e-03, 90% CI [0.00, 5.42e-03]	beta = 63.16, 95% CI [-28.74, 155.06], t(4798) = 1.35, p = 0.178; Std. beta = 0.15, 95% CI [-0.07, 0.37]	F(1) = 3.87, p = 0.049; Eta2 (partial) = 2.34e-03, 90% CI [4.28e-06, 7.84e-03]	beta = 83.39, 95% CI [0.35, 166.43], t(4839) = 1.97, p < .05; Std. beta = 0.20, 95% CI [8.51e-04, 0.40]
Fear - RT	**Statin vs neither**	F(1) = 15.64, p < .001; Eta2 (partial) = 8.63e-03, 90% CI [2.95e-03, 0.02]	beta = 194.48, 95% CI [98.09, 290.87], t(4979) = 3.95, p < .001; Std. beta = 0.38, 95% CI [0.19, 0.56]	F(1) = 1.79, p = 0.181; Eta2 (partial) = 1.01e-03, 90% CI [0.00, 4.98e-03]	beta = 65.62, 95% CI [-30.45, 161.70], t(4970) = 1.34, p = 0.181; Std. beta = 0.13, 95% CI [-0.06, 0.31]	F(1) = 1.19, p = 0.276; Eta2 (partial) = 7.09e-04, 90% CI [0.00, 4.45e-03]	beta = 54.99, 95% CI [-43.93, 153.92], t(4813) = 1.09, p = 0.276; Std. beta = 0.11, 95% CI [-0.08, 0.30]	F(1) = 0.56, p = 0.453; Eta2 (partial) = 3.40e-04, 90% CI [0.00, 2.52e-03]	beta = 42.06, 95% CI [-67.70, 151.83], t(4764) = 0.75, p = 0.453; Std. beta = 0.08, 95% CI [-0.13, 0.29]	F(1) = 1.19, p = 0.275; Eta2 (partial) = 7.13e-04, 90% CI [0.00, 4.46e-03]	beta = 55.13, 95% CI [-43.83, 154.09], t(4803) = 1.09, p = 0.275; Std. beta = 0.11, 95% CI [-0.08, 0.30]
Happiness - RT	**Statin vs neither**	F(1) = 13.97, p < .001; Eta2 (partial) = 7.82e-03, 90% CI [2.45e-03, 0.02]	beta = 114.22, 95% CI [54.32, 174.13], t(5019) = 3.74, p < .001; Std. beta = 0.38, 95% CI [0.18, 0.58]	F(1) = 2.48, p = 0.116; Eta2 (partial) = 1.41e-03, 90% CI [0.00, 5.85e-03]	beta = 48.04, 95% CI [-11.76, 107.84], t(5010) = 1.57, p = 0.115; Std. beta = 0.16, 95% CI [-0.04, 0.36]	F(1) = 2.81, p = 0.094; Eta2 (partial) = 1.70e-03, 90% CI [0.00, 6.64e-03]	beta = 52.90, 95% CI [-8.99, 114.79], t(4851) = 1.68, p = 0.094; Std. beta = 0.18, 95% CI [-0.03, 0.38]	F(1) = 1.00, p = 0.317; Eta2 (partial) = 6.11e-04, 90% CI [0.00, 4.25e-03]	beta = 34.85, 95% CI [-33.42, 103.11], t(4800) = 1.00, p = 0.317; Std. beta = 0.12, 95% CI [-0.11, 0.35]	F(1) = 2.81, p = 0.094; Eta2 (partial) = 1.70e-03, 90% CI [0.00, 6.65e-03]	beta = 52.94, 95% CI [-8.99, 114.86], t(4841) = 1.68, p = 0.094; Std. beta = 0.18, 95% CI [-0.03, 0.38]
Sadness - RT	**Statin vs neither**	(F(1) = 12.66, p < .001; Eta2 (partial) = 7.10e-03, 90% CI [2.06e-03, 0.02]	beta = 130.14, 95% CI [58.45, 201.84], t(5018) = 3.56, p < .001; Std. beta = 0.35, 95% CI [0.16, 0.54]	F(1) = 1.26, p = 0.261; Eta2 (partial) = 7.18e-04, 90% CI [0.00, 4.34e-03]	beta = 40.86, 95% CI [-30.41, 112.14], t(5009) = 1.12, p = 0.261; Std. beta = 0.11, 95% CI [-0.08, 0.30]	F(1) = 2.17, p = 0.141; Eta2 (partial) = 1.31e-03, 90% CI [0.00, 5.86e-03]	beta = 55.25, 95% CI [-18.20, 128.69], t(4850) = 1.47, p = 0.140; Std. beta = 0.15, 95% CI [-0.05, 0.34]	F(1) = 0.99, p = 0.320; Eta2 (partial) = 6.02e-04, 90% CI [0.00, 4.23e-03]	beta = 41.07, 95% CI [-39.93, 122.07], t(4799) = 0.99, p = 0.320; Std. beta = 0.11, 95% CI [-0.11, 0.33]	F(1) = 2.17, p = 0.141; Eta2 (partial) = 1.32e-03, 90% CI [0.00, 5.86e-03]	beta = 55.27, 95% CI [-18.22, 128.75], t(4840) = 1.47, p = 0.140; Std. beta = 0.15, 95% CI [-0.05, 0.34]
Surprise - RT	**Statin vs neither**	F(1) = 12.00, p < .001; Eta2 (partial) = 6.73e-03, 90% CI [1.86e-03, 0.01]	beta = 133.22, 95% CI [57.85, 208.59], t(5019) = 3.46, p < .001; Std. beta = 0.35, 95% CI [0.15, 0.55]	F(1) = 0.47, p = 0.492; Eta2 (partial) = 2.68e-04, 90% CI [0.00, 6.02e-04]	beta = 26.17, 95% CI [-48.46, 100.81], t(5010) = 0.69, p = 0.492; Std. beta = 0.07, 95% CI [-0.13, 0.27]	F(1) = 1.08, p = 0.299; Eta2 (partial) = 6.52e-04, 90% CI [0.00, 4.33e-03]	beta = 40.64, 95% CI [-36.01, 117.28], t(4851) = 1.04, p = 0.299; Std. beta = 0.11, 95% CI [-0.10, 0.31]	F(1) = 0.35, p = 0.555; Eta2 (partial) = 2.12e-04, 90% CI [0.00, 2.97e-03]	beta = 25.53, 95% CI [-59.25, 110.31], t(4800) = 0.59, p = 0.555; Std. beta = 0.07, 95% CI [-0.16, 0.29]	F(1) = 1.08, p = 0.299; Eta2 (partial) = 6.52e-04, 90% CI [0.00, 4.33e-03]	beta = 40.61, 95% CI [-36.07, 117.30], t(4841) = 1.04, p = 0.299; Std. beta = 0.11, 95% CI [-0.10, 0.31]
Neutral - RT	**Statin vs neither**	(F(1) = 11.24, p < .001; Eta2 (partial) = 6.36e-03, 90% CI [1.65e-03, 0.01]	(beta = 116.29, 95% CI [48.30, 184.28], t(5015) = 3.35, p < .001; Std. beta = 0.32, 95% CI [0.13, 0.51]	F(1) = 1.88, p = 0.170; Eta2 (partial) = 1.08e-03, 90% CI [0.00, 5.21e-03]	beta = 47.56, 95% CI [-20.35, 115.47], t(5006) = 1.37, p = 0.170; Std. beta = 0.13, 95% CI [-0.06, 0.32]	F(1) = 1.22, p = 0.269; Eta2 (partial) = 7.45e-04, 90% CI [0.00, 4.62e-03]	beta = 39.30, 95% CI [-30.39, 108.99], t(4848) = 1.11, p = 0.269; Std. beta = 0.11, 95% CI [-0.08, 0.30]	F(1) = 0.58, p = 0.447; Eta2 (partial) = 3.56e-04, 90% CI [0.00, 3.52e-03]	beta = 29.89, 95% CI [-47.10, 106.88], t(4797) = 0.76, p = 0.447; Std. beta = 0.08, 95% CI [-0.13, 0.30]	F(1) = 1.22, p = 0.270; Eta2 (partial) = 7.45e-04, 90% CI [0.00, 4.60e-03]	beta = 39.29, 95% CI [-30.44, 109.03], t(4838) = 1.10, p = 0.269; Std. beta = 0.11, 95% CI [-0.09, 0.30]

PILT

Outcome	Groups	Full dataset (n=1636)						Sensitivity Checks							
		Last 20 trials only						All trials		Excluding non-lipophilic (n=1619)		Excluding small gender groups (n=1631)		Excluding understanding check fails (n=1271)	
		Uncorrected		Corrected for demographics		Corrected for all covariates		Corrected for all covariates							
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear model	ANCOVA	Linear model	ANCOVA	Linear model
Gain trials - choice of advantageous stimulus	**All**	F(3, 1632) = 0.24, p = 0.871; Eta2 = 4.35e-04, 90% CI [0.00, 1.34e-03]	N/A	F(3, 1623) = 0.24, p = 0.870; Eta2 (partial) = 4.40e-04, 90% CI [0.00, 1.36e-03]	N/A	F(3, 1610) = 0.06, p = 0.979; Eta2 (partial) = 1.20e-04, 90% CI [0.00, 0.00]	N/A	F(3, 1610) = 0.24, p = 0.866; Eta2 (partial) = 4.53e-04, 90% CI [0.00, 1.41e-03]	N/A	F(3, 1593) = 0.18, p = 0.909; Eta2 (partial) = 3.41e-04, 90% CI [0.00, 8.33e-04]	N/A	F(3, 1607) = 0.05, p = 0.984; Eta2 (partial) = 9.97e-05, 90% CI [0.00, 0.00]	N/A	F(3, 1245) = 0.67, p = 0.572; Eta2 (partial) = 1.61e-03, 90% CI [0.00, 5.02e-03]	N/A
Loss trials - choice of advantageous stimulus	**All**	F(3, 1632) = 3.91, p = 0.009; Eta2 = 7.13e-03, 90% CI [1.04e-03, 0.01]	N/A	F(3, 1623) = 4.01, p = 0.007; Eta2 (partial) = 7.35e-03, 90% CI [1.14e-03, 0.01]	N/A	F(3, 1610) = 4.73, p = 0.003; Eta2 (partial) = 8.74e-03, 90% CI [1.85e-03, 0.02]	N/A	F(3, 1610) = 4.07, p = 0.007; Eta2 (partial) = 7.52e-03, 90% CI [1.20e-03, 0.01]	N/A	F(3, 1593) = 4.24, p = 0.005; Eta2 (partial) = 7.92e-03, 90% CI [1.38e-03, 0.02]	N/A	F(3, 1607) = 4.67, p = 0.003; Eta2 (partial) = 8.65e-03, 90% CI [1.79e-03, 0.02]	N/A	F(3, 1245) = 2.99, p = 0.030; Eta2 (partial) = 7.16e-03, 90% CI [3.65e-04, 0.02]	N/A
	Statin vs neither	F(1, 1440) = 9.22, p = 0.002; Eta2 = 6.36e-03, 90% CI [1.34e-03, 0.02]	beta = -5.61, 95% CI [-9.16, -2.06], t(1632) = -3.10, p < .01; Std. beta = -0.39, 95% CI [-0.63, -0.14]	F(2, 1430) = 5.05, p = 0.007; Eta2 (partial) = 7.01e-03, 90% CI [1.14e-03, 0.02]	beta = -3.82, 95% CI [-7.43, -0.21], t(1623) = -2.08, p < .05; Std. beta = -0.26, 95% CI [-0.51, -0.01]	F(1, 1418) = 9.90, p = 0.002; Eta2 (partial) = 6.93e-03, 90% CI [1.58e-03, 0.02]	beta = -3.73, 95% CI [-7.33, -0.12], t(1610) = -2.03, p < .05; Std. beta = -0.26, 95% CI [-0.51, -8.50e-03]	F(1, 1418) = 9.60, p = 0.002; Eta2 (partial) = 6.72e-03, 90% CI [1.48e-03, 0.02]	beta = -3.25, 95% CI [-6.24, -0.27], t(1610) = -2.14, p < .05; Std. beta = -0.27, 95% CI [-0.52, -0.02]	F(1, 1405) = 7.53, p = 0.006; Eta2 (partial) = 5.33e-03, 90% CI [8.55e-04, 0.01]	beta = -3.69, 95% CI [-7.64, 0.27], t(1593) = -1.83, p = 0.068; Std. beta = -0.25, 95% CI [-0.53, 0.02]	F(1, 1415) = 9.81, p = 0.002; Eta2 (partial) = 6.89e-03, 90% CI [1.55e-03, 0.02]	beta = -3.72, 95% CI [-7.32, -0.12], t(1607) = -2.03, p < .05; Std. beta = -0.26, 95% CI [-0.50, -8.05e-03]	F(1, 1101) = 4.62, p = 0.032; Eta2 (partial) = 4.18e-03, 90% CI [1.89e-04, 0.01]	beta = -2.73, 95% CI [-6.97, 1.51], t(1245) = -1.26, p = 0.207; Std. beta = -0.19, 95% CI [-0.48, 0.10]
	BP vs neither	F(1, 1476) = 2.52, p = 0.112; Eta2 = 1.71e-03, 90% CI [0.00, 7.04e-03]	beta = -3.00, 95% CI [-5.90, -0.11], t(1632) = -2.03, p < .05; Std. beta = -0.21, 95%	F(2, 1467) = 2.97, p = 0.051; Eta2 (partial) = 4.04e-03, 90% CI [0.00, 0.01]	beta = -1.47, 95% CI [-4.40, 1.46], t(1623) = -0.98, p = 0.326; Std. beta = -0.10, 95%	F(1, 1454) = 4.26, p = 0.039; Eta2 (partial) = 2.92e-03, 90% CI [7.53e-05, 9.38e-03]	beta = -1.61, 95% CI [-4.54, 1.32], t(1610) = -1.08, p = 0.280; Std. beta = -0.11, 95%	F(1, 1454) = 2.63, p = 0.105; Eta2 (partial) = 1.81e-03, 90% CI [0.00, 7.29e-03]	beta = -0.86, 95% CI [-3.29, 1.57], t(1610) = -0.70, p = 0.486; Std. beta = -0.07, 95%	F(1, 1453) = 4.27, p = 0.039; Eta2 (partial) = 2.93e-03, 90% CI [7.69e-05, 9.39e-03]	beta = -1.63, 95% CI [-4.57, 1.31], t(1593) = -1.09, p = 0.277; Std. beta = -0.11, 95%	F(1, 1451) = 4.19, p = 0.041; Eta2 (partial) = 2.88e-03, 90% CI [6.21e-05, 9.31e-03]	beta = -1.61, 95% CI [-4.54, 1.32], t(1607) = -1.08, p = 0.280; Std. beta = -0.11, 95%	F(1, 1132) = 4.74, p = 0.030; Eta2 (partial) = 4.17e-03, 90% CI [2.14e-04, 0.01]	beta = -2.08, 95% CI [-5.42, 1.26], t(1245) = -1.22, p = 0.223; Std. beta = -0.14, 95% CI [-

Outcome	Groups	Full dataset (n=1636)						Sensitivity Checks							
		Last 20 trials only						All trials		Excluding non-lipophilic (n=1619)		Excluding small gender groups (n=1631)		Excluding understanding check fails (n=1271)	
		Uncorrected		Corrected for demographics		Corrected for all covariates		Corrected for all covariates							
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear model	ANCOVA	Linear model	ANCOVA	Linear model
			CI [-0.41, -7.28e-03]		CI [-0.30, 0.10]		CI [-0.31, 0.09]		CI [-0.27, 0.13]		CI [-0.31, 0.09]		CI [-0.31, 0.09]		0.37, 0.09]
	Both vs neither	F(1, 1464) = 0.70, p = 0.402; Eta2 = 4.80e-04, 90% CI [0.00, 4.18e-03]	beta = -1.59, 95% CI [-4.66, 1.48], t(1632) = -1.02, p = 0.309; Std. beta = -0.11, 95% CI [-0.32, 0.10]	F(3, 1454) = 1.57, p = 0.194; Eta2 (partial) = 3.23e-03, 90% CI [0.00, 8.10e-03]	beta = 0.73, 95% CI [-2.47, 3.93], t(1623) = 0.45, p = 0.654; Std. beta = 0.05, 95% CI [-0.17, 0.27]	F(1, 1442) = 1.08, p = 0.299; Eta2 (partial) = 7.47e-04, 90% CI [0.00, 4.97e-03]	beta = 0.30, 95% CI [-2.92, 3.51], t(1610) = 0.18, p = 0.856; Std. beta = 0.02, 95% CI [-0.20, 0.24]	F(1, 1442) = 0.74, p = 0.389; Eta2 (partial) = 5.14e-04, 90% CI [0.00, 4.32e-03]	beta = 0.16, 95% CI [-2.50, 2.83], t(1610) = 0.12, p = 0.905; Std. beta = 0.01, 95% CI [-0.21, 0.24]	F(1, 1437) = 1.97, p = 0.160; Eta2 (partial) = 1.37e-03, 90% CI [0.00, 6.43e-03]	beta = -0.29, 95% CI [-3.58, 3.00], t(1593) = -0.17, p = 0.863; Std. beta = -0.02, 95% CI [-0.25, 0.21]	F(1, 1439) = 1.04, p = 0.307; Eta2 (partial) = 7.25e-04, 90% CI [0.00, 4.91e-03]	beta = 0.31, 95% CI [-2.91, 3.52], t(1607) = 0.19, p = 0.851; Std. beta = 0.02, 95% CI [-0.20, 0.24]	F(1, 1120) = 0.14, p = 0.707; Eta2 (partial) = 1.26e-04, 90% CI [0.00, 3.30e-03]	beta = 1.06, 95% CI [-2.68, 4.80], t(1245) = 0.55, p = 0.580; Std. beta = 0.07, 95% CI [-0.19, 0.33]

N-back

Outcome	Groups	Full dataset (n=1777)						Sensitivity Checks			
								Excluding non-lipophilic (n=1755)		Excluding small gender groups (n=1772)	
		Uncorrected		Corrected for demographics		Corrected for all covariates		Corrected for all covariates			
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
Hits- Zero back (control condition)	**All**	(F(3, 1773) = 0.21, p = 0.888; Eta2 = 3.60e-04, 90% CI [0.00, 1.04e-03]	N/A	F(3) = 1.15, p = 0.329; Eta2 (partial) = 1.94e-03, 90% CI [0.00, 5.32e-03]	N/A	F(3, 1709) = 0.16, p = 0.923; Eta2 (partial) = 2.80e-04, 90% CI [0.00, 5.51e-04]	N/A	F(3, 1687) = 0.20, p = 0.899; Eta2 (partial) = 3.50e-04, 90% CI [0.00, 9.42e-04]	N/A	F(3, 1706) = 0.17, p = 0.918; Eta2 (partial) = 2.96e-04, 90% CI [0.00, 6.65e-04]	N/A
Hits– All test conditions	**All**	Group: F(3) = 3.73, p = 0.011; Eta2 (partial) = 6.28e-03, 90% CI [8.21e-04, 0.01] Interaction: F(6) = 3.80, p < .001; Eta2 (partial) = 6.38e-03, 90% CI [1.63e-03, 9.88e-03]	N/A	Group: F(3) = 1.15, p = 0.329; Eta2 (partial) = 1.94e-03, 90% CI [0.00, 5.32e-03] Interaction: F(6) = 3.80, p < .001; Eta2 (partial) = 6.38e-03, 90% CI [1.63e-03, 9.88e-03]	N/A	Group: F(3) = 1.60, p = 0.187; Eta2 (partial) = 2.80e-03, 90% CI [0.00, 6.27e-03] Interaction: F(6) = 3.77, p < .001; Eta2 (partial) = 6.50e-03, 90% CI [1.63e-03, 0.01]	N/A	Group: F(3) = 2.39, p = 0.067; Eta2 (partial) = 4.23e-03, 90% CI [0.00, 9.46e-03] Interaction: F(6) = 3.55, p = 0.002; Eta2 (partial) = 6.21e-03, 90% CI [1.41e-03, 9.68e-03]	N/A	Group: F(3) = 1.59, p = 0.191; Eta2 (partial) = 2.78e-03, 90% CI [0.00, 6.96e-03] Interaction: F(6) = 3.89, p < .001; Eta2 (partial) = 6.73e-03, 90% CI [1.77e-03, 0.01]	N/A
Hits – One back	**All**	F(3, 1773) = 4.88, p = 0.002; Eta2 = 8.19e-03, 90% CI [1.82e-03, 0.02]	N/A	(F(3, 1764) = 4.92, p = 0.002; Eta2 (partial) = 8.31e-03, 90% CI [1.87e-03, 0.02]	N/A	F(3, 1709) = 4.63, p = 0.003; Eta2 (partial) = 8.06e-03, 90% CI [1.65e-03, 0.02]	N/A	F(3, 1687) = 4.97, p = 0.002; Eta2 (partial) = 8.76e-03, 90% CI [2.00e-03, 0.02]	N/A	F(3, 1706) = 4.74, p = 0.003; Eta2 (partial) = 8.27e-03, 90% CI [1.76e-03, 0.02]	N/A
	Statin vs Neither	F(1, 1553) = 1.06, p = 0.302; Eta2 = 6.85e-04, 90% CI [0.00, 4.59e-03]	beta = -3.20, 95% CI [-9.30, 2.90], t(1773) = -1.03, p = 0.304; Std. beta = -0.12, 95% CI [-0.35, 0.11]	F(1, 1544) = 1.07, p = 0.300; Eta2 (partial) = 6.94e-04, 90% CI [0.00, 4.63e-03]	beta = -1.06, 95% CI [-7.34, 5.21], t(1764) = -0.33, p = 0.740; Std. beta = -0.04, 95% CI [-0.28, 0.20]	F(1, 1494) = 0.29, p = 0.589; Eta2 (partial) = 1.95e-04, 90% CI [0.00, 3.09e-03]	beta = -0.05, 95% CI [-6.46, 6.35], t(1709) = -0.02, p = 0.987; Std. beta = -2.01e-03, 95% CI [-0.24, 0.24]	F(1, 1477) = 0.02, p = 0.898; Eta2 (partial) = 1.11e-05, 90% CI [0.00, 9.69e-04]	beta = 2.03, 95% CI [-5.07, 9.13], t(1687) = 0.56, p = 0.574; Std. beta = 0.08, 95% CI [-0.19, 0.34]	F(1, 1492) = 0.29, p = 0.587; Eta2 (partial) = 1.97e-04, 90% CI [0.00, 3.10e-03]	beta = -0.05, 95% CI [-6.46, 6.36], t(1706) = -0.02, p = 0.988; Std. beta = -1.85e-03, 95% CI [-0.24, 0.24]
	BP vs Neither	F(1, 1596) = 11.14, p < .001; Eta2 = 6.93e-03, 90% CI [1.79e-03, 0.02]	(beta = -8.38, 95% CI [-13.33, -3.42], t(1773) = -3.32, p < .001; Std. beta = -0.31, 95% CI [-0.50, -0.13]	F(1, 1587) = 11.24, p < .001; Eta2 (partial) = 7.03e-03, 90% CI [1.83e-03, 0.02]	beta = -6.80, 95% CI [-11.85, -1.75], t(1764) = -2.64, p < .01; Std. beta = -0.25, 95% CI [-0.44, -0.07]	F(1, 1536) = 11.38, p < .001; Eta2 (partial) = 7.35e-03, 90% CI [1.93e-03, 0.02]	beta = -7.41, 95% CI [-12.56, -2.26], t(1709) = -2.82, p < .01; Std. beta = -0.28, 95% CI [-0.47, -0.08]	F(1, 1534) = 11.42, p < .001; Eta2 (partial) = 7.39e-03, 90% CI [1.95e-03, 0.02]	beta = -7.51, 95% CI [-12.66, -2.37], t(1687) = -2.86, p < .01; Std. beta = -0.28, 95% CI [-0.48, -0.09]	F(1, 1533) = 11.73, p < .001; Eta2 (partial) = 7.59e-03, 90% CI [2.05e-03, 0.02]	beta = -7.44, 95% CI [-12.61, -2.27], t(1706) = -2.82, p < .01; Std. beta = -0.28, 95% CI [-0.47, -0.09]

Outcome	Groups	Full dataset (n=1777)						Sensitivity Checks			
								Excluding non-lipophilic (n=1755)		Excluding small gender groups (n=1772)	
		Uncorrected		Corrected for demographics		Corrected for all covariates		Corrected for all covariates			
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
	Both vs Neither	F(1, 1578) = 3.95, p = 0.047; Eta2 = 2.50e-03, 90% CI [1.73e-05, 8.30e-03]	beta = -5.41, 95% CI [-10.75, -0.06], t(1773) = -1.98, p < .05; Std. beta = -0.20, 95% CI [-0.40, -2.41e-03]	F(1, 1569) = 3.98, p = 0.046; Eta2 (partial) = 2.53e-03, 90% CI [2.27e-05, 8.38e-03]	beta = -3.29, 95% CI [-8.88, 2.29], t(1764) = -1.16, p = 0.247; Std. beta = -0.12, 95% CI [-0.33, 0.09]	F(1, 1521) = 3.32, p = 0.069; Eta2 (partial) = 2.18e-03, 90% CI [0.00, 7.84e-03]	beta = -3.95, 95% CI [-9.64, 1.74], t(1709) = -1.36, p = 0.173; Std. beta = -0.15, 95% CI [-0.36, 0.07]	F(1, 1514) = 4.25, p = 0.039; Eta2 (partial) = 2.80e-03, 90% CI [7.05e-05, 9.00e-03]	beta = -4.68, 95% CI [-10.48, 1.13], t(1687) = -1.58, p = 0.114; Std. beta = -0.18, 95% CI [-0.39, 0.04]	F(1, 1519) = 3.33, p = 0.068; Eta2 (partial) = 2.19e-03, 90% CI [0.00, 7.87e-03]	beta = -3.96, 95% CI [-9.65, 1.73], t(1706) = -1.36, p = 0.172; Std. beta = -0.15, 95% CI [-0.36, 0.06]
Hits – Two back	**All groups**	(F(3, 1773) = 4.33, p = 0.005; Eta2 = 7.27e-03, 90% CI [1.32e-03, 0.01]	N/A	F(3, 1764) = 4.38, p = 0.004; Eta2 (partial) = 7.39e-03, 90% CI [1.37e-03, 0.01]	N/A	F(3, 1709) = 4.28, p = 0.005; Eta2 (partial) = 7.46e-03, 90% CI [1.33e-03, 0.01]	N/A	F(3, 1687) = 5.02, p = 0.002; Eta2 (partial) = 8.85e-03, 90% CI [2.05e-03, 0.02]	N/A	F(3, 1706) = 4.31, p = 0.005; Eta2 (partial) = 7.53e-03, 90% CI [1.36e-03, 0.01]	N/A
	Statin vs Neither	F(1, 1553) = 0.69, p = 0.407; Eta2 = 4.43e-04, 90% CI [0.00, 3.91e-03]	beta = -2.05, 95% CI [-6.87, 2.77], t(1773) = -0.83, p = 0.405; Std. beta = -0.10, 95% CI [-0.33, 0.13]	F(1, 1544) = 0.70, p = 0.404; Eta2 (partial) = 4.50e-04, 90% CI [0.00, 3.97e-03]	beta = 0.14, 95% CI [-4.81, 5.10], t(1764) = 0.06, p = 0.954; Std. beta = 6.88e-03, 95% CI [-0.23, 0.24])	F(1, 1494) = 0.54, p = 0.462; Eta2 (partial) = 3.63e-04, 90% CI [0.00, 3.75e-03]	beta = 0.11, 95% CI [-4.98, 5.20], t(1709) = 0.04, p = 0.966; Std. beta = 5.15e-03, 95% CI [-0.24, 0.25]	F(1, 1477) = 0.10, p = 0.755; Eta2 (partial) = 6.57e-05, 90% CI [0.00, 2.21e-03]	beta = 1.08, 95% CI [-4.57, 6.74], t(1687) = 0.38, p = 0.707; Std. beta = 0.05, 95% CI [-0.22, 0.32]	F(1, 1492) = 0.56, p = 0.455; Eta2 (partial) = 3.74e-04, 90% CI [0.00, 3.79e-03]	beta = 0.10, 95% CI [-4.99, 5.20], t(1706) = 0.04, p = 0.969; Std. beta = 4.84e-03, 95% CI [-0.24, 0.25]
	BP vs Neither	F(1, 1596) = 0.05, p = 0.817; Eta2 = 3.36e-05, 90% CI [0.00, 1.64e-03]	beta = -0.47, 95% CI [-4.38, 3.45], t(1773) = -0.23, p = 0.816; Std. beta = -0.02, 95% CI [-0.21, 0.16]	F(1, 1587) = 0.05, p = 0.816; Eta2 (partial) = 3.42e-05, 90% CI [0.00, 1.67e-03]	beta = 1.08, 95% CI [-2.91, 5.07], t(1764) = 0.53, p = 0.595; Std. beta = 0.05, 95% CI [-0.14, 0.24]	F(1, 1536) = 0.14, p = 0.707; Eta2 (partial) = 9.23e-05, 90% CI [0.00, 2.41e-03]	beta = 0.60, 95% CI [-3.50, 4.69], t(1709) = 0.29, p = 0.775; Std. beta = 0.03, 95% CI [-0.17, 0.22]	F(1, 1534) = 0.14, p = 0.710; Eta2 (partial) = 9.01e-05, 90% CI [0.00, 2.39e-03]	beta = 0.55, 95% CI [-3.55, 4.64], t(1687) = 0.26, p = 0.794; Std. beta = 0.03, 95% CI [-0.17, 0.22]	F(1, 1533) = 0.13, p = 0.719; Eta2 (partial) = 8.43e-05, 90% CI [0.00, 2.34e-03]	beta = 0.61, 95% CI [-3.50, 4.73], t(1706) = 0.29, p = 0.769; Std. beta = 0.03, 95% CI [-0.17, 0.22]
	Both vs Neither	F(1, 1578) = 12.69, p < .001; Eta2 = 7.98e-03, 90% CI [2.32e-03, 0.02]	(beta = -7.63, 95% CI [-11.85, -3.41], t(1773) = -3.55, p < .001; Std. beta = -0.36, 95% CI [-0.56, -0.16]	F(1, 1569) = 12.81, p < .001; Eta2 (partial) = 8.10e-03, 90% CI [2.37e-03, 0.02]	beta = -5.22, 95% CI [-9.63, -0.81], t(1764) = -2.32, p < .05; Std. beta = -0.25, 95% CI [-0.46, -0.04]	F(1, 1521) = 12.65, p < .001; Eta2 (partial) = 8.25e-03, 90% CI [2.39e-03, 0.02]	beta = -6.00, 95% CI [-10.52, -1.48], t(1709) = -2.60, p < .01; Std. beta = -0.28, 95% CI [-0.50, -0.07]	F(1, 1514) = 15.20, p < .001; Eta2 (partial) = 9.94e-03, 90% CI [3.33e-03, 0.02]	beta = -6.97, 95% CI [-11.59, -2.35], t(1687) = -2.96, p < .01; Std. beta = -0.33, 95% CI [-0.55, -0.11]	F(1, 1519) = 12.74, p < .001; Eta2 (partial) = 8.32e-03, 90% CI [2.42e-03, 0.02]	beta = -6.00, 95% CI [-10.53, -1.48], t(1706) = -2.60, p < .01; Std. beta = -0.28, 95% CI [-0.50, -0.07]
Hits – Three back	**All groups**	F(3, 1773) = 0.98, p = 0.401; Eta2 = 1.66e-03, 90% CI [0.00, 4.72e-03]	N/A	F(3, 1764) = 1.00, p = 0.393; Eta2 (partial) = 1.69e-03, 90% CI [0.00, 4.80e-03]	N/A	F(3, 1709) = 1.02, p = 0.381; Eta2 (partial) = 1.79e-03, 90% CI [0.00, 5.05e-03]	N/A	F(3, 1687) = 1.24, p = 0.293; Eta2 (partial) = 2.20e-03, 90% CI [0.00, 5.89e-03]	N/A	F(3, 1706) = 1.01, p = 0.386; Eta2 (partial) = 1.78e-03, 90% CI [0.00, 5.02e-03]	N/A
	Statin vs Neither	F(1, 1553) = 0.70, p = 0.403; Eta2 = 4.50e-04, 90% CI [0.00, 3.93e-03]	beta = 1.93, 95% CI [-2.61, 6.46], t(1773) = 0.83, p = 0.405; Std. beta = 0.10, 95% CI [-0.13, 0.33]	F(1, 1544) = 0.71, p = 0.399; Eta2 (partial) = 4.60e-04, 90% CI [0.00, 3.98e-03]	beta = 4.68, 95% CI [0.03, 9.33], t(1764) = 1.97, p < .05; Std. beta = 0.24, 95% CI [1.49e-03, 0.47]	F(1, 1494) = 1.22, p = 0.270; Eta2 (partial) = 8.14e-04, 90% CI [0.00, 5.05e-03]	beta = 5.34, 95% CI [0.58, 10.10], t(1709) = 2.20, p < .05; Std. beta = 0.27, 95% CI [0.03, 0.51]	F(1, 1477) = 1.08, p = 0.300; Eta2 (partial) = 7.27e-04, 90% CI [0.00, 4.84e-03]	beta = 5.65, 95% CI [0.37, 10.92], t(1687) = 2.10, p < .05; Std. beta = 0.29, 95% CI [0.02, 0.55]	F(1, 1492) = 1.23, p = 0.268; Eta2 (partial) = 8.21e-04, 90% CI [0.00, 5.05e-03]	beta = 5.35, 95% CI [0.58, 10.11], t(1706) = 2.20, p < .05; Std. beta = 0.27, 95% CI [0.03, 0.51]

Outcome	Groups	Full dataset (n=1777)						Sensitivity Checks			
								Excluding non-lipophilic (n=1755)		Excluding small gender groups (n=1772)	
		Uncorrected		Corrected for demographics		Corrected for all covariates		Corrected for all covariates			
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
	BP vs Neither	F(1, 1596) = 0.72, p = 0.396; Eta2 = 4.51e-04, 90% CI [0.00, 3.87e-03]	beta = -1.58, 95% CI [-5.27, 2.10], t(1773) = -0.84, p = 0.399; Std. beta = -0.08, 95% CI [-0.27, 0.11]	F(1, 1587) = 0.73, p = 0.392; Eta2 (partial) = 4.61e-04, 90% CI [0.00, 3.91e-03]	beta = 0.24, 95% CI [-3.50, 3.98], t(1764) = 0.12, p = 0.901; Std. beta = 0.01, 95% CI [-0.18, 0.20]	F(1, 1536) = 0.63, p = 0.428; Eta2 (partial) = 4.09e-04, 90% CI [0.00, 3.83e-03]	beta = 0.37, 95% CI [-3.46, 4.20], t(1709) = 0.19, p = 0.851; Std. beta = 0.02, 95% CI [-0.17, 0.21]	F(1, 1534) = 0.63, p = 0.427; Eta2 (partial) = 4.12e-04, 90% CI [0.00, 3.85e-03]	eta = 0.38, 95% CI [-3.44, 4.21], t(1687) = 0.20, p = 0.844; Std. beta = 0.02, 95% CI [-0.17, 0.21]	F(1, 1533) = 0.60, p = 0.440; Eta2 (partial) = 3.89e-04, 90% CI [0.00, 3.78e-03]	beta = 0.47, 95% CI [-3.37, 4.32], t(1706) = 0.24, p = 0.809; Std. beta = 0.02, 95% CI [-0.17, 0.22]
	Both vs Neither	F(1, 1578) = 1.46, p = 0.227; Eta2 = 9.26e-04, 90% CI [0.00, 5.14e-03]	beta = -2.45, 95% CI [-6.42, 1.52], t(1773) = -1.21, p = 0.227; Std. beta = -0.12, 95% CI [-0.32, 0.08]	F(1, 1569) = 1.49, p = 0.223; Eta2 (partial) = 9.47e-04, 90% CI [0.00, 5.20e-03]	beta = 0.48, 95% CI [-3.65, 4.62], t(1764) = 0.23, p = 0.819; Std. beta = 0.02, 95% CI [-0.18, 0.23]	F(1, 1521) = 1.11, p = 0.293; Eta2 (partial) = 7.28e-04, 90% CI [0.00, 4.76e-03]	beta = 0.58, 95% CI [-3.65, 4.80], t(1709) = 0.27, p = 0.788; Std. beta = 0.03, 95% CI [-0.18, 0.24]	F(1, 1514) = 1.93, p = 0.165; Eta2 (partial) = 1.27e-03, 90% CI [0.00, 6.04e-03]	beta = -0.21, 95% CI [-4.52, 4.10], t(1687) = -0.10, p = 0.924; Std. beta = -0.01, 95% CI [-0.23, 0.21]	F(1, 1519) = 1.10, p = 0.295; Eta2 (partial) = 7.21e-04, 90% CI [0.00, 4.74e-03]	beta = 0.58, 95% CI [-3.65, 4.81], t(1706) = 0.27, p = 0.787; Std. beta = 0.03, 95% CI [-0.18, 0.24]
False alarms - Zero back (control condition)	**All groups**	F(3, 1773) = 2.25, p = 0.081; Eta2 = 3.79e-03, 90% CI [0.00, 8.62e-03]	N/A	F(3, 1764) = 2.28, p = 0.077; Eta2 (partial) = 3.87e-03, 90% CI [0.00, 8.76e-03]	N/A	F(3, 1709) = 2.03, p = 0.108; Eta2 (partial) = 3.55e-03, 90% CI [0.00, 8.29e-03]	N/A	F(3, 1687) = 1.13, p = 0.337; Eta2 (partial) = 2.00e-03, 90% CI [0.00, 5.49e-03]	N/A	F(3, 1706) = 2.02, p = 0.109; Eta2 (partial) = 3.55e-03, 90% CI [0.00, 8.30e-03]	N/A
False alarms – All test conditions	**All groups**	Group: F(3) = 0.10, p = 0.960; Eta2 (partial) = 1.69e-04, 90% CI [0.00, 0.00] Interaction: F(6) = 1.99, p = 0.064; Eta2 (partial) = 3.36e-03, 90% CI [0.00, 5.58e-03]	N/A	Group: F(3) = 0.17, p = 0.920; Eta2 (partial) = 2.82e-04, 90% CI [0.00, 5.96e-04] Interaction: F(6) = 1.99, p = 0.064; Eta2 (partial) = 3.36e-03, 90% CI [0.00, 7.50e-03]	N/A	Group: F(3) = 0.25, p = 0.863; Eta2 (partial) = 4.34e-04, 90% CI [0.00, 1.36e-03] Interaction: F(6) = 1.93, p = 0.073; Eta2 (partial) = 3.33e-03, 90% CI [0.00, 5.55e-03]	N/A	Group: F(3) = 0.47, p = 0.703; Eta2 (partial) = 8.36e-04, 90% CI [0.00, 2.78e-03] Interaction: F(6) = 2.46, p = 0.022; Eta2 (partial) = 4.31e-03, 90% CI [3.18e-04, 7.02e-03]	N/A	Group: F(3) = 0.25, p = 0.862; Eta2 (partial) = 4.38e-04, 90% CI [0.00, 1.38e-03] Interaction: F(6) = 1.89, p = 0.079; Eta2 (partial) = 3.27e-03, 90% CI [0.00, 5.46e-03]	N/A
Correct rejections - Zero back (control condition)	**All groups**	F(3, 1773) = 0.99, p = 0.396; Eta2 = 1.67e-03, 90% CI [0.00, 4.75e-03]	N/A	F(3, 1764) = 1.02, p = 0.384; Eta2 (partial) = 1.73e-03, 90% CI [0.00, 4.87e-03]	N/A	F(3, 1709) = 0.88, p = 0.450; Eta2 (partial) = 1.55e-03, 90% CI [0.00, 4.52e-03]	N/A	F(3, 1687) = 0.68, p = 0.566; Eta2 (partial) = 1.20e-03, 90% CI [0.00, 3.75e-03]	N/A	F(3, 1706) = 0.88, p = 0.453; Eta2 (partial) = 1.54e-03, 90% CI [0.00, 4.51e-03]	N/A
Correct rejections – All test conditions	**All groups**	Group: F(3) = 1.99, p = 0.114; Eta2 (partial) = 3.35e-03, 90% CI [0.00, 7.88e-03] Interaction: F(6) = 0.72, p =	N/A	Group: F(3) = 0.52, p = 0.672; Eta2 (partial) = 8.75e-04, 90% CI [0.00, 2.87e-03] Interaction: F(6) = 0.72, p =	N/A	Group: F(3) = 0.85, p = 0.469; Eta2 (partial) = 1.48e-03, 90% CI [0.00, 4.39e-03] Interaction: F(6) = 0.77, p =	N/A	Group: F(3) = 0.78, p = 0.507; Eta2 (partial) = 1.38e-03, 90% CI [0.00, 4.17e-03] Interaction: F(6) = 0.81, p =	N/A	Group: F(3) = 0.82, p = 0.481; Eta2 (partial) = 1.44e-03, 90% CI [0.00, 4.30e-03] Interaction: F(6) = 0.76, p =	N/A

Outcome	Groups	Full dataset (n=1777)						Sensitivity Checks			
								Excluding non-lipophilic (n=1755)		Excluding small gender groups (n=1772)	
		Uncorrected		Corrected for demographics		Corrected for all covariates		Corrected for all covariates			
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
		0.634; Eta2 (partial) = 1.22e-03, 90% CI [0.00, 1.94e-03]		0.634; Eta2 (partial) = 1.22e-03, 90% CI [0.00, 1.94e-03]		0.593; Eta2 (partial) = 1.34e-03, 90% CI [0.00, 2.99e-03]		0.560; Eta2 (partial) = 1.42e-03, 90% CI [0.00, 2.34e-03]		0.599; Eta2 (partial) = 1.32e-03, 90% CI [0.00, 2.15e-03]	
Misses - Zero back (control condition)	**All groups**	F(3, 1773) = 0.95, p = 0.414; Eta2 = 1.61e-03, 90% CI [0.00, 4.62e-03]	N/A	F(3, 1764) = 0.97, p = 0.405; Eta2 (partial) = 1.65e-03, 90% CI [0.00, 4.71e-03]	N/A	F(3, 1709) = 0.81, p = 0.489; Eta2 (partial) = 1.42e-03, 90% CI [0.00, 4.24e-03]	N/A	F(3, 1687) = 0.85, p = 0.465; Eta2 (partial) = 1.51e-03, 90% CI [0.00, 4.47e-03]	N/A	F(3, 1706) = 0.91, p = 0.437; Eta2 (partial) = 1.59e-03, 90% CI [0.00, 4.53e-03]	N/A
Misses – All test conditions	**All groups**	Group: F(3) = 0.87, p = 0.454; Eta2 (partial) = 1.48e-03, 90% CI [0.00, 4.33e-03] Interaction: F(6) = 4.55, p < .001; Eta2 (partial) = 7.64e-03, 90% CI [2.44e-03, 0.01]	N/A	Group: F(3) = 0.82, p = 0.483; Eta2 (partial) = 1.39e-03, 90% CI [0.00, 4.15e-03] Interaction: F(6) = 4.55, p < .001; Eta2 (partial) = 7.64e-03, 90% CI [2.44e-03, 0.01]	N/A	Group: F(3) = 1.02, p = 0.384; Eta2 (partial) = 1.78e-03, 90% CI [0.00, 5.03e-03] Interaction: F(6) = 4.55, p < .001; Eta2 (partial) = 7.83e-03, 90% CI [2.50e-03, 0.01]	N/A	Group: F(3) = 1.22, p = 0.302; Eta2 (partial) = 2.16e-03, 90% CI [0.00, 5.81e-03] Interaction: F(6) = 4.45, p < .001; Eta2 (partial) = 7.76e-03, 90% CI [2.41e-03, 0.01]	N/A	Group: F(3) = 1.02, p = 0.384; Eta2 (partial) = 1.79e-03, 90% CI [0.00, 5.04e-03] Interaction: F(6) = 4.63, p < .001; Eta2 (partial) = 7.98e-03, 90% CI [2.59e-03, 0.01]	N/A
Misses – One back	**All groups**	F(3, 1773) = 4.10, p = 0.007; Eta2 = 6.89e-03, 90% CI [1.12e-03, 0.01]	N/A	F(3, 1764) = 4.12, p = 0.006; Eta2 (partial) = 6.96e-03, 90% CI [1.15e-03, 0.01]	N/A	F(3, 1709) = 4.40, p = 0.004; Eta2 (partial) = 7.66e-03, 90% CI [1.43e-03, 0.01]	N/A	F(3, 1687) = 4.45, p = 0.004; Eta2 (partial) = 7.85e-03, 90% CI [1.50e-03, 0.01]	N/A	F(3, 1706) = 4.41, p = 0.004; Eta2 (partial) = 7.69e-03, 90% CI [1.44e-03, 0.01]	N/A
	Statin vs Neither	F(1, 1553) = 0.93, p = 0.334; Eta2 = 6.01e-04, 90% CI [0.00, 4.37e-03]	beta = 2.46, 95% CI [-2.57, 7.48], t(1773) = 0.96, p = 0.338; Std. beta = 0.11, 95% CI [-0.12, 0.34]	F(1, 1544) = 0.94, p = 0.333; Eta2 (partial) = 6.08e-04, 90% CI [0.00, 4.40e-03]	beta = 1.15, 95% CI [-4.03, 6.33], t(1764) = 0.43, p = 0.664; Std. beta = 0.05, 95% CI [-0.18, 0.29]	F(1, 1494) = 0.85, p = 0.356; Eta2 (partial) = 5.70e-04, 90% CI [0.00, 4.39e-03]	beta = 1.38, 95% CI [-3.93, 6.69], t(1709) = 0.51, p = 0.611; Std. beta = 0.06, 95% CI [-0.18, 0.30]	F(1, 1477) = 0.02, p = 0.895; Eta2 (partial) = 1.19e-05, 90% CI [0.00, 1.01e-03]	beta = -0.59, 95% CI [-6.46, 5.28], t(1687) = -0.20, p = 0.844; Std. beta = -0.03, 95% CI [-0.29, 0.24]	F(1, 1492) = 0.87, p = 0.351; Eta2 (partial) = 5.82e-04, 90% CI [0.00, 4.42e-03]	beta = 1.37, 95% CI [-3.95, 6.69], t(1706) = 0.51, p = 0.613; Std. beta = 0.06, 95% CI [-0.18, 0.30]
	BP vs Neither	F(1, 1596) = 9.77, p = 0.002; Eta2 = 6.08e-03, 90% CI [1.37e-03, 0.01]	beta = 6.48, 95% CI [2.40, 10.56], t(1773) = 3.12, p < .01; Std. beta = 0.30, 95% CI [0.11, 0.48]	F(1, 1587) = 9.82, p = 0.002; Eta2 (partial) = 6.15e-03, 90% CI [1.39e-03, 0.01]	beta = 5.56, 95% CI [1.39, 9.73], t(1764) = 2.61, p < .01; Std. beta = 0.25, 95% CI [0.06, 0.44]	F(1, 1536) = 10.62, p = 0.001; Eta2 (partial) = 6.87e-03, 90% CI [1.69e-03, 0.02]	beta = 6.04, 95% CI [1.77, 10.32], t(1709) = 2.77, p < .01; Std. beta = 0.27, 95% CI [0.08, 0.47]	F(1, 1534) = 10.77, p = 0.001; Eta2 (partial) = 6.97e-03, 90% CI [1.74e-03, 0.02]	beta = 6.14, 95% CI [1.88, 10.39], t(1687) = 2.83, p < .01; Std. beta = 0.28, 95% CI [0.09, 0.47]	F(1, 1533) = 10.61, p = 0.001; Eta2 (partial) = 6.87e-03, 90% CI [1.69e-03, 0.02]	beta = 5.98, 95% CI [1.69, 10.28], t(1706) = 2.73, p < .01; Std. beta = 0.27, 95% CI [0.08, 0.47]
	Both vs Neither	F(1, 1578) = 2.84, p = 0.092; Eta2 = 1.80e-03, 90% CI [0.00, 6.98e-03]	beta = 3.74, 95% CI [-0.66, 8.14], t(1773) = 1.67, p = 0.096; Std. beta = 0.17, 95% CI [-0.03, 0.37]	(F(1, 1569) = 2.85, p = 0.091; Eta2 (partial) = 1.82e-03, 90% CI [0.00, 7.04e-03]	beta = 2.63, 95% CI [-1.98, 7.24], t(1764) = 1.12, p = 0.263; Std. beta = 0.12, 95% CI [-0.09, 0.33]	F(1, 1521) = 3.01, p = 0.083; Eta2 (partial) = 1.98e-03, 90% CI [0.00, 7.46e-03]	beta = 3.46, 95% CI [-1.25, 8.18], t(1709) = 1.44, p = 0.150; Std. beta = 0.16, 95% CI [-0.06, 0.37]	F(1, 1514) = 3.37, p = 0.066; Eta2 (partial) = 2.22e-03, 90% CI [0.00, 7.95e-03]	beta = 3.77, 95% CI [-1.03, 8.57], t(1687) = 1.54, p = 0.123; Std. beta = 0.17, 95% CI [-0.05, 0.39]	F(1, 1519) = 3.05, p = 0.081; Eta2 (partial) = 2.00e-03, 90% CI [0.00, 7.51e-03]	beta = 3.46, 95% CI [-1.26, 8.18], t(1706) = 1.44, p = 0.150; Std. beta = 0.16, 95% CI [-0.06, 0.37]

Outcome	Groups	Full dataset (n=1777)						Sensitivity Checks			
								Excluding non-lipophilic (n=1755)		Excluding small gender groups (n=1772)	
		Uncorrected		Corrected for demographics		Corrected for all covariates		Corrected for all covariates			
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
Misses – Two back	**All groups**	F(3, 1773) = 2.43, p = 0.064; Eta2 = 4.09e-03, 90% CI [0.00, 9.11e-03]	N/A	F(3, 1764) = 2.43, p = 0.063; Eta2 (partial) = 4.12e-03, 90% CI [0.00, 9.18e-03]	N/A	(F(3, 1709) = 2.56, p = 0.053; Eta2 (partial) = 4.48e-03, 90% CI [0.00, 9.83e-03]	N/A	F(3, 1687) = 2.86, p = 0.036; Eta2 (partial) = 5.06e-03, 90% CI [1.74e-04, 0.01]	N/A	F(3, 1706) = 2.63, p = 0.048; Eta2 (partial) = 4.61e-03, 90% CI [1.56e-05, 0.01]	N/A
	Statin vs Neither	F(1, 1553) = 0.02, p = 0.881; Eta2 = 1.44e-05, 90% CI [0.00, 1.12e-03]	beta = 0.44, 95% CI [-5.38, 6.26], t(1773) = 0.15, p = 0.882; Std. beta = 0.02, 95% CI [-0.21, 0.25]	F(1, 1544) = 0.02, p = 0.881; Eta2 (partial) = 1.46e-05, 90% CI [0.00, 1.17e-03]	beta = 1.34, 95% CI [-4.66, 7.35], t(1764) = 0.44, p = 0.661; Std. beta = 0.05, 95% CI [-0.18, 0.29]	F(1, 1494) = 0.17, p = 0.684; Eta2 (partial) = 1.11e-04, 90% CI [0.00, 2.60e-03]	beta = 1.75, 95% CI [-4.37, 7.88], t(1709) = 0.56, p = 0.575; Std. beta = 0.07, 95% CI [-0.17, 0.31]	F(1, 1477) = 0.18, p = 0.672; Eta2 (partial) = 1.21e-04, 90% CI [0.00, 2.72e-04]	beta = 2.14, 95% CI [-4.66, 8.94], t(1687) = 0.62, p = 0.537; Std. beta = 0.08, 95% CI [-0.18, 0.35]	F(1, 1492) = 0.18, p = 0.669; Eta2 (partial) = 1.22e-04, 90% CI [0.00, 2.68e-03]	beta = 1.77, 95% CI [-4.36, 7.90], t(1706) = 0.57, p = 0.571; Std. beta = 0.07, 95% CI [-0.17, 0.31]
	BP vs Neither	F(1, 1596) = 1.78, p = 0.183; Eta2 = 1.11e-03, 90% CI [0.00, 5.53e-03]	beta = -3.20, 95% CI [-7.93, 1.52], t(1773) = -1.33, p = 0.184; Std. beta = -0.13, 95% CI [-0.31, 0.06]	F(1, 1587) = 1.78, p = 0.182; Eta2 (partial) = 1.12e-03, 90% CI [0.00, 5.56e-03]	beta = -2.56, 95% CI [-7.40, 2.27], t(1764) = -1.04, p = 0.298; Std. beta = -0.10, 95% CI [-0.29, 0.09]	F(1, 1536) = 1.56, p = 0.212; Eta2 (partial) = 1.01e-03, 90% CI [0.00, 5.42e-03]	beta = -2.68, 95% CI [-7.61, 2.25], t(1709) = -1.07, p = 0.287; Std. beta = -0.11, 95% CI [-0.30, 0.09]	F(1, 1534) = 1.56, p = 0.212; Eta2 (partial) = 1.01e-03, 90% CI [0.00, 5.42e-03]	beta = -2.68, 95% CI [-7.60, 2.25], t(1687) = -1.07, p = 0.287; Std. beta = -0.11, 95% CI [-0.30, 0.09]	F(1, 1533) = 1.64, p = 0.201; Eta2 (partial) = 1.07e-03, 90% CI [0.00, 5.55e-03]	beta = -2.63, 95% CI [-7.58, 2.32], t(1706) = -1.04, p = 0.298; Std. beta = -0.10, 95% CI [-0.30, 0.09]
	Both vs Neither	F(1, 1578) = 5.15, p = 0.023; Eta2 = 3.25e-03, 90% CI [2.30e-04, 9.62e-03]	beta = 5.84, 95% CI [0.74, 10.93], t(1773) = 2.25, p < .05; Std. beta = 0.23, 95% CI [0.03, 0.43]	F(1, 1569) = 5.17, p = 0.023; Eta2 (partial) = 3.29e-03, 90% CI [2.35e-04, 9.70e-03]	beta = 6.96, 95% CI [1.62, 12.30], t(1764) = 2.55, p < .05; Std. beta = 0.27, 95% CI [0.06, 0.48]	F(1, 1521) = 5.67, p = 0.017; Eta2 (partial) = 3.72e-03, 90% CI [3.46e-04, 0.01]	beta = 7.25, 95% CI [1.81, 12.69], t(1709) = 2.62, p < .01; Std. beta = 0.29, 95% CI [0.07, 0.50]	F(1, 1514) = 6.53, p = 0.011; Eta2 (partial) = 4.30e-03, 90% CI [5.42e-04, 0.01]	beta = 7.91, 95% CI [2.35, 13.46], t(1687) = 2.79, p < .01; Std. beta = 0.31, 95% CI [0.09, 0.53]	F(1, 1519) = 5.78, p = 0.016; Eta2 (partial) = 3.79e-03, 90% CI [3.70e-04, 0.01]	beta = 7.26, 95% CI [1.82, 12.70], t(1706) = 2.62, p < .01; Std. beta = 0.29, 95% CI [0.07, 0.50]
Misses – Three back	**All groups**	F(3, 1773) = 0.22, p = 0.879; Eta2 = 3.80e-04, 90% CI [0.00, 1.14e-03]	N/A	F(3, 1764) = 0.22, p = 0.880; Eta2 (partial) = 3.81e-04, 90% CI [0.00, 8.54e-04]	N/A	F(3, 1709) = 0.16, p = 0.925; Eta2 (partial) = 2.77e-04, 90% CI [0.00, 5.28e-04]	N/A	F(3, 1687) = 0.11, p = 0.953; Eta2 (partial) = 2.00e-04, 90% CI [0.00, 0.00]	N/A	F(3, 1706) = 0.17, p = 0.918; Eta2 (partial) = 2.95e-04, 90% CI [0.00, 6.41e-04]	N/A
	Statin vs Neither	F(1, 1553) = 0.54, p = 0.462; Eta2 = 3.49e-04, 90% CI [0.00, 3.61e-03]	beta = -2.21, 95% CI [-8.17, 3.75], t(1773) = -0.73, p = 0.467; Std. beta = -0.09, 95% CI [-0.31, 0.14]	F(1, 1544) = 0.54, p = 0.463; Eta2 (partial) = 3.49e-04, 90% CI [0.00, 3.63e-03]	beta = -2.17, 95% CI [-8.34, 4.00], t(1764) = -0.69, p = 0.490; Std. beta = -0.08, 95% CI [-0.32, 0.15]	F(1, 1494) = 0.23, p = 0.630; Eta2 (partial) = 1.56e-04, 90% CI [0.00, 2.88e-03]	beta = -1.76, 95% CI [-8.04, 4.52], t(1709) = -0.55, p = 0.582; Std. beta = -0.07, 95% CI [-0.31, 0.17]	F(1, 1477) = 0.01, p = 0.917; Eta2 (partial) = 7.41e-06, 90% CI [0.00, 6.93e-04]	beta = -0.73, 95% CI [-7.71, 6.25], t(1687) = -0.21, p = 0.837; Std. beta = -0.03, 95% CI [-0.30, 0.24]	F(1, 1492) = 0.23, p = 0.634; Eta2 (partial) = 1.52e-04, 90% CI [0.00, 2.86e-03]	beta = -1.76, 95% CI [-8.05, 4.52], t(1706) = -0.55, p = 0.582; Std. beta = -0.07, 95% CI [-0.31, 0.17]
	BP vs Neither	F(1, 1596) = 0.15, p = 0.695; Eta2 = 9.63e-05, 90% CI [0.00, 2.38e-03]	beta = -0.96, 95% CI [-5.80, 3.88], t(1773) = -0.39, p = 0.697; Std. beta = -0.04, 95% CI [-0.22, 0.15]	F(1, 1587) = 0.15, p = 0.696; Eta2 (partial) = 9.64e-05, 90% CI [0.00, 2.16e-04]	beta = -0.85, 95% CI [-5.82, 4.11], t(1764) = -0.34, p = 0.735; Std. beta = -0.03, 95% CI [-0.22, 0.16]	F(1, 1536) = 0.19, p = 0.659; Eta2 (partial) = 1.27e-04, 90% CI [0.00, 2.66e-03]	beta = -1.15, 95% CI [-6.21, 3.90], t(1709) = -0.45, p = 0.654; Std. beta = -0.04, 95% CI [-0.24, 0.15]	F(1, 1534) = 0.19, p = 0.662; Eta2 (partial) = 1.25e-04, 90% CI [0.00, 2.65e-03]	beta = -1.21, 95% CI [-6.27, 3.85], t(1687) = -0.47, p = 0.639; Std. beta = -0.05, 95% CI [-0.24, 0.15]	F(1, 1533) = 0.23, p = 0.633; Eta2 (partial) = 1.49e-04, 90% CI [0.00, 2.79e-03]	beta = -1.20, 95% CI [-6.28, 3.87], t(1706) = -0.47, p = 0.642; Std. beta = -0.05, 95% CI [-0.24, 0.15]
	Both vs Neither	F(1, 1578) = 8.61e-03, p =	beta = 0.24, 95% CI [-4.97, 5.46],	F(1, 1569) = 8.58e-03, p =	beta = 0.47, 95% CI [-5.02, 5.96],	F(1, 1521) = 0.05, p = 0.823;	beta = 0.81, 95% CI [-4.77, 6.38],	F(1, 1514) = 0.12, p = 0.731;	beta = 1.17, 95% CI [-4.53, 6.88],	F(1, 1519) = 0.05, p = 0.818;	beta = 0.81, 95% CI [-4.77, 6.39],

Outcome	Groups	Full dataset (n=1777)						Sensitivity Checks			
								Excluding non-lipophilic (n=1755)		Excluding small gender groups (n=1772)	
		Uncorrected		Corrected for demographics		Corrected for all covariates		Corrected for all covariates			
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
		0.926; Eta2 = 5.45e-06, 90% CI [0.00, 4.96e-04]	t(1773) = 0.09, p = 0.927; Std. beta = 9.43e-03, 95% CI [-0.19, 0.21]	0.926; Eta2 (partial) = 5.47e-06, 90% CI [0.00, 4.93e-04]	t(1764) = 0.17, p = 0.867; Std. beta = 0.02, 95% CI [-0.19, 0.23]	Eta2 (partial) = 3.28e-05, 90% CI [0.00, 1.68e-03]	t(1709) = 0.28, p = 0.777; Std. beta = 0.03, 95% CI [-0.18, 0.25]	Eta2 (partial) = 7.84e-05, 90% CI [0.00, 2.35e-03]	t(1687) = 0.40, p = 0.687; Std. beta = 0.05, 95% CI [-0.17, 0.26]	Eta2 (partial) = 3.50e-05, 90% CI [0.00, 1.73e-03]	t(1706) = 0.28, p = 0.776; Std. beta = 0.03, 95% CI [-0.18, 0.25]
D-prime	**All groups**	F(3, 1773) = 1.60, p = 0.189; Eta2 = 2.69e-03, 90% CI [0.00, 6.72e-03]	N/A	F(3, 1764) = 1.60, p = 0.187; Eta2 (partial) = 2.72e-03, 90% CI [0.00, 6.78e-03]	N/A	F(3, 1709) = 1.56, p = 0.197; Eta2 (partial) = 2.73e-03, 90% CI [0.00, 6.86e-03]	N/A	F(3, 1687) = 1.54, p = 0.202; Eta2 (partial) = 2.73e-03, 90% CI [0.00, 6.89e-03]	N/A	F(3, 1706) = 1.55, p = 0.200; Eta2 (partial) = 2.72e-03, 90% CI [0.00, 6.84e-03]	N/A
	Statin vs Neither	F(1, 1553) = 0.01, p = 0.917; Eta2 = 7.00e-06, 90% CI [0.00, 6.53e-04]	beta = 9.71e-03, 95% CI [-0.17, 0.19], t(1773) = 0.10, p = 0.917; Std. beta = 0.01, 95% CI [-0.22, 0.24]	F(1, 1544) = 0.01, p = 0.917; Eta2 (partial) = 7.08e-06, 90% CI [0.00, 6.62e-04]	beta = 0.07, 95% CI [-0.11, 0.26], t(1764) = 0.76, p = 0.445; Std. beta = 0.09, 95% CI [-0.14, 0.33]	F(1, 1494) = 1.47e-05, p = 0.997; Eta2 (partial) = 9.83e-09, 90% CI [0.00, 0.00]	beta = 0.07, 95% CI [-0.12, 0.26], t(1709) = 0.74, p = 0.461; Std. beta = 0.09, 95% CI [-0.15, 0.33]	F(1, 1477) = 0.02, p = 0.888; Eta2 (partial) = 1.33e-05, 90% CI [0.00, 1.09e-03]	beta = 0.05, 95% CI [-0.16, 0.27], t(1687) = 0.49, p = 0.622; Std. beta = 0.07, 95% CI [-0.20, 0.34]	F(1, 1492) = 4.47e-05, p = 0.995; Eta2 (partial) = 3.00e-08, 90% CI [0.00, 0.00]	beta = 0.07, 95% CI [-0.12, 0.26], t(1706) = 0.74, p = 0.458; Std. beta = 0.09, 95% CI [-0.15, 0.33]
	BP vs Neither	F(1, 1596) = 0.39, p = 0.531; Eta2 = 2.46e-04, 90% CI [0.00, 5.51e-04]	beta = -0.05, 95% CI [-0.20, 0.10], t(1773) = -0.63, p = 0.528; Std. beta = -0.06, 95% CI [-0.25, 0.13]	F(1, 1587) = 0.39, p = 0.530; Eta2 (partial) = 2.48e-04, 90% CI [0.00, 3.15e-03])	beta = -4.28e-03, 95% CI [-0.16, 0.15], t(1764) = -0.06, p = 0.956; Std. beta = -5.39e-03, 95% CI [-0.20, 0.18]	F(1, 1536) = 0.52, p = 0.470; Eta2 (partial) = 3.40e-04, 90% CI [0.00, 3.61e-03]	beta = -7.36e-03, 95% CI [-0.16, 0.15], t(1709) = -0.09, p = 0.925; Std. beta = -9.30e-03, 95% CI [-0.20, 0.19]	F(1, 1534) = 0.54, p = 0.462; Eta2 (partial) = 3.53e-04, 90% CI [0.00, 3.65e-03]	beta = -7.79e-03, 95% CI [-0.16, 0.15], t(1687) = -0.10, p = 0.921; Std. beta = -9.85e-03, 95% CI [-0.20, 0.18]	F(1, 1533) = 0.44, p = 0.509; Eta2 (partial) = 2.84e-04, 90% CI [0.00, 3.41e-03]	beta = -3.16e-03, 95% CI [-0.16, 0.15], t(1706) = -0.04, p = 0.968; Std. beta = -4.00e-03, 95% CI [-0.20, 0.19]
	Both vs Neither	F(1, 1578) = 4.55, p = 0.033; Eta2 = 2.88e-03, 90% CI [1.20e-04, 8.97e-03]	beta = -0.17, 95% CI [-0.33, -0.01], t(1773) = -2.12, p < .05; Std. beta = -0.22, 95% CI [-0.42, -0.02]	F(1, 1569) = 4.59, p = 0.032; Eta2 (partial) = 2.91e-03, 90% CI [1.27e-04, 9.06e-03]	beta = -0.11, 95% CI [-0.28, 0.05], t(1764) = -1.34, p = 0.181; Std. beta = -0.14, 95% CI [-0.35, 0.07]	F(1, 1521) = 4.40, p = 0.036; Eta2 (partial) = 2.88e-03, 90% CI [9.61e-05, 9.12e-03]	beta = -0.11, 95% CI [-0.28, 0.06], t(1709) = -1.30, p = 0.195; Std. beta = -0.14, 95% CI [-0.36, 0.07]	F(1, 1514) = 4.33, p = 0.038; Eta2 (partial) = 2.85e-03, 90% CI [8.49e-05, 9.09e-03]	beta = -0.12, 95% CI [-0.29, 0.06], t(1687) = -1.31, p = 0.191; Std. beta = -0.15, 95% CI [-0.37, 0.07]	F(1, 1519) = 4.44, p = 0.035; Eta2 (partial) = 2.92e-03, 90% CI [1.05e-04, 9.19e-03]	beta = -0.11, 95% CI [-0.28, 0.06], t(1706) = -1.30, p = 0.195; Std. beta = -0.14, 95% CI [-0.36, 0.07]
Beta	**All groups**	F(3, 1773) = 0.93, p = 0.427; Eta2 = 1.56e-03, 90% CI [0.00, 4.52e-03]	N/A	F(3, 1764) = 0.93, p = 0.428; Eta2 (partial) = 1.57e-03, 90% CI [0.00, 4.54e-03]	N/A	F(3, 1709) = 1.21, p = 0.306; Eta2 (partial) = 2.11e-03, 90% CI [0.00, 5.70e-03]	N/A	F(3, 1687) = 1.50, p = 0.214; Eta2 (partial) = 2.65e-03, 90% CI [0.00, 6.74e-03]	N/A	F(3, 1706) = 1.18, p = 0.315; Eta2 (partial) = 2.07e-03, 90% CI [0.00, 5.61e-03]	N/A
	Statin vs Neither	F(1, 1553) = 0.54, p = 0.462; Eta2 = 3.48e-04, 90% CI [0.00, 3.61e-03]	beta = -0.11, 95% CI [-0.38, 0.17], t(1773) = -0.76, p = 0.448; Std. beta = -0.09, 95% CI [-0.32, 0.14]	F(1, 1544) = 0.54, p = 0.462; Eta2 (partial) = 3.50e-04, 90% CI [0.00, 3.63e-03]	beta = -0.09, 95% CI [-0.37, 0.20], t(1764) = -0.60, p = 0.550; Std. beta = -0.07, 95% CI [-0.31, 0.16]	F(1, 1494) = 0.74, p = 0.390; Eta2 (partial) = 4.95e-04, 90% CI [0.00, 4.17e-03]	beta = -0.08, 95% CI [-0.37, 0.20], t(1709) = -0.57, p = 0.566; Std. beta = -0.07, 95% CI [-0.31, 0.17]	F(1, 1477) = 1.64, p = 0.201; Eta2 (partial) = 1.11e-03, 90% CI [0.00, 5.75e-03]	beta = -0.17, 95% CI [-0.49, 0.15], t(1687) = -1.02, p = 0.309; Std. beta = -0.14, 95% CI [-0.41, 0.13]	F(1, 1492) = 0.75, p = 0.387; Eta2 (partial) = 5.02e-04, 90% CI [0.00, 4.20e-03]	beta = -0.08, 95% CI [-0.37, 0.20], t(1706) = -0.57, p = 0.568; Std. beta = -0.07, 95% CI [-0.31, 0.17]

Outcome	Groups	Full dataset (n=1777)						Sensitivity Checks			
								Excluding non-lipophilic (n=1755)		Excluding small gender groups (n=1772)	
		Uncorrected		Corrected for demographics		Corrected for all covariates		Corrected for all covariates			
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
	BP vs Neither	F(1, 1596) = 2.13, p = 0.145; Eta2 = 1.33e-03, 90% CI [0.00, 6.00e-03]	beta = -0.17, 95% CI [-0.39, 0.05], t(1773) = -1.50, p = 0.135; Std. beta = -0.14, 95% CI [-0.33, 0.04]	F(1, 1587) = 2.13, p = 0.145; Eta2 (partial) = 1.34e-03, 90% CI [0.00, 6.03e-03]	beta = -0.13, 95% CI [-0.36, 0.10], t(1764) = -1.14, p = 0.255; Std. beta = -0.11, 95% CI [-0.30, 0.08]	F(1, 1536) = 2.80, p = 0.094; Eta2 (partial) = 1.82e-03, 90% CI [0.00, 7.12e-03]	beta = -0.14, 95% CI [-0.37, 0.10], t(1709) = -1.15, p = 0.252; Std. beta = -0.11, 95% CI [-0.31, 0.08]	F(1, 1534) = 2.81, p = 0.094; Eta2 (partial) = 1.83e-03, 90% CI [0.00, 7.14e-03]	beta = -0.13, 95% CI [-0.36, 0.10], t(1687) = -1.12, p = 0.262; Std. beta = -0.11, 95% CI [-0.31, 0.08]	F(1, 1533) = 2.71, p = 0.100; Eta2 (partial) = 1.77e-03, 90% CI [0.00, 7.02e-03]	beta = -0.13, 95% CI [-0.37, 0.10], t(1706) = -1.13, p = 0.259; Std. beta = -0.11, 95% CI [-0.31, 0.08]
	Both vs Neither	F(1, 1578) = 0.18, p = 0.670; Eta2 = 1.15e-04, 90% CI [0.00, 2.53e-03]	beta = -0.05, 95% CI [-0.29, 0.19], t(1773) = -0.44, p = 0.662; Std. beta = -0.04, 95% CI [-0.25, 0.16]	F(1, 1569) = 0.18, p = 0.670; Eta2 (partial) = 1.16e-04, 90% CI [0.00, 2.55e-03]	beta = -0.03, 95% CI [-0.28, 0.22], t(1764) = -0.24, p = 0.813; Std. beta = -0.03, 95% CI [-0.24, 0.19]	F(1, 1521) = 0.13, p = 0.714; Eta2 (partial) = 8.81e-05, 90% CI [0.00, 2.39e-03]	beta = -2.95e-03, 95% CI [-0.26, 0.25], t(1709) = -0.02, p = 0.982; Std. beta = -2.47e-03, 95% CI [-0.22, 0.21]	F(1, 1514) = 0.01, p = 0.910; Eta2 (partial) = 8.43e-06, 90% CI [0.00, 1.89e-05]	beta = 0.04, 95% CI [-0.22, 0.30], t(1687) = 0.28, p = 0.779; Std. beta = 0.03, 95% CI [-0.19, 0.25]	F(1, 1519) = 0.14, p = 0.709; Eta2 (partial) = 9.14e-05, 90% CI [0.00, 2.42e-03]	beta = -2.76e-03, 95% CI [-0.26, 0.25], t(1706) = -0.02, p = 0.983; Std. beta = -2.32e-03, 95% CI [-0.22, 0.21]
RT – All test conditions	**All groups**	Group: F(3) = 5.39, p = 0.001; Eta2 (partial) = 9.03e-03, 90% CI [2.30e-03, 0.02] Interaction: F(9) = 1.18, p = 0.304; Eta2 (partial) = 1.99e-03, 90% CI [0.00, 2.63e-03]	N/A	Group: F(3) = 0.08, p = 0.971; Eta2 (partial) = 1.35e-04, 90% CI [0.00, 0.00] Interaction: F(9) = 1.18, p = 0.304; Eta2 (partial) = 1.99e-03, 90% CI [0.00, 3.87e-03]	N/A	Group: F(3) = 0.23, p = 0.875; Eta2 (partial) = 4.06e-04, 90% CI [0.00, 1.24e-03] Interaction: F(9) = 1.00, p = 0.434; Eta2 (partial) = 1.74e-03, 90% CI [0.00, 2.20e-03]	N/A	Group: F(3) = 0.30, p = 0.827; Eta2 (partial) = 5.30e-04, 90% CI [0.00, 1.19e-03] Interaction: F(9) = 0.96, p = 0.473; Eta2 (partial) = 1.68e-03, 90% CI [0.00, 2.09e-03]	N/A	Group: F(3) = 0.24, p = 0.868; Eta2 (partial) = 4.22e-04, 90% CI [0.00, 1.31e-03] Interaction: F(9) = 1.03, p = 0.415; Eta2 (partial) = 1.78e-03, 90% CI [0.00, 2.28e-03]	N/A

Predicting long-term outcomes

Outcome	Predictor	Full dataset			Sensitivity Checks	
					Excluding non-lipophilic	Excluding small gender groups
		Uncorrected	Corrected for demographics	Corrected for all covariates	Corrected for all covariates	
Total CESD – T2	**Statin vs Neither**	beta = -3.95, 95% CI [-6.75, -1.15], t(1919) = -2.77, p < .01; Std. beta = -0.32, 95% CI [-0.55, -0.09]	beta = 0.46, 95% CI [-2.27, 3.19], t(1910) = 0.33, p = 0.741; Std. beta = 0.04, 95% CI [-0.18, 0.26]	beta = 0.42, 95% CI [-1.11, 1.94], t(1893) = 0.54, p = 0.592; Std. beta = 0.03, 95% CI [-0.09, 0.16]	beta = -0.41, 95% CI [-2.09, 1.27], t(1871) = -0.48, p = 0.634; Std. beta = -0.03, 95% CI [-0.17, 0.10]	beta = 0.42, 95% CI [-1.11, 1.94], t(1890) = 0.54, p = 0.593; Std. beta = 0.03, 95% CI [-0.09, 0.16]
	BP vs Neither	beta = -1.70, 95% CI [-3.99, 0.58], t(1919) = -1.46, p = 0.144; Std. beta = -0.14, 95% CI [-0.33, 0.05]	beta = 1.36, 95% CI [-0.86, 3.58], t(1910) = 1.20, p = 0.231; Std. beta = 0.11, 95% CI [-0.07, 0.29]	beta = 0.04, 95% CI [-1.19, 1.28], t(1893) = 0.07, p = 0.943; Std. beta = 3.66e-03, 95% CI [-0.10, 0.10]	beta = 0.04, 95% CI [-1.19, 1.27], t(1871) = 0.07, p = 0.945; Std. beta = 3.51e-03, 95% CI [-0.10, 0.10]	beta = 0.03, 95% CI [-1.21, 1.27], t(1890) = 0.05, p = 0.963; Std. beta = 2.38e-03, 95% CI [-0.10, 0.10]
	Both vs Neither	beta = -2.04, 95% CI [-4.44, 0.35], t(1919) = -1.67, p = 0.095; Std. beta = -0.17, 95% CI [-0.36, 0.03]	beta = 2.85, 95% CI [0.47, 5.24], t(1910) = 2.35, p < .05; Std. beta = 0.23, 95% CI [0.04, 0.43]	beta = 0.54, 95% CI [-0.79, 1.88], t(1893) = 0.80, p = 0.425; Std. beta = 0.04, 95% CI [-0.06, 0.15]	beta = 0.57, 95% CI [-0.79, 1.94], t(1871) = 0.83, p = 0.409; Std. beta = 0.05, 95% CI [-0.06, 0.16]	beta = 0.55, 95% CI [-0.79, 1.88], t(1890) = 0.80, p = 0.425; Std. beta = 0.04, 95% CI [-0.06, 0.15]
	UBHR – angry faces	beta = 3.93, 95% CI [-0.20, 8.06], t(1894) = 1.87, p = 0.062; Std. beta = 0.04, 95% CI [-2.25e-03, 0.09]	beta = 0.65, 95% CI [-3.31, 4.60], t(1885) = 0.32, p = 0.749; Std. beta = 7.24e-03, 95% CI [-0.04, 0.05]	beta = 0.39, 95% CI [-1.80, 2.59], t(1868) = 0.35, p = 0.727; Std. beta = 4.37e-03, 95% CI [-0.02, 0.03]	beta = 0.42, 95% CI [-1.79, 2.63], t(1846) = 0.37, p = 0.710; Std. beta = 4.67e-03, 95% CI [-0.02, 0.03]	beta = 0.39, 95% CI [-1.81, 2.59], t(1865) = 0.35, p = 0.728; Std. beta = 4.37e-03, 95% CI [-0.02, 0.03]
	UBHR – fearful faces	beta = 3.47, 95% CI [-0.30, 7.25], t(1894) = 1.80, p = 0.072; Std. beta = 0.04, 95% CI [-3.74e-03, 0.09]	beta = 2.68, 95% CI [-0.92, 6.27], t(1885) = 1.46, p = 0.144; Std. beta = 0.03, 95% CI [-0.01, 0.08]	beta = 1.07, 95% CI [-0.92, 3.06], t(1868) = 1.05, p = 0.293; Std. beta = 0.01, 95% CI [-0.01, 0.04]	beta = 1.01, 95% CI [-1.01, 3.02], t(1846) = 0.98, p = 0.328; Std. beta = 0.01, 95% CI [-0.01, 0.04]	beta = 1.10, 95% CI [-0.90, 3.09], t(1865) = 1.08, p = 0.280; Std. beta = 0.01, 95% CI [-0.01, 0.04]
Total CESD – T3	**Statin vs Neither**	beta = -2.90, 95% CI [-5.83, 0.02], t(1827) = -1.94, p = 0.052; Std. beta = -0.23, 95% CI [-0.46, 1.94e-03]	beta = 1.45, 95% CI [-1.43, 4.32], t(1818) = 0.99, p = 0.325; Std. beta = 0.11, 95% CI [-0.11, 0.34]	beta = 1.01, 95% CI [-0.82, 2.85], t(1762) = 1.08, p = 0.280; Std. beta = 0.08, 95% CI [-0.07, 0.23]	beta = 0.87, 95% CI [-1.19, 2.93], t(1740) = 0.83, p = 0.407; Std. beta = 0.07, 95% CI [-0.09, 0.23]	beta = 1.02, 95% CI [-0.82, 2.86], t(1759) = 1.09, p = 0.275; Std. beta = 0.08, 95% CI [-0.07, 0.23]
	BP vs Neither	beta = -0.69, 95% CI [-3.04, 1.65], t(1827) = -0.58, p = 0.563; Std. beta = -0.05, 95% CI [-0.24, 0.13]	beta = 2.14, 95% CI [-0.15, 4.42], t(1818) = 1.83, p = 0.067; Std. beta = 0.17, 95% CI [-0.01, 0.35]	beta = 0.36, 95% CI [-1.10, 1.82], t(1762) = 0.48, p = 0.631; Std. beta = 0.03, 95% CI [-0.09, 0.15]	beta = 0.37, 95% CI [-1.10, 1.84], t(1740) = 0.50, p = 0.620; Std. beta = 0.03, 95% CI [-0.09, 0.15]	beta = 0.40, 95% CI [-1.07, 1.87], t(1759) = 0.54, p = 0.590; Std. beta = 0.03, 95% CI [-0.08, 0.15]
	Both vs Neither	beta = -1.83, 95% CI [-4.31, 0.66], t(1827) = -1.44, p = 0.149; Std. beta = -0.14, 95% CI [-0.34, 0.05]	beta = 2.76, 95% CI [0.28, 5.25], t(1818) = 2.18, p < .05; Std. beta = 0.22, 95% CI [0.02, 0.42]	beta = 0.36, 95% CI [-1.22, 1.95], t(1762) = 0.45, p = 0.652; Std. beta = 0.03, 95% CI [-0.10, 0.16]	beta = 0.30, 95% CI [-1.32, 1.92], t(1740) = 0.36, p = 0.719; Std. beta = 0.02, 95% CI [-0.11, 0.15]	beta = 0.38, 95% CI [-1.21, 1.96], t(1759) = 0.47, p = 0.640; Std. beta = 0.03, 95% CI [-0.10, 0.16]
	UBHR – angry faces	beta = 5.01, 95% CI [0.70, 9.32], t(1802) = 2.28, p < .05; Std. beta = 0.06, 95% CI [7.74e-03, 0.10]	beta = 1.96, 95% CI [-2.20, 6.12], t(1793) = 0.92, p = 0.356; Std. beta = 0.02, 95% CI [-0.02, 0.07]	beta = 1.52, 95% CI [-1.13, 4.16], t(1740) = 1.13, p = 0.261; Std. beta = 0.02, 95% CI [-0.01, 0.05]	beta = 1.70, 95% CI [-0.97, 4.37], t(1718) = 1.25, p = 0.211; Std. beta = 0.02, 95% CI [-0.01, 0.05]	beta = 1.48, 95% CI [-1.16, 4.13], t(1737) = 1.10, p = 0.271; Std. beta = 0.02, 95% CI [-0.01, 0.05]
	UBHR – fearful faces	beta = 0.90, 95% CI [-3.11, 4.92], t(1802) = 0.44, p = 0.659; Std. beta = 0.01, 95% CI [-0.04, 0.06]	beta = 0.12, 95% CI [-3.74, 3.97], t(1793) = 0.06, p = 0.952; Std. beta = 1.40e-03, 95% CI [-0.04, 0.05]	beta = -0.57, 95% CI [-3.00, 1.87], t(1740) = -0.46, p = 0.649; Std. beta = -6.74e-03, 95% CI [-0.04, 0.02]	beta = -0.66, 95% CI [-3.13, 1.82], t(1718) = -0.52, p = 0.602; Std. beta = -7.75e-03, 95% CI [-0.04, 0.02]	beta = -0.53, 95% CI [-2.97, 1.90], t(1737) = -0.43, p = 0.669; Std. beta = -6.33e-03, 95% CI [-0.04, 0.02]

Outcome	Predictor	Full dataset			Sensitivity Checks	
					Excluding non-lipophilic	Excluding small gender groups
		Uncorrected	Corrected for demographics	Corrected for all covariates	Corrected for all covariates	
Total CESD – T4	**Statin vs Neither**	beta = -2.33, 95% CI [-5.33, 0.68], t(1703) = -1.52, p = 0.130; Std. beta = -0.18, 95% CI [-0.42, 0.05]	beta = 2.37, 95% CI [-0.58, 5.32], t(1694) = 1.58, p = 0.115; Std. beta = 0.19, 95% CI [-0.05, 0.42]	beta = 1.35, 95% CI [-0.79, 3.50], t(1625) = 1.24, p = 0.216; Std. beta = 0.11, 95% CI [-0.06, 0.28]	beta = 1.72, 95% CI [-0.64, 4.09], t(1606) = 1.43, p = 0.154; Std. beta = 0.14, 95% CI [-0.05, 0.32]	beta = 1.36, 95% CI [-0.78, 3.51], t(1622) = 1.25, p = 0.213; Std. beta = 0.11, 95% CI [-0.06, 0.28]
	BP vs Neither	beta = -1.74, 95% CI [-4.15, 0.67], t(1703) = -1.42, p = 0.156; Std. beta = -0.14, 95% CI [-0.32, 0.05]	(beta = 1.40, 95% CI [-0.95, 3.75], t(1694) = 1.17, p = 0.243; Std. beta = 0.11, 95% CI [-0.07, 0.29]	beta = -0.37, 95% CI [-2.09, 1.34], t(1625) = -0.43, p = 0.670; Std. beta = -0.03, 95% CI [-0.16, 0.11]	beta = -0.34, 95% CI [-2.07, 1.38], t(1606) = -0.39, p = 0.696; Std. beta = -0.03, 95% CI [-0.16, 0.11]	beta = -0.36, 95% CI [-2.09, 1.36], t(1622) = -0.41, p = 0.682; Std. beta = -0.03, 95% CI [-0.16, 0.11]
	Both vs Neither	beta = -3.23, 95% CI [-5.83, -0.64], t(1703) = -2.45, p < .05; Std. beta = -0.25, 95% CI [-0.46, -0.05]	beta = 1.89, 95% CI [-0.70, 4.48], t(1694) = 1.43, p = 0.153; Std. beta = 0.15, 95% CI [-0.06, 0.35]	beta = -0.29, 95% CI [-2.17, 1.59], t(1625) = -0.31, p = 0.758; Std. beta = -0.02, 95% CI [-0.17, 0.12]	beta = -0.41, 95% CI [-2.34, 1.51], t(1606) = -0.42, p = 0.674; Std. beta = -0.03, 95% CI [-0.18, 0.12]	beta = -0.29, 95% CI [-2.17, 1.59], t(1622) = -0.30, p = 0.763; Std. beta = -0.02, 95% CI [-0.17, 0.13]
	UBHR – angry faces	beta = 7.68, 95% CI [3.09, 12.26], t(1681) = 3.28, p < .01; Std. beta = 0.08, 95% CI [0.03, 0.13	beta = 4.32, 95% CI [-0.08, 8.72], t(1672) = 1.92, p = 0.054; Std. beta = 0.05, 95% CI [-8.98e-04, 0.09]	beta = 3.61, 95% CI [0.42, 6.80], t(1606) = 2.22, p < .05; Std. beta = 0.04, 95% CI [4.55e-03, 0.07]	beta = 3.71, 95% CI [0.49, 6.93], t(1587) = 2.26, p < .05; Std. beta = 0.04, 95% CI [5.23e-03, 0.07]	beta = 3.57, 95% CI [0.38, 6.76], t(1603) = 2.19, p < .05; Std. beta = 0.04, 95% CI [4.08e-03, 0.07]
	UBHR – fearful faces	beta = 1.25, 95% CI [-2.98, 5.47], t(1681) = 0.58, p = 0.563; Std. beta = 0.01, 95% CI [-0.03, 0.06]	beta = 0.18, 95% CI [-3.86, 4.21], t(1672) = 0.09, p = 0.932; Std. beta = 2.06e-03, 95% CI [-0.05, 0.05]	beta = -0.03, 95% CI [-2.93, 2.88], t(1606) = -0.02, p = 0.985; Std. beta = -3.23e-04, 95% CI [-0.03, 0.03]	beta = -0.29, 95% CI [-3.24, 2.65], t(1587) = -0.20, p = 0.845; Std. beta = -3.42e-03, 95% CI [-0.04, 0.03]	beta = 0.08, 95% CI [-2.83, 2.99], t(1603) = 0.06, p = 0.956; Std. beta = 9.68e-04, 95% CI [-0.03, 0.04]
Change in CESD – BL to T2	**Statin vs Neither**	beta = 0.62, 95% CI [-0.90, 2.14], t(1916) = 0.80, p = 0.423; Std. beta = 0.09, 95% CI [-0.14, 0.32]	beta = 0.50, 95% CI [-1.06, 2.07], t(1907) = 0.63, p = 0.528; Std. beta = 0.08, 95% CI [-0.16, 0.31]	beta = 0.37, 95% CI [-1.15, 1.89], t(1898) = 0.48, p = 0.633; Std. beta = 0.06, 95% CI [-0.17, 0.28]	beta = -0.44, 95% CI [-2.12, 1.25], t(1876) = -0.51, p = 0.610; Std. beta = -0.07, 95% CI [-0.32, 0.19]	beta = 0.37, 95% CI [-1.15, 1.89], t(1895) = 0.48, p = 0.632; Std. beta = 0.06, 95% CI [-0.17, 0.28]
	BP vs Neither	beta = -0.07, 95% CI [-1.31, 1.17], t(1916) = -0.11, p = 0.913; Std. beta = -0.01, 95% CI [-0.20, 0.18]	beta = -0.15, 95% CI [-1.42, 1.12], t(1907) = -0.23, p = 0.820; Std. beta = -0.02, 95% CI [-0.21, 0.17]	beta = -9.29e-03, 95% CI [-1.24, 1.22], t(1898) = -0.01, p = 0.988; Std. beta = -1.40e-03, 95% CI [-0.19, 0.18]	beta = -0.02, 95% CI [-1.24, 1.21], t(1876) = -0.03, p = 0.978; Std. beta = -2.63e-03, 95% CI [-0.19, 0.18]	beta = -0.02, 95% CI [-1.26, 1.21], t(1895) = -0.03, p = 0.973; Std. beta = -3.17e-03, 95% CI [-0.19, 0.18]
	Both vs Neither	beta = 0.48, 95% CI [-0.83, 1.79], t(1916) = 0.72, p = 0.471; Std. beta = 0.07, 95% CI [-0.12, 0.27]	beta = 0.40, 95% CI [-0.97, 1.77], t(1907) = 0.57, p = 0.567; Std. beta = 0.06, 95% CI [-0.15, 0.27]	beta = 0.50, 95% CI [-0.83, 1.84], t(1898) = 0.74, p = 0.460; Std. beta = 0.08, 95% CI [-0.13, 0.28]	beta = 0.53, 95% CI [-0.83, 1.89], t(1876) = 0.76, p = 0.445; Std. beta = 0.08, 95% CI [-0.13, 0.29]	beta = 0.50, 95% CI [-0.83, 1.84], t(1895) = 0.74, p = 0.459; Std. beta = 0.08, 95% CI [-0.13, 0.28]
	UBHR – angry faces	beta = 7.68, 95% CI [3.09, 12.26], t(1681) = 3.28, p < .01; Std. beta = 0.08, 95% CI [0.03, 0.13]	beta = 0.29, 95% CI [-1.98, 2.56], t(1882) = 0.25, p = 0.801; Std. beta = 6.02e-03, 95% CI [-0.04, 0.05]	beta = 0.39, 95% CI [-1.80, 2.59], t(1868) = 0.35, p = 0.727; Std. beta = 8.05e-03, 95% CI [-0.04, 0.05]	beta = 0.42, 95% CI [-1.79, 2.63], t(1846) = 0.37, p = 0.710; Std. beta = 8.63e-03, 95% CI [-0.04, 0.05]	beta = 0.39, 95% CI [-1.81, 2.59], t(1865) = 0.35, p = 0.728; Std. beta = 8.04e-03, 95% CI [-0.04, 0.05]
	UBHR – fearful faces	beta = 1.25, 95% CI [-2.98, 5.47], t(1681) = 0.58, p = 0.563; Std. beta = 0.01, 95% CI [-0.03, 0.06]	beta = 0.87, 95% CI [-1.19, 2.93], t(1882) = 0.83, p = 0.409; Std. beta = 0.02, 95% CI [-0.03, 0.07]	beta = 1.07, 95% CI [-0.92, 3.06], t(1868) = 1.05, p = 0.293; Std. beta = 0.02, 95% CI [-0.02, 0.07]	beta = 1.01, 95% CI [-1.01, 3.02], t(1846) = 0.98, p = 0.328; Std. beta = 0.02, 95% CI [-0.02, 0.07]	beta = 1.10, 95% CI [-0.90, 3.09], t(1865) = 1.08, p = 0.280; Std. beta = 0.02, 95% CI [-0.02, 0.07]
Change in CESD – BL to T3	**Statin vs Neither**	beta = 1.27, 95% CI [-0.55, 3.09], t(1827) = 1.37, p = 0.171; Std. beta = 0.16, 95% CI [-0.07, 0.39]	beta = 1.07, 95% CI [-0.81, 2.94], t(1818) = 1.12, p = 0.264; Std. beta = 0.14, 95% CI [-0.10, 0.38]	beta = 0.97, 95% CI [-0.87, 2.81], t(1767) = 1.03, p = 0.303; Std. beta = 0.12, 95% CI [-0.11, 0.36]	beta = 0.85, 95% CI [-1.21, 2.91], t(1745) = 0.81, p = 0.417; Std. beta = 0.11, 95% CI [-0.15, 0.37]	beta = 0.98, 95% CI [-0.86, 2.82], t(1764) = 1.04, p = 0.298; Std. beta = 0.13, 95% CI [-0.11, 0.36]
	BP vs Neither	beta = 0.22, 95% CI [-1.24, 1.68], t(1827) = 0.30, p =	beta = 0.12, 95% CI [-1.37, 1.61], t(1818) = 0.16, p =	beta = 0.30, 95% CI [-1.16, 1.76], t(1767) = 0.40, p =	beta = 0.31, 95% CI [-1.16, 1.77], t(1745) = 0.41, p =	beta = 0.35, 95% CI [-1.11, 1.82], t(1764) = 0.47, p =

Outcome	Predictor	Full dataset			Sensitivity Checks	
					Excluding non-lipophilic	Excluding small gender groups
		Uncorrected	Corrected for demographics	Corrected for all covariates	Corrected for all covariates	
		0.765; Std. beta = 0.03, 95% CI [-0.16, 0.21]	0.872; Std. beta = 0.02, 95% CI [-0.17, 0.21]	0.687; Std. beta = 0.04, 95% CI [-0.15, 0.23]	0.679; Std. beta = 0.04, 95% CI [-0.15, 0.23]	0.639; Std. beta = 0.04, 95% CI [-0.14, 0.23]
	Both vs Neither	beta = 0.32, 95% CI [-1.22, 1.87], t(1827) = 0.41, p = 0.682; Std. beta = 0.04, 95% CI [-0.16, 0.24]	beta = 0.26, 95% CI [-1.36, 1.88], t(1818) = 0.31, p = 0.754; Std. beta = 0.03, 95% CI [-0.17, 0.24]	beta = 0.25, 95% CI [-1.33, 1.83], t(1767) = 0.31, p = 0.756; Std. beta = 0.03, 95% CI [-0.17, 0.23]	beta = 0.17, 95% CI [-1.45, 1.79], t(1745) = 0.20, p = 0.840; Std. beta = 0.02, 95% CI [-0.19, 0.23]	beta = 0.26, 95% CI [-1.32, 1.85], t(1764) = 0.33, p = 0.744; Std. beta = 0.03, 95% CI [-0.17, 0.24]
	UBHR – angry faces	beta = 0.81, 95% CI [-1.88, 3.50], t(1802) = 0.59, p = 0.554; Std. beta = 0.01, 95% CI [-0.03, 0.06]	beta = 1.23, 95% CI [-1.48, 3.95], t(1793) = 0.89, p = 0.374; Std. beta = 0.02, 95% CI [-0.03, 0.07]	beta = 1.52, 95% CI [-1.13, 4.16], t(1740) = 1.13, p = 0.261; Std. beta = 0.03, 95% CI [-0.02, 0.07]	beta = 1.70, 95% CI [-0.97, 4.37], t(1718) = 1.25, p = 0.211; Std. beta = 0.03, 95% CI [-0.02, 0.08]	beta = 1.48, 95% CI [-1.16, 4.13], t(1737) = 1.10, p = 0.271; Std. beta = 0.03, 95% CI [-0.02, 0.07]
	UBHR – fearful faces	beta = -0.78, 95% CI [-3.29, 1.73], t(1802) = -0.61, p = 0.543; Std. beta = -0.01, 95% CI [-0.06, 0.03]	beta = -0.65, 95% CI [-3.17, 1.87], t(1793) = -0.51, p = 0.613; Std. beta = -0.01, 95% CI [-0.06, 0.04]	beta = -0.57, 95% CI [-3.00, 1.87], t(1740) = -0.46, p = 0.649; Std. beta = -0.01, 95% CI [-0.06, 0.04]	beta = -0.66, 95% CI [-3.13, 1.82], t(1718) = -0.52, p = 0.602; Std. beta = -0.01, 95% CI [-0.06, 0.03]	beta = -0.53, 95% CI [-2.97, 1.90], t(1737) = -0.43, p = 0.669; Std. beta = -0.01, 95% CI [-0.06, 0.04]
Change in CESD – BL to T4	**Statin vs Neither**	beta = 1.44, 95% CI [-0.70, 3.57], t(1700) = 1.32, p = 0.187; Std. beta = 0.16, 95% CI [-0.08, 0.39]	beta = 1.49, 95% CI [-0.72, 3.70], t(1691) = 1.33, p = 0.185; Std. beta = 0.16, 95% CI [-0.08, 0.41]	beta = 1.32, 95% CI [-0.83, 3.47], t(1630) = 1.21, p = 0.228; Std. beta = 0.14, 95% CI [-0.09, 0.38]	beta = 1.72, 95% CI [-0.65, 4.09], t(1611) = 1.42, p = 0.155; Std. beta = 0.19, 95% CI [-0.07, 0.45]	beta = 1.33, 95% CI [-0.81, 3.48], t(1627) = 1.22, p = 0.224; Std. beta = 0.15, 95% CI [-0.09, 0.38]
	BP vs Neither	beta = -0.74, 95% CI [-2.46, 0.98], t(1700) = -0.84, p = 0.399; Std. beta = -0.08, 95% CI [-0.27, 0.11]	beta = -0.67, 95% CI [-2.43, 1.09], t(1691) = -0.74, p = 0.456; Std. beta = -0.07, 95% CI [-0.27, 0.12]	beta = -0.49, 95% CI [-2.20, 1.22], t(1630) = -0.56, p = 0.576; Std. beta = -0.05, 95% CI [-0.24, 0.13]	beta = -0.47, 95% CI [-2.18, 1.25], t(1611) = -0.53, p = 0.595; Std. beta = -0.05, 95% CI [-0.24, 0.14]	beta = -0.47, 95% CI [-2.19, 1.25], t(1627) = -0.54, p = 0.592; Std. beta = -0.05, 95% CI [-0.24, 0.14]
	Both vs Neither	beta = -0.72, 95% CI [-2.57, 1.13], t(1700) = -0.76, p = 0.448; Std. beta = -0.08, 95% CI [-0.28, 0.12]	beta = -0.59, 95% CI [-2.54, 1.35], t(1691) = -0.60, p = 0.551; Std. beta = -0.07, 95% CI [-0.28, 0.15]	beta = -0.37, 95% CI [-2.24, 1.51], t(1630) = -0.38, p = 0.702; Std. beta = -0.04, 95% CI [-0.25, 0.17]	beta = -0.49, 95% CI [-2.41, 1.44], t(1611) = -0.50, p = 0.619; Std. beta = -0.05, 95% CI [-0.26, 0.16]	beta = -0.36, 95% CI [-2.24, 1.52], t(1627) = -0.37, p = 0.709; Std. beta = -0.04, 95% CI [-0.25, 0.17]
	UBHR – angry faces	beta = 3.60, 95% CI [0.32, 6.88], t(1678) = 2.15, p < .05; Std. beta = 0.05, 95% CI [4.83e-03, 0.10]	beta = 3.71, 95% CI [0.40, 7.02], t(1669) = 2.20, p < .05; Std. beta = 0.06, 95% CI [6.05e-03, 0.11]	beta = 3.61, 95% CI [0.42, 6.80], t(1606) = 2.22, p < .05; Std. beta = 0.05, 95% CI [6.33e-03, 0.10]	beta = 3.71, 95% CI [0.49, 6.93], t(1587) = 2.26, p < .05; Std. beta = 0.06, 95% CI [7.29e-03, 0.10]	beta = 3.57, 95% CI [0.38, 6.76], t(1603) = 2.19, p < .05; Std. beta = 0.05, 95% CI [5.68e-03, 0.10]
	UBHR – fearful faces	beta = -0.06, 95% CI [-3.08, 2.96], t(1678) = -0.04, p = 0.970; Std. beta = -9.56e-04, 95% CI [-0.05, 0.05]	beta = -0.06, 95% CI [-3.09, 2.97], t(1669) = -0.04, p = 0.969; Std. beta = -9.78e-04, 95% CI [-0.05, 0.05]	beta = -0.03, 95% CI [-2.93, 2.88], t(1606) = -0.02, p = 0.985; Std. beta = -4.49e-04, 95% CI [-0.05, 0.05]	beta = -0.29, 95% CI [-3.24, 2.65], t(1587) = -0.20, p = 0.845; Std. beta = -4.77e-03, 95% CI [-0.05, 0.04]	beta = 0.08, 95% CI [-2.83, 2.99], t(1603) = 0.06, p = 0.956; Std. beta = 1.35e-03, 95% CI [-0.05, 0.05]
GAD-7 – T2	**Statin vs Neither**	beta = -2.26, 95% CI [-3.42, -1.09], t(1919) = -3.80, p < .001; Std. beta = -0.44, 95% CI [-0.67, -0.21]	beta = -0.48, 95% CI [-1.63, 0.66], t(1910) = -0.83, p = 0.407; Std. beta = -0.09, 95% CI [-0.32, 0.13]	beta = -0.49, 95% CI [-1.30, 0.33], t(1893) = -1.17, p = 0.242; Std. beta = -0.09, 95% CI [-0.25, 0.06]	beta = -0.73, 95% CI [-1.63, 0.17], t(1871) = -1.58, p = 0.114; Std. beta = -0.14, 95% CI [-0.32, 0.03]	beta = -0.48, 95% CI [-1.30, 0.33], t(1890) = -1.16, p = 0.245; Std. beta = -0.09, 95% CI [-0.25, 0.06]
	BP vs Neither	beta = -0.18, 95% CI [-1.13, 0.77], t(1919) = -0.37, p = 0.711; Std. beta = -0.04, 95% CI [-0.22, 0.15]	beta = 1.03, 95% CI [0.10, 1.96], t(1910) = 2.17, p < .05; Std. beta = 0.20, 95% CI [0.02, 0.38]	beta = 0.60, 95% CI [-0.06, 1.26], t(1893) = 1.78, p = 0.075; Std. beta = 0.12, 95% CI [-0.01, 0.25]	beta = 0.59, 95% CI [-0.06, 1.25], t(1871) = 1.77, p = 0.077; Std. beta = 0.12, 95% CI [-0.01, 0.24]	beta = 0.61, 95% CI [-0.05, 1.28], t(1890) = 1.82, p = 0.069; Std. beta = 0.12, 95% CI [-9.32e-03, 0.25]
	Both vs Neither	beta = -1.17, 95% CI [-2.17, -0.17], t(1919) = -2.30, p < .05; Std. beta = -0.23, 95% CI [-0.42, -0.03]	beta = 0.79, 95% CI [-0.22, 1.79], t(1910) = 1.54, p = 0.124; Std. beta = 0.15, 95% CI [-0.04, 0.35]	beta = 1.37e-03, 95% CI [-0.71, 0.72], t(1893) = 3.76e-03, p = 0.997; Std. beta = 2.68e-04, 95% CI [-0.14, 0.14]	beta = -0.04, 95% CI [-0.77, 0.69], t(1871) = -0.12, p = 0.907; Std. beta = -8.52e-03, 95% CI [-0.15, 0.13]	beta = 3.84e-03, 95% CI [-0.71, 0.72], t(1890) = 0.01, p = 0.992; Std. beta = 7.50e-04, 95% CI [-0.14, 0.14]

Outcome	Predictor	Full dataset			Sensitivity Checks	
					Excluding non-lipophilic	Excluding small gender groups
		Uncorrected	Corrected for demographics	Corrected for all covariates	Corrected for all covariates	
	UBHR – angry faces	beta = 1.93, 95% CI [0.21, 3.65], t(1894) = 2.20, p < .05; Std. beta = 0.05, 95% CI [5.60e-03, 0.10]	beta = 0.59, 95% CI [-1.07, 2.25], t(1885) = 0.70, p = 0.487; Std. beta = 0.02, 95% CI [-0.03, 0.06]	beta = 0.70, 95% CI [-0.36, 1.76], t(1868) = 1.30, p = 0.193; Std. beta = 0.02, 95% CI [-9.55e-03, 0.05]	beta = 0.66, 95% CI [-0.40, 1.73], t(1846) = 1.22, p = 0.223; Std. beta = 0.02, 95% CI [-0.01, 0.05]	beta = 0.70, 95% CI [-0.36, 1.76], t(1865) = 1.29, p = 0.198; Std. beta = 0.02, 95% CI [-9.75e-03, 0.05]
	UBHR – fearful faces	beta = 1.15, 95% CI [-0.42, 2.72], t(1894) = 1.43, p = 0.152; Std. beta = 0.03, 95% CI [-0.01, 0.08]	beta = 0.79, 95% CI [-0.72, 2.30], t(1885) = 1.02, p = 0.306; Std. beta = 0.02, 95% CI [-0.02, 0.07]	beta = 0.67, 95% CI [-0.29, 1.63], t(1868) = 1.37, p = 0.171; Std. beta = 0.02, 95% CI [-8.54e-03, 0.05]	beta = 0.64, 95% CI [-0.33, 1.62], t(1846) = 1.30, p = 0.194; Std. beta = 0.02, 95% CI [-9.59e-03, 0.05]	beta = 0.68, 95% CI [-0.29, 1.64], t(1865) = 1.38, p = 0.169; Std. beta = 0.02, 95% CI [-8.42e-03, 0.05]
GAD-7 – T3	**Statin vs Neither**	beta = -1.80, 95% CI [-3.00, -0.59], t(1824) = -2.92, p < .01; Std. beta = -0.34, 95% CI [-0.58, -0.11]	beta = -0.01, 95% CI [-1.21, 1.18], t(1815) = -0.02, p = 0.983; Std. beta = -2.48e-03, 95% CI [-0.23, 0.23]	beta = -0.19, 95% CI [-1.08, 0.71], t(1759) = -0.41, p = 0.683; Std. beta = -0.04, 95% CI [-0.21, 0.14]	beta = -0.35, 95% CI [-1.35, 0.66], t(1737) = -0.68, p = 0.499; Std. beta = -0.07, 95% CI [-0.26, 0.13]	beta = -0.18, 95% CI [-1.07, 0.72], t(1756) = -0.39, p = 0.698; Std. beta = -0.03, 95% CI [-0.21, 0.14]
	BP vs Neither	beta = 0.16, 95% CI [-0.80, 1.13], t(1824) = 0.33, p = 0.740; Std. beta = 0.03, 95% CI [-0.15, 0.22]	beta = 1.24, 95% CI [0.29, 2.19], t(1815) = 2.56, p < .05; Std. beta = 0.24, 95% CI [0.06, 0.42]	beta = 0.50, 95% CI [-0.21, 1.21], t(1759) = 1.38, p = 0.169; Std. beta = 0.10, 95% CI [-0.04, 0.23]	beta = 0.49, 95% CI [-0.22, 1.21], t(1737) = 1.35, p = 0.178; Std. beta = 0.09, 95% CI [-0.04, 0.23]	beta = 0.57, 95% CI [-0.15, 1.28], t(1756) = 1.56, p = 0.118; Std. beta = 0.11, 95% CI [-0.03, 0.25]
	Both vs Neither	beta = -1.19, 95% CI [-2.21, -0.16], t(1824) = -2.28, p < .05; Std. beta = -0.23, 95% CI [-0.42, -0.03]	beta = 0.65, 95% CI [-0.38, 1.68], t(1815) = 1.24, p = 0.216; Std. beta = 0.12, 95% CI [-0.07, 0.32]	beta = -0.17, 95% CI [-0.94, 0.60], t(1759) = -0.44, p = 0.663; Std. beta = -0.03, 95% CI [-0.18, 0.12]	beta = -0.20, 95% CI [-0.99, 0.59], t(1737) = -0.50, p = 0.619; Std. beta = -0.04, 95% CI [-0.19, 0.11]	beta = -0.16, 95% CI [-0.92, 0.61], t(1756) = -0.40, p = 0.693; Std. beta = -0.03, 95% CI [-0.18, 0.12]
	UBHR – angry faces	beta = 2.63, 95% CI [0.84, 4.41], t(1799) = 2.89, p < .01; Std. beta = 0.07, 95% CI [0.02, 0.12]	beta = 1.28, 95% CI [-0.45, 3.01], t(1790) = 1.45, p = 0.148; Std. beta = 0.03, 95% CI [-0.01, 0.08]	beta = 1.14, 95% CI [-0.11, 2.39], t(1737) = 1.79, p = 0.073; Std. beta = 0.03, 95% CI [-2.89e-03, 0.06]	beta = 1.14, 95% CI [-0.12, 2.40], t(1715) = 1.77, p = 0.077; Std. beta = 0.03, 95% CI [-3.29e-03, 0.06]	beta = 1.11, 95% CI [-0.13, 2.36], t(1734) = 1.75, p = 0.080; Std. beta = 0.03, 95% CI [-3.60e-03, 0.06]
	UBHR – fearful faces	beta = 0.06, 95% CI [-1.60, 1.72], t(1799) = 0.07, p = 0.945; Std. beta = 1.66e-03, 95% CI [-0.05, 0.05]	beta = -0.37, 95% CI [-1.97, 1.23], t(1790) = -0.45, p = 0.650; Std. beta = -0.01, 95% CI [-0.06, 0.04]	beta = -0.36, 95% CI [-1.51, 0.79], t(1737) = -0.62, p = 0.539; Std. beta = -0.01, 95% CI [-0.04, 0.02]	beta = -0.36, 95% CI [-1.53, 0.81], t(1715) = -0.61, p = 0.543; Std. beta = -0.01, 95% CI [-0.04, 0.02]	beta = -0.38, 95% CI [-1.52, 0.77], t(1734) = -0.64, p = 0.519; Std. beta = -0.01, 95% CI [-0.04, 0.02]
GAD-7 - T4	**Statin vs Neither**	beta = -1.76, 95% CI [-3.06, -0.46], t(1703) = -2.65, p < .01; Std. beta = -0.32, 95% CI [-0.55, -0.08]	beta = 0.11, 95% CI [-1.18, 1.40], t(1694) = 0.16, p = 0.871; Std. beta = 0.02, 95% CI [-0.21, 0.25]	beta = -0.35, 95% CI [-1.39, 0.68], t(1625) = -0.67, p = 0.505; Std. beta = -0.06, 95% CI [-0.25, 0.12]	beta = -0.31, 95% CI [-1.46, 0.83], t(1606) = -0.53, p = 0.595; Std. beta = -0.06, 95% CI [-0.26, 0.15]	beta = -0.34, 95% CI [-1.38, 0.69], t(1622) = -0.65, p = 0.514; Std. beta = -0.06, 95% CI [-0.25, 0.13]
	BP vs Neither	beta = -0.06, 95% CI [-1.10, 0.98], t(1703) = -0.12, p = 0.908; Std. beta = -0.01, 95% CI [-0.20, 0.18]	beta = 1.19, 95% CI [0.16, 2.21], t(1694) = 2.26, p < .05; Std. beta = 0.21, 95% CI [0.03, 0.40]	beta = 0.33, 95% CI [-0.50, 1.16], t(1625) = 0.79, p = 0.432; Std. beta = 0.06, 95% CI [-0.09, 0.21]	beta = 0.34, 95% CI [-0.49, 1.17], t(1606) = 0.81, p = 0.421; Std. beta = 0.06, 95% CI [-0.09, 0.21]	beta = 0.37, 95% CI [-0.46, 1.21], t(1622) = 0.88, p = 0.381; Std. beta = 0.07, 95% CI [-0.08, 0.22]
	Both vs Neither	beta = -1.85, 95% CI [-2.97, -0.73], t(1703) = -3.24, p < .01; Std. beta = -0.33, 95% CI [-0.54, -0.13]	beta = 0.18, 95% CI [-0.95, 1.32], t(1694) = 0.32, p = 0.751; Std. beta = 0.03, 95% CI [-0.17, 0.24]	beta = -0.59, 95% CI [-1.50, 0.32], t(1625) = -1.28, p = 0.202; Std. beta = -0.11, 95% CI [-0.27, 0.06]	beta = -0.69, 95% CI [-1.62, 0.24], t(1606) = -1.46, p = 0.145; Std. beta = -0.13, 95% CI [-0.29, 0.04]	beta = -0.59, 95% CI [-1.49, 0.32], t(1622) = -1.27, p = 0.206; Std. beta = -0.11, 95% CI [-0.27, 0.06]
	UBHR – angry faces	beta = 3.75, 95% CI [1.76, 5.74], t(1681) = 3.70, p < .001; Std. beta = 0.09, 95% CI [0.04, 0.14]	beta = 2.40, 95% CI [0.48, 4.33], t(1672) = 2.45, p < .05; Std. beta = 0.06, 95% CI [0.01, 0.11]	beta = 2.37, 95% CI [0.89, 3.85], t(1606) = 3.13, p < .01; Std. beta = 0.06, 95% CI [0.02, 0.10]	beta = 2.37, 95% CI [0.87, 3.87], t(1587) = 3.10, p < .01; Std. beta = 0.06, 95% CI [0.02, 0.10]	beta = 2.34, 95% CI [0.86, 3.82], t(1603) = 3.09, p < .01; Std. beta = 0.06, 95% CI [0.02, 0.10]
	UBHR – fearful faces	beta = -0.50, 95% CI [-2.33, 1.33], t(1681) = -0.54, p =	beta = -0.92, 95% CI [-2.68, 0.85], t(1672) = -1.02, p =	beta = -0.68, 95% CI [-2.03, 0.67], t(1606) = -0.99, p =	beta = -0.75, 95% CI [-2.12, 0.63], t(1587) = -1.07, p =	beta = -0.65, 95% CI [-2.01, 0.70], t(1603) = -0.94, p =

Outcome	Predictor	Full dataset			Sensitivity Checks	
					Excluding non-lipophilic	Excluding small gender groups
		Uncorrected	Corrected for demographics	Corrected for all covariates	Corrected for all covariates	
		0.592; Std. beta = -0.01, 95% CI [-0.06, 0.04]	0.309; Std. beta = -0.02, 95% CI [-0.07, 0.02]	0.323; Std. beta = -0.02, 95% CI [-0.06, 0.02]	0.286; Std. beta = -0.02, 95% CI [-0.06, 0.02]	0.345; Std. beta = -0.02, 95% CI [-0.05, 0.02]
Change in GAD-7 – BL to T2	**Statin vs Neither**	beta = 0.15, 95% CI [-0.62, 0.92], t(1916) = 0.38, p = 0.701; Std. beta = 0.04, 95% CI [-0.18, 0.27]	beta = -0.05, 95% CI [-0.84, 0.75], t(1907) = -0.11, p = 0.909; Std. beta = -0.01, 95% CI [-0.25, 0.22]	beta = -0.04, 95% CI [-0.83, 0.75], t(1898) = -0.09, p = 0.928; Std. beta = -0.01, 95% CI [-0.24, 0.22]	beta = -0.31, 95% CI [-1.18, 0.56], t(1876) = -0.70, p = 0.486; Std. beta = -0.09, 95% CI [-0.35, 0.17]	beta = -0.03, 95% CI [-0.82, 0.75], t(1895) = -0.09, p = 0.932; Std. beta = -0.01, 95% CI [-0.24, 0.22]
	BP vs Neither	beta = 0.56, 95% CI [-0.07, 1.19], t(1916) = 1.73, p = 0.083; Std. beta = 0.17, 95% CI [-0.02, 0.35]	beta = 0.44, 95% CI [-0.20, 1.09], t(1907) = 1.34, p = 0.179; Std. beta = 0.13, 95% CI [-0.06, 0.32]	beta = 0.51, 95% CI [-0.13, 1.14], t(1898) = 1.56, p = 0.119; Std. beta = 0.15, 95% CI [-0.04, 0.34]	beta = 0.51, 95% CI [-0.13, 1.15], t(1876) = 1.57, p = 0.117; Std. beta = 0.15, 95% CI [-0.04, 0.34]	beta = 0.52, 95% CI [-0.12, 1.16], t(1895) = 1.59, p = 0.111; Std. beta = 0.15, 95% CI [-0.04, 0.34]
	Both vs Neither	beta = 0.50, 95% CI [-0.16, 1.17], t(1916) = 1.48, p = 0.139; Std. beta = 0.15, 95% CI [-0.05, 0.34]	beta = 0.29, 95% CI [-0.40, 0.99], t(1907) = 0.82, p = 0.411; Std. beta = 0.09, 95% CI [-0.12, 0.29]	beta = 0.41, 95% CI [-0.29, 1.10], t(1898) = 1.15, p = 0.250; Std. beta = 0.12, 95% CI [-0.08, 0.32]	beta = 0.37, 95% CI [-0.33, 1.08], t(1876) = 1.04, p = 0.300; Std. beta = 0.11, 95% CI [-0.10, 0.32]	beta = 0.41, 95% CI [-0.28, 1.10], t(1895) = 1.16, p = 0.248; Std. beta = 0.12, 95% CI [-0.08, 0.33]
	UBHR – angry faces	beta = 0.58, 95% CI [-0.56, 1.72], t(1891) = 0.99, p = 0.321; Std. beta = 0.02, 95% CI [-0.02, 0.07]	beta = 0.79, 95% CI [-0.36, 1.94], t(1882) = 1.35, p = 0.176; Std. beta = 0.03, 95% CI [-0.01, 0.08]	beta = 0.70, 95% CI [-0.36, 1.76], t(1868) = 1.30, p = 0.193; Std. beta = 0.03, 95% CI [-0.01, 0.07]	beta = 0.66, 95% CI [-0.40, 1.73], t(1846) = 1.22, p = 0.223; Std. beta = 0.03, 95% CI [-0.02, 0.07]	beta = 0.70, 95% CI [-0.36, 1.76], t(1865) = 1.29, p = 0.198; Std. beta = 0.03, 95% CI [-0.01, 0.07]
	UBHR – fearful faces	beta = 0.57, 95% CI [-0.48, 1.61], t(1891) = 1.07, p = 0.287; Std. beta = 0.03, 95% CI [-0.02, 0.07]	beta = 0.67, 95% CI [-0.37, 1.72], t(1882) = 1.26, p = 0.207; Std. beta = 0.03, 95% CI [-0.02, 0.08]	beta = 0.67, 95% CI [-0.29, 1.63], t(1868) = 1.37, p = 0.171; Std. beta = 0.03, 95% CI [-0.01, 0.07]	beta = 0.64, 95% CI [-0.33, 1.62], t(1846) = 1.30, p = 0.194; Std. beta = 0.03, 95% CI [-0.01, 0.07]	beta = 0.68, 95% CI [-0.29, 1.64], t(1865) = 1.38, p = 0.169; Std. beta = 0.03, 95% CI [-0.01, 0.07]
Change in GAD-7 – BL to T3	**Statin vs Neither**	beta = 0.55, 95% CI [-0.36, 1.46], t(1824) = 1.19, p = 0.234; Std. beta = 0.14, 95% CI [-0.09, 0.37]	beta = 0.36, 95% CI [-0.57, 1.30], t(1815) = 0.76, p = 0.445; Std. beta = 0.09, 95% CI [-0.15, 0.33]	beta = 0.31, 95% CI [-0.63, 1.24], t(1764) = 0.64, p = 0.522; Std. beta = 0.08, 95% CI [-0.16, 0.32]	beta = 0.11, 95% CI [-0.94, 1.15], t(1742) = 0.20, p = 0.843; Std. beta = 0.03, 95% CI [-0.24, 0.30]	beta = 0.31, 95% CI [-0.62, 1.25], t(1761) = 0.66, p = 0.512; Std. beta = 0.08, 95% CI [-0.16, 0.32]
	BP vs Neither	beta = 0.54, 95% CI [-0.18, 1.27], t(1824) = 1.47, p = 0.142; Std. beta = 0.14, 95% CI [-0.05, 0.33]	beta = 0.38, 95% CI [-0.36, 1.12], t(1815) = 1.00, p = 0.315; Std. beta = 0.10, 95% CI [-0.09, 0.29]	beta = 0.40, 95% CI [-0.34, 1.14], t(1764) = 1.05, p = 0.292; Std. beta = 0.10, 95% CI [-0.09, 0.29]	beta = 0.39, 95% CI [-0.35, 1.14], t(1742) = 1.04, p = 0.299; Std. beta = 0.10, 95% CI [-0.09, 0.29]	beta = 0.47, 95% CI [-0.28, 1.21], t(1761) = 1.23, p = 0.219; Std. beta = 0.12, 95% CI [-0.07, 0.31]
	Both vs Neither	beta = 0.36, 95% CI [-0.41, 1.13], t(1824) = 0.92, p = 0.360; Std. beta = 0.09, 95% CI [-0.10, 0.29]	beta = 0.18, 95% CI [-0.62, 0.99], t(1815) = 0.44, p = 0.658; Std. beta = 0.05, 95% CI [-0.16, 0.25]	beta = 0.24, 95% CI [-0.57, 1.04], t(1764) = 0.58, p = 0.561; Std. beta = 0.06, 95% CI [-0.15, 0.27]	beta = 0.22, 95% CI [-0.60, 1.05], t(1742) = 0.53, p = 0.597; Std. beta = 0.06, 95% CI [-0.15, 0.27]	beta = 0.25, 95% CI [-0.55, 1.06], t(1761) = 0.61, p = 0.539; Std. beta = 0.06, 95% CI [-0.14, 0.27]
	UBHR – angry faces	beta = 0.92, 95% CI [-0.42, 2.27], t(1799) = 1.35, p = 0.178; Std. beta = 0.03, 95% CI [-0.01, 0.08]	beta = 1.11, 95% CI [-0.24, 2.47], t(1790) = 1.61, p = 0.107; Std. beta = 0.04, 95% CI [-8.57e-03, 0.09]	beta = 1.14, 95% CI [-0.11, 2.39], t(1737) = 1.79, p = 0.073; Std. beta = 0.04, 95% CI [-3.83e-03, 0.08]	beta = 1.14, 95% CI [-0.12, 2.40], t(1715) = 1.77, p = 0.077; Std. beta = 0.04, 95% CI [-4.36e-03, 0.08]	beta = 1.11, 95% CI [-0.13, 2.36], t(1734) = 1.75, p = 0.080; Std. beta = 0.04, 95% CI [-4.78e-03, 0.08]
	UBHR – fearful faces	beta = -0.31, 95% CI [-1.57, 0.94], t(1799) = -0.49, p = 0.623; Std. beta = -0.01, 95% CI [-0.06, 0.04]	beta = -0.30, 95% CI [-1.56, 0.96], t(1790) = -0.47, p = 0.640; Std. beta = -0.01, 95% CI [-0.06, 0.04]	beta = -0.36, 95% CI [-1.51, 0.79], t(1737) = -0.62, p = 0.539; Std. beta = -0.01, 95% CI [-0.06, 0.03]	beta = -0.36, 95% CI [-1.53, 0.81], t(1715) = -0.61, p = 0.543; Std. beta = -0.01, 95% CI [-0.06, 0.03]	beta = -0.38, 95% CI [-1.52, 0.77], t(1734) = -0.64, p = 0.519; Std. beta = -0.01, 95% CI [-0.06, 0.03]
Change in GAD-7 – BL to T4	**Statin vs Neither**	beta = 0.45, 95% CI [-0.57, 1.48], t(1700) = 0.87, p =	beta = 0.33, 95% CI [-0.73, 1.38], t(1691) = 0.61, p =	beta = 0.19, 95% CI [-0.88, 1.26], t(1630) = 0.35, p =	beta = 0.20, 95% CI [-0.98, 1.38], t(1611) = 0.33, p =	beta = 0.20, 95% CI [-0.87, 1.26], t(1627) = 0.36, p =

Outcome	Predictor	Full dataset			Sensitivity Checks	
					Excluding non-lipophilic	Excluding small gender groups
		Uncorrected	Corrected for demographics	Corrected for all covariates	Corrected for all covariates	
		0.385; Std. beta = 0.10, 95% CI [-0.13, 0.34]	0.545; Std. beta = 0.08, 95% CI [-0.17, 0.32]	0.730; Std. beta = 0.04, 95% CI [-0.20, 0.29]	0.738; Std. beta = 0.05, 95% CI [-0.22, 0.32]	0.720; Std. beta = 0.04, 95% CI [-0.20, 0.29]
	BP vs Neither	beta = 0.28, 95% CI [-0.55, 1.10], t(1700) = 0.66, p = 0.509; Std. beta = 0.06, 95% CI [-0.13, 0.25]	beta = 0.23, 95% CI [-0.62, 1.07], t(1691) = 0.53, p = 0.597; Std. beta = 0.05, 95% CI [-0.14, 0.25]	beta = 0.23, 95% CI [-0.62, 1.08], t(1630) = 0.53, p = 0.595; Std. beta = 0.05, 95% CI [-0.14, 0.25]	beta = 0.24, 95% CI [-0.62, 1.09], t(1611) = 0.55, p = 0.585; Std. beta = 0.05, 95% CI [-0.14, 0.25]	beta = 0.27, 95% CI [-0.59, 1.13], t(1627) = 0.62, p = 0.536; Std. beta = 0.06, 95% CI [-0.13, 0.26]
	Both vs Neither	beta = -0.09, 95% CI [-0.97, 0.80], t(1700) = -0.19, p = 0.847; Std. beta = -0.02, 95% CI [-0.22, 0.18]	beta = -0.21, 95% CI [-1.14, 0.72], t(1691) = -0.44, p = 0.657; Std. beta = -0.05, 95% CI [-0.26, 0.17]	beta = -0.11, 95% CI [-1.04, 0.83], t(1630) = -0.22, p = 0.825; Std. beta = -0.02, 95% CI [-0.24, 0.19]	beta = -0.20, 95% CI [-1.16, 0.76], t(1611) = -0.40, p = 0.689; Std. beta = -0.04, 95% CI [-0.26, 0.17]	beta = -0.10, 95% CI [-1.04, 0.83], t(1627) = -0.21, p = 0.833; Std. beta = -0.02, 95% CI [-0.24, 0.19]
	UBHR – angry faces	beta = 2.15, 95% CI [0.59, 3.72], t(1678) = 2.70, p < .01; Std. beta = 0.07, 95% CI [0.02, 0.12]	beta = 2.31, 95% CI [0.73, 3.89], t(1669) = 2.87, p < .01; Std. beta = 0.07, 95% CI [0.02, 0.12]	beta = 2.37, 95% CI [0.89, 3.85], t(1606) = 3.13, p < .01; Std. beta = 0.07, 95% CI [0.03, 0.12]	beta = 2.37, 95% CI [0.87, 3.87], t(1587) = 3.10, p < .01; Std. beta = 0.07, 95% CI [0.03, 0.12]	beta = 2.34, 95% CI [0.86, 3.82], t(1603) = 3.09, p < .01; Std. beta = 0.07, 95% CI [0.03, 0.12]
	UBHR – fearful faces	beta = -0.58, 95% CI [-2.02, 0.86], t(1678) = -0.80, p = 0.426; Std. beta = -0.02, 95% CI [-0.07, 0.03]	beta = -0.52, 95% CI [-1.96, 0.93], t(1669) = -0.70, p = 0.484; Std. beta = -0.02, 95% CI [-0.07, 0.03]	beta = -0.68, 95% CI [-2.03, 0.67], t(1606) = -0.99, p = 0.323; Std. beta = -0.02, 95% CI [-0.07, 0.02]	beta = -0.75, 95% CI [-2.12, 0.63], t(1587) = -1.07, p = 0.286; Std. beta = -0.03, 95% CI [-0.07, 0.02]	beta = -0.65, 95% CI [-2.01, 0.70], t(1603) = -0.94, p = 0.345; Std. beta = -0.02, 95% CI [-0.07, 0.02]

ECAT and EREC

Outcome	Groups	Full dataset (n=2013)						Sensitivity Analyses							
								Excluding non-lipophilic (n=1991)		Excluding small gender groups (n=2007)		Excluding poor ECAT performance (<90%) (n=1445)		Excluding EREC poor performance (zero correct words) (n=1975)	
		Uncorrected		Corrected for demographics		Corrected for all covariates		Corrected for all covariates							
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
ECAT – Accuracy (both valences)	**All**	Group: F(3) = 1.58, p = 0.193; Eta2 (partial) = 2.54e-03, 90% CI [0.00, 6.36e-03] Interaction: F(3) = 9.22, p < .001; Eta2 (partial) = 3.10e-03, 90% CI [1.28e-03, 5.07e-03]	N/A	Group: F(3) = 0.52, p = 0.669; Eta2 (partial) = 8.43e-04, 90% CI [0.00, 2.76e-03] Interaction: F(3) = 9.22, p < .001; Eta2 (partial) = 3.10e-03, 90% CI [1.28e-03, 5.07e-03]	N/A	Group: F(3) = 0.49, p = 0.687; Eta2 (partial) = 8.44e-04, 90% CI [0.00, 2.79e-03] Interaction: F(3) = 8.73, p < .001; Eta2 (partial) = 3.00e-03, 90% CI [1.19e-03, 4.97e-03]	N/A	Group: F(3) = 0.50, p = 0.684; Eta2 (partial) = 8.63e-04, 90% CI [0.00, 2.85e-03] Interaction: F(3) = 8.78, p < .001; Eta2 (partial) = 3.05e-03, 90% CI [1.22e-03, 5.05e-03]	N/A	Group: F(3) = 0.43, p = 0.728; Eta2 (partial) = 7.46e-04, 90% CI [0.00, 2.50e-03] Interaction: F(3) = 8.46, p < .001; Eta2 (partial) = 2.91e-03, 90% CI [1.13e-03, 4.86e-03]	N/A	Group: F(3) = 1.27, p = 0.284; Eta2 (partial) = 2.87e-03, 90% CI [0.00, 7.62e-03] Interaction: F(3) = 9.40, p < .001; Eta2 (partial) = 4.29e-03, 90% CI [1.79e-03, 6.99e-03]	N/A	Group: F(3) = 0.60, p = 0.614; Eta2 (partial) = 1.05e-03, 90% CI [0.00, 3.35e-03] Interaction: F(3) = 8.95, p < .001; Eta2 (partial) = 3.12e-03, 90% CI [1.26e-03, 5.14e-03]	N/A
ECAT – Accuracy (positive)	**All**	F(3) = 5.54, p < .001; Eta2 (partial) = 8.69e-03, 90% CI [2.29e-03, 0.02]	N/A	F(3) = 0.20, p = 0.899; Eta2 (partial) = 3.13e-04, 90% CI [0.00, 8.39e-04]	N/A	F(3) = 0.14, p = 0.933; Eta2 (partial) = 2.44e-04, 90% CI [0.00, 3.54e-04]	N/A	F(3) = 0.13, p = 0.945; Eta2 (partial) = 2.14e-04, 90% CI [0.00, 1.14e-04]	N/A	F(3) = 0.16, p = 0.920; Eta2 (partial) = 2.79e-04, 90% CI [0.00, 5.83e-04]	N/A	F(3) = 0.52, p = 0.672; Eta2 (partial) = 1.17e-03, 90% CI [0.00, 3.85e-03]	N/A	F(3) = 0.14, p = 0.933; Eta2 (partial) = 2.48e-04, 90% CI [0.00, 3.60e-04]	N/A
	Statin vs Neither	F(1) = 4.70, p = 0.030; Eta2 (partial) = 2.80e-03, 90% CI [1.39e-04, 8.61e-03]	beta = 1.38, 95% CI [0.16, 2.60], t(5510) = 2.22, p < .05; Std. beta = 0.20, 95% CI [0.02, 0.38]	F(1) = 0.02, p = 0.902; Eta2 (partial) = 9.08e-06, 90% CI [0.00, 8.11e-04]	beta = -0.04, 95% CI [-1.25, 1.17], t(5501) = -0.06, p = 0.949; Std. beta = -5.80e-03, 95% CI [-0.18, 0.17]	F(1) = 0.06, p = 0.813; Eta2 (partial) = 3.55e-05, 90% CI [0.00, 1.73e-03]	beta = -0.11, 95% CI [-1.35, 1.13], t(5329) = -0.17, p = 0.864; Std. beta = -0.02, 95% CI [-0.20, 0.17]	F(1) = 0.04, p = 0.835; Eta2 (partial) = 2.79e-05, 90% CI [0.00, 1.55e-03]	beta = -0.11, 95% CI [-1.49, 1.26], t(5267) = -0.16, p = 0.871; Std. beta = -0.02, 95% CI [-0.22, 0.19]	F(1) = 0.06, p = 0.814; Eta2 (partial) = 3.50e-05, 90% CI [0.00, 1.69e-03]	beta = -0.10, 95% CI [-1.34, 1.14], t(5316) = -0.16, p = 0.872; Std. beta = -0.02, 95% CI [-0.20, 0.17]	F(1) = 0.51, p = 0.474; Eta2 (partial) = 4.41e-04, 90% CI [0.00, 4.72e-03]	beta = 0.36, 95% CI [-0.58, 1.31], t(3927) = 0.76, p = 0.448; Std. beta = 0.08, 95% CI [-0.12, 0.27]	F(1) = 3.49e-03, p = 0.953; Eta2 (partial) = 2.26e-06, 90% CI [0.00, 0.00]	beta = 7.73e-03, 95% CI [-1.24, 1.25], t(5248) = 0.01, p = 0.990; Std. beta = 1.14e-03, 95% CI [-0.18, 0.19]

Outcome	Groups	Full dataset (n=2013)						Sensitivity Analyses							
								Excluding non-lipophilic (n=1991)		Excluding small gender groups (n=2007)		Excluding poor ECAT performance (<90%) (n=1445)		Excluding EREC poor performance (zero correct words) (n=1975)	
		Uncorrected		Corrected for demographics		Corrected for all covariates		Corrected for all covariates							
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
	BP vs Neither	F(1) = 6.73, p = 0.010; Eta2 (partial) = 3.91e-03, 90% CI [5.21e-04, 0.01]	beta = 1.34, 95% CI [0.33, 2.34], t(5510) = 2.61, p < .01; Std. beta = 0.20, 95% CI [0.05, 0.34]	F(1) = 0.29, p = 0.592; Eta2 (partial) = 1.69e-04, 90% CI [0.00, 2.70e-03]	beta = 0.30, 95% CI [-0.69, 1.28], t(5501) = 0.59, p = 0.556; Std. beta = 0.04, 95% CI [-0.10, 0.19]	F(1) = 0.10, p = 0.758; Eta2 (partial) = 5.97e-05, 90% CI [0.00, 2.04e-03]	beta = 0.19, 95% CI [-0.83, 1.20], t(5329) = 0.36, p = 0.721; Std. beta = 0.03, 95% CI [-0.12, 0.18]	F(1) = 0.09, p = 0.760; Eta2 (partial) = 5.87e-05, 90% CI [0.00, 1.89e-03]	beta = 0.17, 95% CI [-0.85, 1.19], t(5267) = 0.32, p = 0.747; Std. beta = 0.02, 95% CI [-0.13, 0.17]	F(1) = 0.15, p = 0.701; Eta2 (partial) = 9.30e-05, 90% CI [0.00, 2.36e-03]	beta = 0.23, 95% CI [-0.79, 1.25], t(5316) = 0.44, p = 0.661; Std. beta = 0.03, 95% CI [-0.12, 0.18]	F(1) = 0.41, p = 0.521; Eta2 (partial) = 3.50e-04, 90% CI [0.00, 4.37e-03]	beta = 0.27, 95% CI [-0.51, 1.04], t(3927) = 0.68, p = 0.498; Std. beta = 0.06, 95% CI [-0.11, 0.22]	F(1) = 0.07, p = 0.787; Eta2 (partial) = 4.65e-05, 90% CI [0.00, 1.89e-03]	beta = 0.16, 95% CI [-0.86, 1.19], t(5248) = 0.31, p = 0.753; Std. beta = 0.02, 95% CI [-0.13, 0.18]
	Both vs Neither	F(1) = 6.57, p = 0.010; Eta2 (partial) = 3.83e-03, 90% CI [4.88e-04, 0.01]	beta = 1.40, 95% CI [0.35, 2.45], t(5510) = 2.60, p < .01; Std. beta = 0.21, 95% CI [0.05, 0.36]	F(1) = 0.23, p = 0.633; Eta2 (partial) = 1.35e-04, 90% CI [0.00, 2.54e-03]	beta = -0.23, 95% CI [-1.29, 0.84], t(5501) = -0.41, p = 0.678; Std. beta = -0.03, 95% CI [-0.19, 0.12]	F(1) = 0.26, p = 0.610; Eta2 (partial) = 1.63e-04, 90% CI [0.00, 2.86e-03]	beta = -0.27, 95% CI [-1.37, 0.82], t(5329) = -0.48, p = 0.628; Std. beta = -0.04, 95% CI [-0.20, 0.12]	F(1) = 0.22, p = 0.642; Eta2 (partial) = 1.36e-04, 90% CI [0.00, 2.65e-03]	beta = -0.26, 95% CI [-1.38, 0.86], t(5267) = -0.46, p = 0.646; Std. beta = -0.04, 95% CI [-0.20, 0.13]	F(1) = 0.26, p = 0.612; Eta2 (partial) = 1.62e-04, 90% CI [0.00, 2.79e-03]	beta = -0.26, 95% CI [-1.36, 0.83], t(5316) = -0.47, p = 0.638; Std. beta = -0.04, 95% CI [-0.20, 0.12]	F(1) = 0.37, p = 0.541; Eta2 (partial) = 3.15e-04, 90% CI [0.00, 4.20e-03]	beta = -0.26, 95% CI [-1.08, 0.57], t(3927) = -0.61, p = 0.545; Std. beta = -0.05, 95% CI [-0.23, 0.12]	F(1) = 0.32, p = 0.572; Eta2 (partial) = 2.03e-04, 90% CI [0.00, 3.02e-03]	beta = -0.30, 95% CI [-1.42, 0.81], t(5248) = -0.53, p = 0.593; Std. beta = -0.04, 95% CI [-0.21, 0.12]
ECAT – Accuracy (negative)	**All**	(F(3) = 0.15, p = 0.932; Eta2 (partial) = 2.44e-04, 90% CI [0.00, 3.73e-04]	N/A	F(3) = 1.37, p = 0.250; Eta2 (partial) = 2.29e-03, 90% CI [0.00, 5.95e-03]	N/A	F(3) = 1.20, p = 0.307; Eta2 (partial) = 2.12e-03, 90% CI [0.00, 5.71e-03]	N/A	F(3) = 1.22, p = 0.302; Eta2 (partial) = 2.16e-03, 90% CI [0.00, 5.81e-03]	N/A	F(3) = 1.05, p = 0.367; Eta2 (partial) = 1.86e-03, 90% CI [0.00, 5.19e-03]	N/A	F(3) = 2.59, p = 0.052; Eta2 (partial) = 5.89e-03, 90% CI [0.00, 0.01]	N/A	F(3) = 1.41, p = 0.238; Eta2 (partial) = 2.53e-03, 90% CI [0.00, 6.53e-03]	N/A
	Statin vs Neither	F(1) = 0.04, p = 0.849; Eta2 (partial) = 2.30e-05, 90% CI [0.00, 1.41e-03])	beta = 0.12, 95% CI [-1.09, 1.32], t(5510) = 0.19, p = 0.850; Std. beta = 0.02, 95% CI [-0.16, 0.19]	F(1) = 0.25, p = 0.616; Eta2 (partial) = 1.60e-04, 90% CI [0.00, 2.80e-03]	beta = -0.28, 95% CI [-1.49, 0.93], t(5501) = -0.45, p = 0.653; Std. beta = -0.04, 95% CI [-0.22, 0.14]	F(1) = 0.28, p = 0.599; Eta2 (partial) = 1.83e-04, 90% CI [0.00, 4.11e-04]	beta = -0.29, 95% CI [-1.52, 0.94], t(5329) = -0.46, p = 0.647; Std. beta = -0.04, 95% CI [-0.22, 0.14]	F(1) = 0.82, p = 0.365; Eta2 (partial) = 5.48e-04, 90% CI [0.00, 4.32e-03]	beta = -0.57, 95% CI [-1.93, 0.80], t(5267) = -0.81, p = 0.415; Std. beta = -0.08, 95% CI [-0.28, 0.12]	F(1) = 0.28, p = 0.599; Eta2 (partial) = 1.84e-04, 90% CI [0.00, 3.02e-03]	beta = -0.28, 95% CI [-1.51, 0.95], t(5316) = -0.44, p = 0.658; Std. beta = -0.04, 95% CI [-0.22, 0.14]	F(1) = 0.17, p = 0.680; Eta2 (partial) = 1.47e-04, 90% CI [0.00, 3.38e-03]	beta = -0.18, 95% CI [-1.07, 0.71], t(3927) = -0.40, p = 0.690; Std. beta = -0.04, 95% CI [-0.22, 0.15]	F(1) = 0.17, p = 0.681; Eta2 (partial) = 1.14e-04, 90% CI [0.00, 2.64e-03]	beta = -0.21, 95% CI [-1.44, 1.02], t(5248) = -0.34, p = 0.736; Std. beta = -0.03, 95% CI [-0.21, 0.15]

Outcome	Groups	Full dataset (n=2013)						Sensitivity Analyses							
								Excluding non-lipophilic (n=1991)		Excluding small gender groups (n=2007)		Excluding poor ECAT performance (<90%) (n=1445)		Excluding EREC poor performance (zero correct words) (n=1975)	
		Uncorrected		Corrected for demographics		Corrected for all covariates		Corrected for all covariates							
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
	BP vs Neither	(F(1) = 0.14, p = 0.705; Eta2 (partial) = 8.80e-05, 90% CI [0.00, 2.32e-03]	beta = -0.19, 95% CI [-1.18, 0.79], t(5510) = -0.39, p = 0.700; Std. beta = -0.03, 95% CI [-0.17, 0.12]	F(1) = 1.82, p = 0.178; Eta2 (partial) = 1.12e-03, 90% CI [0.00, 5.50e-03]	beta = -0.67, 95% CI [-1.66, 0.31], t(5501) = -1.34, p = 0.181; Std. beta = -0.10, 95% CI [-0.24, 0.05]	F(1) = 2.36, p = 0.125; Eta2 (partial) = 1.54e-03, 90% CI [0.00, 6.59e-03]	beta = -0.77, 95% CI [-1.78, 0.24], t(5329) = -1.49, p = 0.136; Std. beta = -0.11, 95% CI [-0.26, 0.04]	F(1) = 2.39, p = 0.122; Eta2 (partial) = 1.57e-03, 90% CI [0.00, 6.64e-03]	beta = -0.78, 95% CI [-1.79, 0.23], t(5267) = -1.51, p = 0.132; Std. beta = -0.11, 95% CI [-0.26, 0.03]	F(1) = 1.89, p = 0.169; Eta2 (partial) = 1.24e-03, 90% CI [0.00, 5.96e-03]	beta = -0.69, 95% CI [-1.70, 0.33], t(5316) = -1.33, p = 0.184; Std. beta = -0.10, 95% CI [-0.25, 0.05]	F(1) = 3.98, p = 0.046; Eta2 (partial) = 3.38e-03, 90% CI [2.86e-05, 0.01]	beta = -0.71, 95% CI [-1.44, 0.02], t(3927) = -1.90, p = 0.057; Std. beta = -0.15, 95% CI [-0.30, 4.55e-03]	F(1) = 2.54, p = 0.111; Eta2 (partial) = 1.69e-03, 90% CI [0.00, 6.96e-03]	beta = -0.80, 95% CI [-1.81, 0.21], t(5248) = -1.55, p = 0.121; Std. beta = -0.12, 95% CI [-0.27, 0.03]
	Both vs Neither	(F(1) = 0.26, p = 0.613; Eta2 (partial) = 1.58e-04, 90% CI [0.00, 2.74e-03]	beta = -0.27, 95% CI [-1.31, 0.77], t(5510) = -0.51, p = 0.611; Std. beta = -0.04, 95% CI [-0.19, 0.11]	F(1) = 3.43, p = 0.064; Eta2 (partial) = 2.13e-03, 90% CI [0.00, 7.56e-03]	beta = -0.90, 95% CI [-1.96, 0.16], t(5501) = -1.66, p = 0.098; Std. beta = -0.13, 95% CI [-0.29, 0.02]	F(1) = 2.38, p = 0.123; Eta2 (partial) = 1.56e-03, 90% CI [0.00, 6.61e-03]	beta = -0.74, 95% CI [-1.83, 0.34], t(5329) = -1.34, p = 0.181; Std. beta = -0.11, 95% CI [-0.27, 0.05]	F(1) = 2.00, p = 0.157; Eta2 (partial) = 1.31e-03, 90% CI [0.00, 6.11e-03]	beta = -0.68, 95% CI [-1.78, 0.43], t(5267) = -1.19, p = 0.232; Std. beta = -0.10, 95% CI [-0.26, 0.06]	F(1) = 2.40, p = 0.122; Eta2 (partial) = 1.57e-03, 90% CI [0.00, 6.65e-03]	beta = -0.73, 95% CI [-1.82, 0.35], t(5316) = -1.32, p = 0.186; Std. beta = -0.11, 95% CI [-0.27, 0.05]	F(1) = 5.68, p = 0.017; Eta2 (partial) = 4.79e-03, 90% CI [4.48e-04, 0.01]	beta = -0.89, 95% CI [-1.67, -0.11], t(3927) = -2.24, p < .05; Std. beta = -0.19, 95% CI [-0.35, -0.02]	F(1) = 3.03, p = 0.082; Eta2 (partial) = 2.02e-03, 90% CI [0.00, 7.59e-03]	beta = -0.86, 95% CI [-1.96, 0.24], t(5248) = -1.53, p = 0.127; Std. beta = -0.13, 95% CI [-0.29, 0.04]
ECAT – RT	**All**	Group: F(3) = 1.27, p = 0.284; Eta2 (partial) = 1.92e-03, 90% CI [0.00, 5.11e-03] Interaction: F(3) = 0.63, p = 0.592; Eta2 (partial) = 2.12e-04, 90% CI [0.00, 6.70e-04]	N/A	Group: F(3) = 0.18, p = 0.913; Eta2 (partial) = 2.68e-04, 90% CI [0.00, 6.29e-04] Interaction: F(3) = 0.63, p = 0.592; Eta2 (partial) = 2.12e-04, 90% CI [0.00, 4.75e-04]	N/A	Group: F(3) = 0.31, p = 0.815; Eta2 (partial) = 5.10e-04, 90% CI [0.00, 1.71e-03] Interaction: F(3) = 0.64, p = 0.591; Eta2 (partial) = 2.17e-04, 90% CI [0.00, 6.87e-04]	N/A	Group: F(3) = 0.17, p = 0.915; Eta2 (partial) = 2.83e-04, 90% CI [0.00, 6.48e-04] Interaction: F(3) = 0.22, p = 0.886; Eta2 (partial) = 7.42e-05, 90% CI [0.00, 2.16e-04]	N/A	Group: F(3) = 0.29, p = 0.831; Eta2 (partial) = 4.74e-04, 90% CI [0.00, 1.57e-03] Interaction: F(3) = 0.61, p = 0.606; Eta2 (partial) = 2.10e-04, 90% CI [0.00, 6.69e-04]	N/A	Group: F(3) = 0.57, p = 0.632; Eta2 (partial) = 1.29e-03, 90% CI [0.00, 4.16e-03] Interaction: F(3) = 1.25, p = 0.290; Eta2 (partial) = 5.74e-04, 90% CI [0.00, 1.53e-03]	N/A	Group: F(3) = 0.37, p = 0.775; Eta2 (partial) = 6.08e-04, 90% CI [0.00, 2.05e-03] Interaction: F(3) = 0.61, p = 0.606; Eta2 (partial) = 2.13e-04, 90% CI [0.00, 6.78e-04]	N/A

Outcome	Groups	Full dataset (n=2013)						Sensitivity Analyses							
								Excluding non-lipophilic (n=1991)		Excluding small gender groups (n=2007)		Excluding poor ECAT performance (<90%) (n=1445)		Excluding EREC poor performance (zero correct words) (n=1975)	
		Uncorrected		Corrected for demographics		Corrected for all covariates		Corrected for all covariates							
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
EREC - Correct words (both valences)	**All**	Group: F(3) = 6.43, p < .001; Eta2 (partial) = 9.59e-03, 90% CI [2.98e-03, 0.02] Interaction: F(3) = 4.00, p = 0.007; Eta2 (partial) = 1.26e-03, 90% CI [1.96e-04, 2.48e-03]	N/A	Group: F(3) = 0.94, p = 0.420; Eta2 (partial) = 1.42e-03, 90% CI [0.00, 4.09e-03] Interaction: F(3) = 4.00, p = 0.007; Eta2 (partial) = 1.26e-03, 90% CI [1.96e-04, 2.48e-03]	N/A	Group: F(3) = 0.61, p = 0.607; Eta2 (partial) = 9.73e-04, 90% CI [0.00, 3.10e-03] Interaction: F(3) = 3.71, p = 0.011; Eta2 (partial) = 1.19e-03, 90% CI [1.53e-04, 2.39e-03]	N/A	Group: F(3) = 0.79, p = 0.499; Eta2 (partial) = 1.27e-03, 90% CI [0.00, 3.82e-03] Interaction: F(3) = 3.58, p = 0.013; Eta2 (partial) = 1.17e-03, 90% CI [1.36e-04, 2.36e-03]	N/A	Group: F(3) = 0.61, p = 0.608; Eta2 (partial) = 9.73e-04, 90% CI [0.00, 3.10e-03] Interaction: F(3) = 3.71, p = 0.011; Eta2 (partial) = 1.19e-03, 90% CI [1.53e-04, 2.40e-03]	N/A	Group: F(3) = 3.15, p = 0.024; Eta2 (partial) = 7.04e-03, 90% CI [4.94e-04, 0.01] Interaction: F(3) = 4.25, p = 0.005; Eta2 (partial) = 1.91e-03, 90% CI [3.36e-04, 3.71e-03]	N/A	Group: F(3) = 0.34, p = 0.799; Eta2 (partial) = 5.44e-04, 90% CI [0.00, 1.83e-03] Interaction: F(3) = 3.34, p = 0.018; Eta2 (partial) = 1.09e-03, 90% CI [9.98e-05, 2.25e-03]	N/A
EREC– Correct words (positive)	**All**	F(3) = 7.67, p < .001; Eta2 (partial) = 0.01, 90% CI [4.13e-03, 0.02]	N/A	F(3) = 1.83, p = 0.140; Eta2 (partial) = 2.75e-03, 90% CI [0.00, 6.63e-03]	N/A	F(3) = 1.26, p = 0.287; Eta2 (partial) = 2.01e-03, 90% CI [0.00, 5.35e-03]	N/A	F(3) = 1.48, p = 0.219; Eta2 (partial) = 2.38e-03, 90% CI [0.00, 6.07e-03]	N/A	F(3) = 1.26, p = 0.288; Eta2 (partial) = 2.01e-03, 90% CI [0.00, 5.35e-03]	N/A	F(3) = 4.07, p = 0.007; Eta2 (partial) = 9.10e-03, 90% CI [1.46e-03, 0.02]	N/A	F(3) = 0.80, p = 0.492; Eta2 (partial) = 1.31e-03, 90% CI [0.00, 3.98e-03]	N/A
	Statin vs Neither	F(1) = 6.76, p = 0.009; Eta2 (partial) = 3.80e-03, 90% CI [5.11e-04, 0.01]	beta = -0.52, 95% CI [-0.90, -0.13], t(5782) = -2.61, p < .01; Std. beta = -0.23, 95% CI [-0.40, -0.06]	F(1) = 1.01, p = 0.314; Eta2 (partial) = 5.75e-04, 90% CI [0.00, 3.97e-03]	beta = -0.21, 95% CI [-0.60, 0.18], t(5773) = -1.04, p = 0.300; Std. beta = -0.09, 95% CI [-0.27, 0.08]	F(1) = 0.39, p = 0.531; Eta2 (partial) = 2.37e-04, 90% CI [0.00, 3.04e-03]	beta = -0.14, 95% CI [-0.55, 0.26], t(5595) = -0.70, p = 0.481; Std. beta = -0.06, 95% CI [-0.24, 0.11]	F(1) = 0.35, p = 0.552; Eta2 (partial) = 2.14e-04, 90% CI [0.00, 2.97e-03]	beta = -0.15, 95% CI [-0.60, 0.29], t(5529) = -0.68, p = 0.497; Std. beta = -0.07, 95% CI [-0.27, 0.13]	F(1) = 0.39, p = 0.531; Eta2 (partial) = 2.36e-04, 90% CI [0.00, 3.00e-03]	beta = -0.14, 95% CI [-0.55, 0.26], t(5582) = -0.70, p = 0.481; Std. beta = -0.06, 95% CI [-0.24, 0.11]	F(1) = 5.43, p = 0.020; Eta2 (partial) = 4.57e-03, 90% CI [3.78e-04, 0.01]	beta = -0.54, 95% CI [-1.00, -0.09], t(3985) = -2.35, p < .05; Std. beta = -0.24, 95% CI [-0.45, -0.04]	F(1) = 0.38, p = 0.540; Eta2 (partial) = 2.29e-04, 90% CI [0.00, 3.04e-03]	beta = -0.14, 95% CI [-0.54, 0.26], t(5497) = -0.69, p = 0.493; Std. beta = -0.06, 95% CI [-0.24, 0.12]
	BP vs Neither	F(1) = 3.18, p = 0.075; Eta2 (partial) = 1.76e-03, 90% CI	beta = -0.29, 95% CI [-0.60, 0.03], t(5782) = -1.78, p = 0.076; Std.	F(1) = 1.15, p = 0.284; Eta2 (partial) = 6.38e-04, 90% CI	beta = -0.16, 95% CI [-0.48, 0.15], t(5773) = -1.02, p = 0.310; Std.	F(1) = 0.80, p = 0.372; Eta2 (partial) = 4.70e-04, 90% CI	beta = -0.13, 95% CI [-0.46, 0.19], t(5595) = -0.81, p = 0.420; Std.	F(1) = 0.82, p = 0.364; Eta2 (partial) = 4.86e-04, 90% CI	beta = -0.14, 95% CI [-0.47, 0.18], t(5529) = -0.85, p = 0.396; Std.	F(1) = 0.81, p = 0.368; Eta2 (partial) = 4.78e-04, 90% CI	beta = -0.14, 95% CI [-0.46, 0.19], t(5582) = -0.81, p = 0.417; Std.	F(1) = 1.37, p = 0.243; Eta2 (partial) = 1.14e-03, 90% CI	beta = -0.22, 95% CI [-0.59, 0.16], t(3985) = -1.15, p = 0.251; Std.	F(1) = 0.55, p = 0.459; Eta2 (partial) = 3.28e-04, 90% CI	beta = -0.11, 95% CI [-0.44, 0.22], t(5497) = -0.66, p = 0.511;

Outcome	Groups	Full dataset (n=2013)						Sensitivity Analyses							
								Excluding non-lipophilic (n=1991)		Excluding small gender groups (n=2007)		Excluding poor ECAT performance (<90%) (n=1445)		Excluding EREC poor performance (zero correct words) (n=1975)	
		Uncorrected		Corrected for demographics		Corrected for all covariates		Corrected for all covariates							
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
		[0.00, 6.49e-03]	beta = -0.13, 95% CI [-0.27, 0.01]	[0.00, 4.09e-03]	beta = -0.07, 95% CI [-0.21, 0.07]	[0.00, 3.78e-03]	beta = -0.06, 95% CI [-0.20, 0.09]	[0.00, 3.82e-03]	beta = -0.06, 95% CI [-0.21, 0.08]	[0.00, 1.07e-03]	beta = -0.06, 95% CI [-0.21, 0.09]	[0.00, 6.57e-03]	beta = -0.10, 95% CI [-0.27, 0.07]	[0.00, 3.37e-03]	Std. beta = -0.05, 95% CI [-0.19, 0.10]
	Both vs Neither	F(1) = 15.36, p < .001; Eta2 (partial) = 8.55e-03, 90% CI [2.89e-03, 0.02]	(beta = -0.66, 95% CI [-1.00, -0.33], t(5782) = -3.90, p < .001; Std. beta = -0.30, 95% CI [-0.44, -0.15]	F(1) = 5.33, p = 0.021; Eta2 (partial) = 3.00e-03, 90% CI [2.37e-04, 8.75e-03]	beta = -0.36, 95% CI [-0.71, -0.02], t(5773) = -2.09, p < .05; Std. beta = -0.16, 95% CI [-0.32, -9.81e-03]	F(1) = 3.87, p = 0.049; Eta2 (partial) = 2.30e-03, 90% CI [2.80e-06, 7.71e-03]	beta = -0.32, 95% CI [-0.68, 0.03], t(5595) = -1.80, p = 0.072; Std. beta = -0.14, 95% CI [-0.30, 0.01]	F(1) = 4.45, p = 0.035; Eta2 (partial) = 2.65e-03, 90% CI [9.58e-05, 8.36e-03]	beta = -0.36, 95% CI [-0.72, -2.23e-03], t(5529) = -1.97, p < .05; Std. beta = -0.16, 95% CI [-0.32, -9.93e-04]	F(1) = 3.85, p = 0.050; Eta2 (partial) = 2.29e-03, 90% CI [6.43e-08, 7.70e-03]	beta = -0.32, 95% CI [-0.68, 0.03], t(5582) = -1.80, p = 0.072; Std. beta = -0.14, 95% CI [-0.30, 0.01]	F(1) = 7.87, p = 0.005; Eta2 (partial) = 6.57e-03, 90% CI [1.12e-03, 0.02]	beta = -0.56, 95% CI [-0.96, -0.17], t(3985) = -2.78, p < .01; Std. beta = -0.25, 95% CI [-0.43, -0.07]	F(1) = 2.37, p = 0.124; Eta2 (partial) = 1.44e-03, 90% CI [0.00, 6.12e-03]	beta = -0.25, 95% CI [-0.61, 0.10], t(5497) = -1.39, p = 0.163; Std. beta = -0.11, 95% CI [-0.27, 0.05]
EREC – Correct words (negative)	**All**	F(3) = 3.50, p = 0.015; Eta2 (partial) = 5.28e-03, 90% CI [5.68e-04, 0.01]	N/A	F(3) = 0.86, p = 0.461; Eta2 (partial) = 1.31e-03, 90% CI [0.00, 3.86e-03]	N/A	F(3) = 0.76, p = 0.517; Eta2 (partial) = 1.21e-03, 90% CI [0.00, 3.67e-03]	N/A	F(3) = 0.85, p = 0.466; Eta2 (partial) = 1.37e-03, 90% CI [0.00, 4.04e-03]	N/A	F(3) = 0.74, p = 0.530; Eta2 (partial) = 1.18e-03, 90% CI [0.00, 3.60e-03]	N/A	F(3) = 1.68, p = 0.169; Eta2 (partial) = 3.78e-03, 90% CI [0.00, 9.30e-03]	N/A	F(3) = 0.73, p = 0.533; Eta2 (partial) = 1.19e-03, 90% CI [0.00, 3.63e-03]	N/A
	Statin vs Neither	F(1) = 1.50, p = 0.220; Eta2 (partial) = 8.57e-04, 90% CI [0.00, 4.68e-03]	beta = -0.20, 95% CI [-0.53, 0.12], t(5782) = -1.23, p = 0.217; Std. beta = -0.11, 95% CI [-0.28, 0.06]	F(1) = 0.30, p = 0.584; Eta2 (partial) = 1.72e-04, 90% CI [0.00, 2.67e-03]	beta = 0.10, 95% CI [-0.23, 0.42], t(5773) = 0.57, p = 0.571; Std. beta = 0.05, 95% CI [-0.12, 0.23]	F(1) = 0.85, p = 0.357; Eta2 (partial) = 5.09e-04, 90% CI [0.00, 3.93e-03]	beta = 0.15, 95% CI [-0.19, 0.48], t(5595) = 0.85, p = 0.395; Std. beta = 0.08, 95% CI [-0.10, 0.26]	F(1) = 0.93, p = 0.335; Eta2 (partial) = 5.61e-04, 90% CI [0.00, 4.09e-03]	beta = 0.17, 95% CI [-0.21, 0.54], t(5529) = 0.87, p = 0.384; Std. beta = 0.09, 95% CI [-0.11, 0.29]	F(1) = 0.85, p = 0.356; Eta2 (partial) = 5.12e-04, 90% CI [0.00, 3.94e-03]	beta = 0.15, 95% CI [-0.19, 0.48], t(5582) = 0.85, p = 0.395; Std. beta = 0.08, 95% CI [-0.10, 0.26]	F(1) = 0.58, p = 0.447; Eta2 (partial) = 4.88e-04, 90% CI [0.00, 4.84e-03]	beta = -0.16, 95% CI [-0.55, 0.23], t(3985) = -0.82, p = 0.415; Std. beta = -0.09, 95% CI [-0.30, 0.12]	F(1) = 0.84, p = 0.361; Eta2 (partial) = 5.09e-04, 90% CI [0.00, 3.96e-03]	beta = 0.14, 95% CI [-0.19, 0.48], t(5497) = 0.84, p = 0.399; Std. beta = 0.08, 95% CI [-0.10, 0.26]
	BP vs Neither	F(1) = 5.86e-03, p = 0.939; Eta2 (partial) = 3.29e-06, 90% CI	beta = 0.01, 95% CI [-0.25, 0.27], t(5782) = 0.08, p = 0.939; Std. beta =	F(1) = 1.27, p = 0.259; Eta2 (partial) = 7.18e-04, 90% CI [0.00, 4.32e-03]	beta = 0.16, 95% CI [-0.11, 0.42], t(5773) = 1.15, p = 0.252; Std. beta =	F(1) = 1.05, p = 0.307; Eta2 (partial) = 6.15e-04, 90% CI [0.00, 4.17e-03]	beta = 0.15, 95% CI [-0.12, 0.42], t(5595) = 1.07, p = 0.284; Std. beta =	F(1) = 1.02, p = 0.312; Eta2 (partial) = 6.04e-04, 90% CI [0.00, 4.14e-03]	beta = 0.14, 95% CI [-0.13, 0.42], t(5529) = 1.05, p = 0.296; Std. beta =	F(1) = 0.97, p = 0.326; Eta2 (partial) = 5.70e-04, 90% CI [0.00, 4.05e-03]	beta = 0.14, 95% CI [-0.13, 0.42], t(5582) = 1.04, p = 0.300; Std. beta =	F(1) = 0.25, p = 0.616; Eta2 (partial) = 2.10e-04, 90% CI [0.00, 3.68e-03]	beta = 0.08, 95% CI [-0.24, 0.40], t(3985) = 0.49, p = 0.625; Std. beta =	F(1) = 1.33, p = 0.248; Eta2 (partial) = 7.98e-04, 90% CI [0.00, 4.67e-03]	beta = 0.17, 95% CI [-0.11, 0.44], t(5497) = 1.20, p = 0.229; Std. beta

Outcome	Groups	Full dataset (n=2013)						Sensitivity Analyses							
								Excluding non-lipophilic (n=1991)		Excluding small gender groups (n=2007)		Excluding poor ECAT performance (<90%) (n=1445)		Excluding EREC poor performance (zero correct words) (n=1975)	
		Uncorrected		Corrected for demographics		Corrected for all covariates		Corrected for all covariates							
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
		[0.00, 2.24e-04]	5.47e-03, 95% CI [-0.14, 0.15]		0.08, 95% CI [-0.06, 0.22]		0.08, 95% CI [-0.07, 0.22]		0.08, 95% CI [-0.07, 0.22]		0.08, 95% CI [-0.07, 0.22]		0.04, 95% CI [-0.13, 0.22]		= 0.09, 95% CI [-0.06, 0.24]
	Both vs Neither	F(1) = 9.26, p = 0.002; Eta2 (partial) = 5.22e-03, 90% CI [1.10e-03, 0.01]	beta = -0.43, 95% CI [-0.71, -0.15], t(5782) = -3.04, p < .01; Std. beta = -0.23, 95% CI [-0.38, -0.08]	F(1) = 1.33, p = 0.249; Eta2 (partial) = 7.59e-04, 90% CI [0.00, 4.45e-03]	beta = -0.12, 95% CI [-0.41, 0.17], t(5773) = -0.83, p = 0.405; Std. beta = -0.07, 95% CI [-0.22, 0.09]	F(1) = 0.57, p = 0.452; Eta2 (partial) = 3.36e-04, 90% CI [0.00, 3.38e-03]	beta = -0.08, 95% CI [-0.37, 0.22], t(5595) = -0.53, p = 0.599; Std. beta = -0.04, 95% CI [-0.20, 0.11]	F(1) = 0.80, p = 0.371; Eta2 (partial) = 4.77e-04, 90% CI [0.00, 3.82e-03]	beta = -0.11, 95% CI [-0.41, 0.19], t(5529) = -0.70, p = 0.484; Std. beta = -0.06, 95% CI [-0.22, 0.10]	F(1) = 0.57, p = 0.450; Eta2 (partial) = 3.40e-04, 90% CI [0.00, 3.40e-03]	beta = -0.08, 95% CI [-0.37, 0.21], t(5582) = -0.53, p = 0.593; Std. beta = -0.04, 95% CI [-0.20, 0.11]	F(1) = 4.30, p = 0.038; Eta2 (partial) = 3.60e-03, 90% CI [9.97e-05, 0.01]	beta = -0.35, 95% CI [-0.69, -0.01], t(3985) = -2.03, p < .05; Std. beta = -0.19, 95% CI [-0.37, -6.68e-03]	F(1) = 0.20, p = 0.657; Eta2 (partial) = 1.20e-04, 90% CI [0.00, 2.69e-04]	beta = -0.04, 95% CI [-0.34, 0.26], t(5497) = -0.23, p = 0.815; Std. beta = -0.02, 95% CI [-0.18, 0.14]

FERT – split by time-point

Outcome	Groups	FERT split by time point – all fully corrected					
		Baseline (n=2013)		Phase 2 (n=1892)		Phase 3 (n=1794)	
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
All emotions - UBHR	All	Group: F(3) = 2.79, p = 0.039; Eta2 (partial) = 4.45e-03, 90% CI [1.13e-04, 9.56e-03] Interaction: F(18) = 2.78, p < .001; Eta2 (partial) = 4.39e-03, 90% CI [1.29e-03, 5.00e-03]	N/A	Group: F(3) = 4.73, p = 0.003; Eta2 (partial) = 7.53e-03, 90% CI [1.59e-03, 0.01] Interaction: F(18) = 2.51, p < .001; Eta2 (partial) = 3.97e-03, 90% CI [9.77e-04, 4.48e-03]	N/A	Group: F(3) = 1.39, p = 0.245; Eta2 (partial) = 2.40e-03, 90% CI [0.00, 6.22e-03] Interaction: F(18) = 2.45, p < .001; Eta2 (partial) = 4.19e-03, 90% CI [9.83e-04, 4.71e-03]	N/A
Angry - UBHR	All	F(3, 1869) = 6.05, p < .001; Eta2 (partial) = 9.62e-03, 90% CI [2.80e-03, 0.02]	N/A	F(3, 1865) = 9.77, p < .001; Eta2 (partial) = 0.02, 90% CI [6.65e-03, 0.02]	N/A	F(3, 1727) = 3.00, p = 0.029; Eta2 (partial) = 5.19e-03, 90% CI [2.72e-04, 0.01]	N/A
	Statins vs Neither	F(1, 1650) = 15.23, p < .001; Eta2 (partial) = 9.15e-03, 90% CI [3.07e-03, 0.02]	beta = -0.05, 95% CI [-0.08, -0.01], t(1869) = -2.82, p < .01; Std. beta = -0.34, 95% CI [-0.58, -0.10]	F(1, 1643) = 12.79, p < .001; Eta2 (partial) = 7.72e-03, 90% CI [2.26e-03, 0.02]	beta = -0.06, 95% CI [-0.09, -0.02], t(1865) = -3.00, p < .01; Std. beta = -0.36, 95% CI [-0.60, -0.12]	F(1, 1513) = 3.70, p = 0.054; Eta2 (partial) = 2.44e-03, 90% CI [0.00, 8.35e-03]	beta = -0.03, 95% CI [-0.07, 7.72e-03], t(1727) = -1.59, p = 0.113; Std. beta = -0.19, 95% CI [-0.43, 0.05]
	BP vs neither	F(1, 1690) = 0.54, p = 0.461; Eta2 (partial) = 3.21e-04, 90% CI [0.00, 3.32e-03]	beta = -1.00e-04, 95% CI [-0.03, 0.03], t(1869) = -7.43e-03, p = 0.994; Std. beta = -7.29e-04, 95% CI [-0.19, 0.19]	F(1, 1685) = 2.01, p = 0.156; Eta2 (partial) = 1.19e-03, 90% CI [0.00, 5.54e-03]	beta = -0.01, 95% CI [-0.04, 0.01], t(1865) = -0.99, p = 0.321; Std. beta = -0.10, 95% CI [-0.29, 0.09]	F(1, 1552) = 2.77, p = 0.096; Eta2 (partial) = 1.78e-03, 90% CI [0.00, 7.00e-03]	beta = -0.03, 95% CI [-0.06, 5.35e-03], t(1727) = -1.64, p = 0.100; Std. beta = -0.16, 95% CI [-0.36, 0.03]
	Both vs neither	F(1, 1679) = 3.66, p = 0.056; Eta2 (partial) = 2.18e-03, 90% CI [0.00, 7.49e-03]	beta = -0.01, 95% CI [-0.04, 0.02], t(1869) = -0.72, p = 0.472; Std. beta = -0.08, 95% CI [-0.28, 0.13]	F(1, 1675) = 17.24, p < .001; Eta2 (partial) = 0.01, 90% CI [3.72e-03, 0.02]	beta = -0.06, 95% CI [-0.09, -0.02], t(1865) = -3.38, p < .001; Std. beta = -0.35, 95% CI [-0.56, -0.15]	F(1, 1540) = 3.63, p = 0.057; Eta2 (partial) = 2.35e-03, 90% CI [0.00, 8.12e-03]	beta = -0.03, 95% CI [-0.07, 2.64e-03], t(1727) = -1.82, p = 0.069; Std. beta = -0.20, 95% CI [-0.41, 0.02]
Fear - UBHR	All	F(3, 1869) = 5.54, p < .001; Eta2 (partial) = 8.81e-03, 90% CI [2.32e-03, 0.02]	N/A	F(3, 1861) = 4.17, p = 0.006; Eta2 (partial) = 6.67e-03, 90% CI [1.12e-03, 0.01]	N/A	F(3, 1727) = 4.92, p = 0.002; Eta2 (partial) = 8.47e-03, 90% CI [1.90e-03, 0.02]	N/A
	Statin vs neither	F(1, 1650) = 11.64, p < .001; Eta2 (partial) = 7.01e-03, 90% CI [1.88e-03, 0.02]	beta = -0.05, 95% CI [-0.09, -0.02], t(1869) = -2.91, p < .01; Std. beta = -0.35, 95% CI [-0.59, -0.12]	F(1, 1639) = 5.59, p = 0.018; Eta2 (partial) = 3.40e-03, 90% CI [3.06e-04, 9.72e-03]	beta = -0.03, 95% CI [-0.06, 2.56e-03], t(1861) = -1.81, p = 0.071; Std. beta = -0.22, 95% CI [-0.46, 0.02]	F(1, 1513) = 5.89, p = 0.015; Eta2 (partial) = 3.88e-03, 90% CI [3.95e-04, 0.01]	beta = -0.03, 95% CI [-0.07, 2.06e-03], t(1727) = -1.84, p = 0.066; Std. beta = -0.22, 95% CI [-0.46, 0.01]
	BP vs neither	F(1, 1690) = 1.17, p = 0.279; Eta2 (partial) = 6.92e-04, 90% CI [0.00, 4.38e-03]	beta = -0.01, 95% CI [-0.04, 0.01], t(1869) = -1.00, p = 0.315; Std. beta = -0.10, 95% CI [-0.29, 0.09]	F(1, 1682) = 2.73, p = 0.099; Eta2 (partial) = 1.62e-03, 90% CI [0.00, 6.42e-03]	beta = -0.02, 95% CI [-0.04, 0.01], t(1861) = -1.14, p = 0.254; Std. beta = -0.11, 95% CI [-0.30, 0.08]	F(1, 1552) = 2.00, p = 0.158; Eta2 (partial) = 1.28e-03, 90% CI [0.00, 5.99e-03]	beta = -0.02, 95% CI [-0.04, 0.01], t(1727) = -1.10, p = 0.271; Std. beta = -0.11, 95% CI [-0.30, 0.09]
	Both vs neither	F(1, 1679) = 5.05, p = 0.025; Eta2 (partial) = 3.00e-03, 90% CI [1.99e-04, 8.95e-03]	beta = -0.03, 95% CI [-0.06, 2.76e-03], t(1869) = -1.79, p = 0.074; Std. beta = -0.19, 95% CI [-0.40, 0.02]	F(1, 1672) = 5.26, p = 0.022; Eta2 (partial) = 3.14e-03, 90% CI [2.38e-04, 9.20e-03]	beta = -0.02, 95% CI [-0.05, 4.22e-03], t(1861) = -1.67, p = 0.096; Std. beta = -0.18, 95% CI [-0.38, 0.03]	F(1, 1540) = 8.28, p = 0.004; Eta2 (partial) = 5.35e-03, 90% CI [9.81e-04, 0.01]	beta = -0.04, 95% CI [-0.07, -5.90e-03], t(1727) = -2.35, p < .05; Std. beta = -0.25, 95% CI [-0.47, -0.04]

Outcome	Groups	FERT split by time point – all fully corrected					
		Baseline (n=2013)		Phase 2 (n=1892)		Phase 3 (n=1794)	
		ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
Anger – misclassifications (all)	**All**	Group: F(3, 11319) = 4.42, p = 0.004; Eta2 (partial) = 1.17e-03, 90% CI [2.20e-04, 2.25e-03] Interaction: F(15, 11319) = 1.20, p = 0.266; Eta2 (partial) = 1.58e-03, 90% CI [0.00, 1.57e-03]	N/A	Group: F(3, 11295) = 8.89, p < .001; Eta2 (partial) = 2.35e-03, 90% CI [9.48e-04, 3.89e-03] Interaction: F(15, 11295) = 2.92, p < .001; Eta2 (partial) = 3.86e-03, 90% CI [1.12e-03, 4.63e-03]	N/A	Group: F(3, 10467) = 3.69, p = 0.011; Eta2 (partial) = 1.06e-03, 90% CI [1.34e-04, 2.12e-03] Interaction: F(15, 10467) = 1.37, p = 0.150; Eta2 (partial) = 1.96e-03, 90% CI [0.00, 2.07e-03]	N/A
Anger – misclassifications (surprise)	**Statin vs neither**	(F(1, 1650) = 1.51, p = 0.220; Eta2 (partial) = 9.12e-04, 90% CI [0.00, 4.98e-03]	beta = 0.08, 95% CI [-0.06, 0.22], t(1650) = 1.08, p = 0.281; Std. beta = 0.13, 95% CI [-0.11, 0.37]	F(1, 1643) = 2.08, p = 0.150; Eta2 (partial) = 1.26e-03, 90% CI [0.00, 5.77e-03]	beta = 0.14, 95% CI [0.01, 0.26], t(1643) = 2.17, p < .05; Std. beta = 0.26, 95% CI [0.03, 0.50]	F(1, 1513) = 9.71, p = 0.002; Eta2 (partial) = 6.38e-03, 90% CI [1.42e-03, 0.01]	beta = 0.29, 95% CI [0.15, 0.43], t(1513) = 4.12, p < .001; Std. beta = 0.50, 95% CI [0.26, 0.74]
Fear – misclassifications (all)	**All**	Group: F(3, 11319) = 2.98, p = 0.030; Eta2 (partial) = 7.90e-04, 90% CI [4.01e-05, 1.68e-03] Interaction: F(15, 11319) = 3.23, p < .001; Eta2 (partial) = 4.26e-03, 90% CI [1.41e-03, 8.06e-03]	N/A	Group: F(3, 11295) = 2.87, p = 0.035; Eta2 (partial) = 7.61e-04, 90% CI [2.73e-05, 1.63e-03] Interaction: F(15, 11295) = 0.81, p = 0.667; Eta2 (partial) = 1.07e-03, 90% CI [0.00, 7.84e-04]	N/A	Group: F(3, 10467) = 4.78, p = 0.002; Eta2 (partial) = 1.37e-03, 90% CI [2.94e-04, 2.58e-03] Interactions: F(15, 10467) = 1.20, p = 0.264; Eta2 (partial) = 1.71e-03, 90% CI [0.00, 1.70e-03]	N/A
Fear – misclassifications (surprise)	**Statin vs neither**	F(1, 1650) = 0.25, p = 0.618; Eta2 (partial) = 1.50e-04, 90% CI [0.00, 2.66e-03]	beta = 1.19, 95% CI [0.09, 2.29], t(1650) = 2.11, p < .05; Std. beta = 0.25, 95% CI [0.02, 0.49]	F(1, 1643) = 0.61, p = 0.434; Eta2 (partial) = 3.72e-04, 90% CI [0.00, 3.55e-03]	beta = 0.85, 95% CI [-0.19, 1.88], t(1643) = 1.60, p = 0.109; Std. beta = 0.19, 95% CI [-0.04, 0.43]	F(1, 1513) = 0.67, p = 0.414; Eta2 (partial) = 4.40e-04, 90% CI [0.00, 3.97e-03]	beta = 0.72, 95% CI [-0.21, 1.64], t(1513) = 1.52, p = 0.129; Std. beta = 0.19, 95% CI [-0.05, 0.43]
All emotions - RT	**All**	Group: F(3) = 1.96, p = 0.119; Eta2 (partial) = 3.13e-03, 90% CI [0.00, 7.39e-03] Interaction: F(18) = 3.12, p < .001; Eta2 (partial) = 4.94e-03, 90% CI [1.70e-03, 5.69e-03]	N/A	Group: F(3) = 0.81, p = 0.488; Eta2 (partial) = 1.30e-03, 90% CI [0.00, 2.92e-03] Interaction: F(18) = 2.70, p < .001; Eta2 (partial) = 4.28e-03, 90% CI [1.20e-03, 4.87e-03]	N/A	Group: F(3) = 1.61, p = 0.185; Eta2 (partial) = 2.79e-03, 90% CI [0.00, 6.95e-03] Interaction: F(18) = 2.20, p = 0.002; Eta2 (partial) = 3.76e-03, 90% CI [6.75e-04, 4.16e-03]	N/A
Anger - RT	**Statin vs neither**	F(1, 1649) = 43.20, p < .001; Eta2 (partial) = 0.03, 90% CI [0.01, 0.04]	beta = 148.35, 95% CI [50.87, 245.84], t(1649) = 2.98, p < .01; Std. beta = 0.34, 95% CI [0.12, 0.56]	F(1, 1642) = 18.68, p < .001; Eta2 (partial) = 0.01, 90% CI [4.33e-03, 0.02]	beta = 91.08, 95% CI [-11.87, 194.02], t(1642) = 1.74, p = 0.083; Std. beta = 0.20, 95% CI [-0.03, 0.43]	F(1, 1513) = 23.10, p < .001; Eta2 (partial) = 0.02, 90% CI [6.54e-03, 0.03]	beta = 119.98, 95% CI [25.93, 214.03], t(1513) = 2.50, p < .05; Std. beta = 0.30, 95% CI [0.06, 0.53]

Interactions with age and gender

FERT

Outcome	Interaction with Age		Interaction with Gender	
	ANCOVA	Linear regression	ANCOVA	Linear regression
All emotions - UBHR	Three way interaction (emotion, group, age): F(18) = 2.26, p = 0.002; Eta2 (partial) = 1.08e-03, 90% CI [2.10e-04, 1.20e-03]	N/A	Three way interaction (emotion, group, gender): F(24) = 1.56, p = 0.039; Eta2 (partial) = 9.93e-04, 90% CI [1.94e-05, 9.06e-04]	N/A
Angry - UBHR	Interaction (age and group): F(3) = 1.66, p = 0.173; Eta2 (partial) = 2.68e-03, 90% CI [0.00, 6.61e-03]	Interaction (both medications): beta = -3.51e-03, 95% CI [-6.94e-03, -7.83e-05], t(5502) = -2.00, p < .05; Std. beta = -0.32, 95% CI [-0.63, -7.06e-03] Interaction (bp med): beta = -7.49e-04, 95% CI [-2.74e-03, 1.24e-03], t(5502) = -0.74, p = 0.461; Std. beta = -0.07, 95% CI [-0.25, 0.11] Interaction (statin): beta = -1.08e-03, 95% CI [-3.71e-03, 1.55e-03], t(5502) = -0.81, p = 0.420; Std. beta = -0.10, 95% CI [-0.33, 0.14]	Interaction (gender and group): F(4) = 1.03, p = 0.391; Eta2 (partial) = 2.21e-03, 90% CI [0.00, 5.01e-03]	Interaction effect (male, both medications): beta = 0.02, 95% CI [-0.03, 0.07], t(5501) = 0.76, p = 0.446; Std. beta = 0.12, 95% CI [-0.20, 0.44] Interaction (male, bp med): beta = -0.03, 95% CI [-0.07, 0.02], t(5501) = -1.05, p = 0.295; Std. beta = -0.16, 95% CI [-0.47, 0.14] Interaction (male, statin):beta = -0.03, 95% CI [-0.09, 0.03], t(5501) = -1.04, p = 0.298; Std. beta = -0.20, 95% CI [-0.58, 0.18]
Disgust - UBHR	Interaction (age and group): F(3) = 0.86, p = 0.460; Eta2 (partial) = 1.40e-03, 90% CI [0.00, 4.13e-03]	Interaction (both medications): beta = 4.58e-04, 95% CI [-2.25e-03, 3.17e-03], t(5502) = 0.33, p = 0.740; Std. beta = 0.05, 95% CI [-0.24, 0.33] Interaction (bp med): beta = 1.03e-03, 95% CI [-5.42e-04, 2.61e-03], t(5502) = 1.29, p = 0.199; Std. beta = 0.11, 95% CI [-0.06, 0.27] Interaction (statin): beta = -9.21e-04, 95% CI [-3.00e-03, 1.16e-03], t(5502) = -0.87, p = 0.386; Std. beta = -0.10, 95% CI [-0.32, 0.12]	Interaction (gender and group): F(4) = 0.46, p = 0.767; Eta2 (partial) = 9.94e-04, 90% CI [0.00, 2.27e-03]	Interaction effect (male, both medications): beta = 0.02, 95% CI [-0.02, 0.06], t(5501) = 1.02, p = 0.309; Std. beta = 0.15, 95% CI [-0.14, 0.45] Interaction (male, bp med): beta = -0.01, 95% CI [-0.05, 0.03], t(5501) = -0.63, p = 0.529; Std. beta = -0.09, 95% CI [-0.37, 0.19] Interaction (male, statin): beta = -4.87e-03, 95% CI [-0.05, 0.04], t(5501) = -0.20, p = 0.840; Std. beta = -0.04, 95% CI [-0.39, 0.32]
Fear - UBHR	Interaction (age and group): F(3) = 0.60, p = 0.612; Eta2 (partial) = 9.71e-04, 90% CI [0.00, 3.10e-03]	Interaction effect (both medications): beta = -1.82e-03, 95% CI [-5.08e-03, 1.44e-03], t(5498) = -1.10, p = 0.273; Std. beta = -0.18, 95% CI [-0.50, 0.14] Interaction (bp med): beta = -7.27e-04, 95% CI [-2.62e-03, 1.17e-03], t(5498) = -0.75, p = 0.452; Std. beta = -0.07, 95% CI [-0.26, 0.11] Interaction (statin): beta = -4.89e-04, 95% CI [-2.99e-03, 2.01e-03], t(5498) = -0.38, p = 0.701; Std. beta = -0.05, 95% CI [-0.29, 0.20]	Interaction (gender and group): F(4) = 1.69, p = 0.151; Eta2 (partial) = 3.61e-03, 90% CI [0.00, 7.52e-03]	Interaction effect (male, both medications): beta = 0.03, 95% CI [-0.02, 0.07], t(5497) = 1.06, p = 0.287; Std. beta = 0.18, 95% CI [-0.15, 0.51] Interaction (male, bp med): beta = 2.31e-03, 95% CI [-0.04, 0.05], t(5497) = 0.10, p = 0.921; Std. beta = 0.02, 95% CI [-0.30, 0.33] Interaction (male, statin): beta = -0.07, 95% CI [-0.12, -9.91e-03], t(5497) = -2.30, p < .05; Std. beta = -0.46, 95% CI [-0.86, -0.07]
Happiness - UBHR	Interaction (age and group): F(3) = 3.88, p = 0.009; Eta2 (partial) = 6.32e-03, 90% CI [9.12e-04, 0.01]	Interaction effect (both medications): beta = -8.39e-04, 95% CI [-3.03e-03, 1.35e-03], t(5502) = -0.75, p = 0.453; Std. beta = -0.11, 95% CI [-0.39, 0.17]	Interaction (gender and group): F(4) = 0.45, p = 0.773; Eta2 (partial) = 9.81e-04, 90% CI [0.00, 2.23e-03]	Interaction effect (male, both medications): beta = -7.47e-03, 95% CI [-0.04, 0.02], t(5501) = -0.46, p = 0.649; Std. beta = -0.07, 95% CI [-0.36, 0.23]

Outcome	Interaction with Age		Interaction with Gender	
	ANCOVA	Linear regression	ANCOVA	Linear regression
		Interaction (bp med): beta = -8.57e-05, 95% CI [-1.36e-03, 1.19e-03], t(5502) = -0.13, p = 0.895; Std. beta = -0.01, 95% CI [-0.18, 0.15] Interaction (statin): beta = -2.87e-03, 95% CI [-4.55e-03, -1.19e-03], t(5502) = -3.34, p < .001; Std. beta = -0.37, 95% CI [-0.59, -0.15]		Interaction (male, bp med): beta = -9.09e-03, 95% CI [-0.04, 0.02], t(5501) = -0.58, p = 0.562; Std. beta = -0.08, 95% CI [-0.36, 0.20] Interaction (male, statin): beta = -0.02, 95% CI [-0.06, 0.02], t(5501) = -1.18, p = 0.237; Std. beta = -0.21, 95% CI [-0.56, 0.14]]
Sadness - UBHR	Interaction (age and group): F(3) = 1.54, p = 0.202; Eta2 (partial) = 2.49e-03, 90% CI [0.00, 6.28e-03]	Interaction effect (both medications): beta = 1.47e-03, 95% CI [-1.34e-03, 4.28e-03], t(5502) = 1.02, p = 0.306; Std. beta = 0.14, 95% CI [-0.13, 0.41] Interaction (bp med): beta = -4.81e-04, 95% CI [-2.11e-03, 1.15e-03], t(5502) = -0.58, p = 0.564; Std. beta = -0.05, 95% CI [-0.20, 0.11] Interaction (statin): beta = -1.96e-03, 95% CI [-4.12e-03, 1.92e-04], t(5502) = -1.79, p = 0.074; Std. beta = -0.19, 95% CI [-0.40, 0.02]	Interaction (gender and group): F(4) = 1.85, p = 0.116; Eta2 (partial) = 3.99e-03, 90% CI [0.00, 8.18e-03]	Interaction effect (male, both medications): beta = 0.02, 95% CI [-0.02, 0.06], t(5501) = 0.94, p = 0.350; Std. beta = 0.13, 95% CI [-0.15, 0.42] Interaction (male, bp med): beta = 4.12e-03, 95% CI [-0.04, 0.04], t(5501) = 0.21, p = 0.837; Std. beta = 0.03, 95% CI [-0.24, 0.30] Interaction (male, statin): beta = -0.05, 95% CI [-0.10, -1.69e-03], t(5501) = -2.03, p < .05; Std. beta = -0.35, 95% CI [-0.68, -0.01]
Surprise - UBHR	Interaction (age and group): F(3) = 0.33, p = 0.803; Eta2 (partial) = 5.40e-04, 90% CI [0.00, 1.82e-03]	Interaction effect (both medications): beta = 5.03e-04, 95% CI [-1.84e-03, 2.85e-03], t(5502) = 0.42, p = 0.674; Std. beta = 0.06, 95% CI [-0.22, 0.34] Interaction (bp med): beta = 6.25e-04, 95% CI [-7.37e-04, 1.99e-03], t(5502) = 0.90, p = 0.369; Std. beta = 0.07, 95% CI [-0.09, 0.24] Interaction (statin): beta = -1.32e-04, 95% CI [-1.93e-03, 1.67e-03], t(5502) = -0.14, p = 0.886; Std. beta = -0.02, 95% CI [-0.23, 0.20]	Interaction (gender and group): F(4) = 0.15, p = 0.962; Eta2 (partial) = 3.34e-04, 90% CI [0.00, 0.00]	Interaction effect (male, both medications): beta = 6.97e-03, 95% CI [-0.03, 0.04], t(5501) = 0.40, p = 0.690; Std. beta = 0.06, 95% CI [-0.23, 0.35] Interaction (male, bp med): beta = -7.08e-03, 95% CI [-0.04, 0.03], t(5501) = -0.42, p = 0.672; Std. beta = -0.06, 95% CI [-0.34, 0.22] Interaction (male, statin): beta = 8.95e-03, 95% CI [-0.03, 0.05], t(5501) = 0.43, p = 0.668; Std. beta = 0.08, 95% CI [-0.27, 0.42]
All emotions - RT	Three way interaction (emotion, group, age): F(18) = 1.90, p = 0.012; Eta2 (partial) = 9.29e-04, 90% CI [9.25e-05, 9.97e-04]	N/A	Three way interaction (emotion, group, gender): F(24) = 1.63, p = 0.027; Eta2 (partial) = 1.06e-03, 90% CI [4.89e-05, 9.88e-04]	N/A
Anger - RT	Interaction (age and group): F(1) = 1.58e-03, p = 0.968; Eta2 (partial) = 9.61e-07, 90% CI [0.00, 0.00]	Interaction (statin): beta = 0.15, 95% CI [-7.48, 7.79], t(4848) = 0.04, p = 0.968; Std. beta = 4.95e-03, 95% CI [-0.24, 0.25]	Interaction (gender and group): F(1) = 0.36, p = 0.549; Eta2 (partial) = 2.17e-04, 90% CI [0.00, 2.97e-03]	Interaction (male, statin): beta = 53.00, 95% CI [-120.29, 226.29], t(4848) = 0.60, p = 0.549; Std. beta = 0.12, 95% CI [-0.28, 0.52]
Disgust - RT	Interaction (age and group): F(1) = 0.12, p = 0.734; Eta2 (partial) = 7.04e-05, 90% CI [0.00, 2.11e-03]	Interaction (statin): beta = -1.27, 95% CI [-8.59, 6.05], t(4848) = -0.34, p = 0.734; Std. beta = -0.04, 95% CI [-0.29, 0.20]	Interaction (gender and group): F(1) = 0.05, p = 0.824; Eta2 (partial) = 2.98e-05, 90% CI [0.00, 1.54e-03]	Interaction (male, statin): beta = -18.85, 95% CI [-184.94, 147.24], t(4848) = -0.22, p = 0.824; Std. beta = -0.05, 95% CI [-0.44, 0.35]
Fear - RT	Interaction (age and group): F(1) = 0.31, p = 0.576; Eta2 (partial) = 1.90e-04, 90% CI [0.00, 2.87e-03]	Interaction (statin): beta = -2.48, 95% CI [-11.16, 6.21], t(4812) = -0.56, p = 0.576; Std. beta = -0.07, 95% CI [-0.30, 0.17]	Interaction (gender and group): F(1) = 0.44, p = 0.507; Eta2 (partial) = 2.64e-04, 90% CI [0.00, 3.14e-03]	Interaction (male, statin): beta = 67.05, 95% CI [-130.77, 264.87], t(4812) = 0.66, p = 0.506; Std. beta = 0.13, 95% CI [-0.25, 0.51]
Happiness - RT	Interaction (age and group): F(1) = 0.35, p = 0.552; Eta2 (partial) = 2.16e-04, 90% CI [0.00, 2.98e-03]	Interaction (statin): beta = -1.66, 95% CI [-7.11, 3.80], t(4850) = -0.60, p = 0.552; Std. beta = -0.08, 95% CI [-0.33, 0.18]	Interaction (gender and group): F(1) = 2.21, p = 0.137; Eta2 (partial) = 1.34e-03, 90% CI [0.00, 5.90e-03]	Interaction (male, statin): beta = 93.96, 95% CI [-29.79, 217.71], t(4850) = 1.49, p = 0.137; Std. beta = 0.31, 95% CI [-0.10, 0.73]
Sadness - RT	Interaction (age and group): F(1) = 0.94, p = 0.331; Eta2 (partial) = 5.75e-04, 90% CI [0.00, 4.15e-03]	Interaction (statin): beta = 3.21, 95% CI [-3.26, 9.68], t(4849) = 0.97, p = 0.331; Std. beta = 0.12, 95% CI [-0.12, 0.36]	Interaction (gender and group): F(1) = 1.49, p = 0.223; Eta2 (partial) = 8.95e-04, 90% CI [0.00, 4.92e-03]	Interaction (male, statin): beta = 91.36, 95% CI [-55.56, 238.28], t(4849) = 1.22, p = 0.223; Std. beta = 0.24, 95% CI [-0.15, 0.63]

Outcome	Interaction with Age		Interaction with Gender	
	ANCOVA	Linear regression	ANCOVA	Linear regression
Surprise - RT	Interaction (age and group): F(1) = 1.34e-03, p = 0.971; Eta2 (partial) = 8.15e-07, 90% CI [0.00, 0.00]	Interaction (statin): beta = 0.13, 95% CI [-6.63, 6.89], t(4850) = 0.04, p = 0.971; Std. beta = 4.65e-03, 95% CI [-0.24, 0.25]	Interaction (gender and group): F(1) = 1.69, p = 0.193; Eta2 (partial) = 1.02e-03, 90% CI [0.00, 5.20e-03]	Interaction (male, statin): beta = 101.79, 95% CI [-51.50, 255.08], t(4850) = 1.30, p = 0.193; Std. beta = 0.27, 95% CI [-0.14, 0.68]
Neutral - RT	Interaction (age and group): F(1) = 5.12e-03, p = 0.943; Eta2 (partial) = 3.15e-06, 90% CI [0.00, 1.62e-04]	Interaction (statin): beta = -0.22, 95% CI [-6.37, 5.92], t(4847) = -0.07, p = 0.943; Std. beta = -8.68e-03, 95% CI [-0.25, 0.23]	Interaction (gender and group): F(1) = 0.14, p = 0.709; Eta2 (partial) = 8.45e-05, 90% CI [0.00, 2.24e-03]	Interaction (male, statin): beta = 26.53, 95% CI [-112.97, 166.04], t(4847) = 0.37, p = 0.709; Std. beta = 0.07, 95% CI [-0.32, 0.46]

PILT

Outcome	Interaction with Age		Interaction with Gender	
	ANCOVA	Linear regression	ANCOVA	Linear regression
Gain trials - choice of advantageous stimulus	Interaction (age and group): F(3, 1607) = 1.96, p = 0.118; Eta2 (partial) = 3.65e-03, 90% CI [0.00, 8.61e-03]	Interaction effect (both medications): beta = -0.34, 95% CI [-0.89, 0.21], t(1607) = -1.20, p = 0.230; Std. beta = -0.25, 95% CI [-0.67, 0.16] Interaction (bp med): beta = -0.33, 95% CI [-0.65, -5.00e-03], t(1607) = -1.99, p < .05; Std. beta = -0.24, 95% CI [-0.49, -3.75e-03] Interaction (statin): beta = 0.17, 95% CI [-0.29, 0.62], t(1607) = 0.72, p = 0.474; Std. beta = 0.12, 95% CI [-0.22, 0.46]	Interaction (gender and group): F(3, 1607) = 0.36, p = 0.785; Eta2 (partial) = 6.63e-04, 90% CI [0.00, 2.24e-03]	Interaction (male, both): beta = -3.49, 95% CI [-11.67, 4.68], t(1607) = -0.84, p = 0.402; Std. beta = -0.19, 95% CI [-0.62, 0.25] Interaction (male, BP med): beta = -1.47, 95% CI [-9.08, 6.13], t(1607) = -0.38, p = 0.704; Std. beta = -0.08, 95% CI [-0.48, 0.33] Interaction (male, statin): beta = -2.76, 95% CI [-12.22, 6.71], t(1607) = -0.57, p = 0.568; Std. beta = -0.15, 95% CI [-0.65, 0.36]
Loss trials - choice of advantageous stimulus	Interaction (age and group): F(3, 1607) = 0.45, p = 0.714; Eta2 (partial) = 8.48e-04, 90% CI [0.00, 2.83e-03]	Interaction effect (both medications): beta = -0.15, 95% CI [-0.57, 0.27], t(1607) = -0.70, p = 0.483; Std. beta = -0.15, 95% CI [-0.55, 0.26] Interaction (bp med): beta = 0.08, 95% CI [-0.16, 0.32], t(1607) = 0.64, p = 0.521; Std. beta = 0.08, 95% CI [-0.16, 0.32] Interaction (statin): beta = 0.11, 95% CI [-0.23, 0.46], t(1607) = 0.65, p = 0.514; Std. beta = 0.11, 95% CI [-0.22, 0.45]	Interaction (gender and group): F(3, 1607) = 1.24, p = 0.294; Eta2 (partial) = 2.31e-03, 90% CI [0.00, 6.18e-03]	Interaction (male, both): beta = -4.20, 95% CI [-10.39, 2.00], t(1607) = -1.33, p = 0.184; Std. beta = -0.29, 95% CI [-0.72, 0.14] Interaction (male, BP med): beta = -4.32, 95% CI [-10.09, 1.44], t(1607) = -1.47, p = 0.142; Std. beta = -0.30, 95% CI [-0.70, 0.10] Interaction (male, statin): beta = 0.25, 95% CI [-6.93, 7.42], t(1607) = 0.07, p = 0.946; Std. beta = 0.02, 95% CI [-0.48, 0.51]

N-back

Outcome	Interaction with Age		Interaction with Gender	
	ANCOVA	**Linear regression**	**ANCOVA**	**Linear regression**
Hits– All test conditions	Interaction (age and group): F(6) = 1.66, p = 0.126; Eta2 (partial) = 2.88e-03, 90% CI [0.00, 6.45e-03]	N/A	Interaction (gender and group): F(8) = 0.35, p = 0.945; Eta2 (partial) = 8.20e-04, 90% CI [0.00, 8.57e-05]	N/A
Hits – One back	Interaction (age and group): F(3, 1706) = 0.97, p = 0.408; Eta2 (partial) = 1.70e-03, 90% CI [0.00, 4.85e-03]	Interaction effect (both medications): beta = -0.46, 95% CI [-1.20, 0.28], t(1706) = -1.23, p = 0.220; Std. beta = -0.24, 95% CI [-0.63, 0.14] Interaction (bp med): beta = -0.21, 95% CI [-0.65, 0.22], t(1706) = -0.96, p = 0.336; Std. beta = -0.11, 95% CI [-0.34, 0.12] Interaction (statin): beta = -0.24, 95% CI [-0.80, 0.33], t(1706) = -0.82, p = 0.412; Std. beta = -0.12, 95% CI [-0.42, 0.17]	Interaction (gender and group): F(4, 1705) = 0.05, p = 0.995; Eta2 (partial) = 1.26e-04, 90% CI [0.00, 0.00]	Interaction (male, both): beta = 0.49, 95% CI [-10.46, 11.45], t(1705) = 0.09, p = 0.930; Std. beta = 0.02, 95% CI [-0.39, 0.43] Interaction (male, BP med): beta = 0.65, 95% CI [-9.63, 10.92], t(1705) = 0.12, p = 0.902; Std. beta = 0.02, 95% CI [-0.36, 0.41] Interaction (male, statin): beta = -2.65, 95% CI [-15.57, 10.27], t(1705) = -0.40, p = 0.688; Std. beta = -0.10, 95% CI [-0.58, 0.39]
Hits – Two back	Interaction (age and group): F(3, 1706) = 1.83, p = 0.140; Eta2 (partial) = 3.20e-03, 90% CI [0.00, 7.71e-03]	Interaction effect (both medications): beta = -0.09, 95% CI [-0.67, 0.50], t(1706) = -0.30, p = 0.767; Std. beta = -0.06, 95% CI [-0.45, 0.33] Interaction (bp med): beta = -0.05, 95% CI [-0.39, 0.30], t(1706) = -0.27, p = 0.789; Std. beta = -0.03, 95% CI [-0.26, 0.20] Interaction (statin): beta = -0.53, 95% CI [-0.98, -0.08], t(1706) = -2.32, p < .05; Std. beta = -0.35, 95% CI [-0.65, -0.05]	Interaction (gender and group): F(4, 1705) = 0.20, p = 0.940; Eta2 (partial) = 4.62e-04, 90% CI [0.00, 2.47e-04]	Interaction (male, both): beta = 0.54, 95% CI [-8.16, 9.24], t(1705) = 0.12, p = 0.903; Std. beta = 0.03, 95% CI [-0.39, 0.44] Interaction (male, BP med): beta = 3.64, 95% CI [-4.53, 11.80], t(1705) = 0.87, p = 0.383; Std. beta = 0.17, 95% CI [-0.21, 0.56] Interaction (male, statin): beta = -0.30, 95% CI [-10.57, 9.97], t(1705) = -0.06, p = 0.954; Std. beta = -0.01, 95% CI [-0.50, 0.47]
Hits – Three back	Interaction (age and group): F(3, 1706) = 0.58, p = 0.629; Eta2 (partial) = 1.02e-03, 90% CI [0.00, 2.28e-03]	Interaction effect (both medications): beta = -0.30, 95% CI [-0.85, 0.25], t(1706) = -1.08, p = 0.282; Std. beta = -0.21, 95% CI [-0.60, 0.17] Interaction (bp med): beta = 0.10, 95% CI [-0.22, 0.43], t(1706) = 0.64, p = 0.525; Std. beta = 0.07, 95% CI [-0.15, 0.30] Interaction (statin): beta = 0.07, 95% CI [-0.35, 0.49], t(1706) = 0.33, p = 0.741; Std. beta = 0.05, 95% CI [-0.25, 0.35]	Interaction (gender and group): F(4, 1705) = 0.86, p = 0.488; Eta2 (partial) = 2.01e-03, 90% CI [0.00, 4.66e-03]	Interaction (male, both): beta = -2.03, 95% CI [-10.15, 6.10], t(1705) = -0.49, p = 0.625; Std. beta = -0.10, 95% CI [-0.51, 0.31] Interaction (male, BP med): beta = 1.64, 95% CI [-5.98, 9.27], t(1705) = 0.42, p = 0.673; Std. beta = 0.08, 95% CI [-0.30, 0.47] Interaction (male, statin): beta = -7.86, 95% CI [-17.45, 1.73], t(1705) = -1.61, p = 0.108; Std. beta = -0.40, 95% CI [-0.88, 0.09]
False alarms – All test conditions	Interaction (age and group):F(6) = 0.56, p = 0.766; Eta2 (partial) = 9.64e-04, 90% CI [0.00, 2.16e-03]	N/A	Interaction (gender and group): F(8) = 0.38, p = 0.934; Eta2 (partial) = 8.71e-04, 90% CI [0.00, 2.24e-04]	N/A
Correct rejections – All test conditions	Interaction (age and group): F(6) = 1.74, p = 0.108; Eta2 (partial) = 3.01e-03, 90% CI [0.00, 5.06e-03]	N/A	Interaction (gender and group): F(8) = 0.44, p = 0.899; Eta2 (partial) = 1.02e-03, 90% CI [0.00, 6.03e-04]	N/A
Misses – All test conditions	Interaction (age and group): F(6) = 0.68, p = 0.670; Eta2 (partial) = 1.17e-03, 90% CI [0.00, 1.85e-03]	N/A	Interaction (gender and group): F(8) = 0.81, p = 0.591; Eta2 (partial) = 1.88e-03, 90% CI [0.00, 2.41e-03]	N/A
Misses – One back	Interaction (age and group): F(3, 1706) = 1.94, p = 0.122;	Interaction effect (both medications): beta = 0.14, 95% CI [-0.47, 0.75], t(1706) = 0.46, p = 0.644; Std. beta = 0.09, 95% CI [-0.30, 0.48]	Interaction (gender and group): F(4, 1705) = 0.22, p =	Interaction (male, both): beta = 0.51, 95% CI [-8.57, 9.59], t(1705) = 0.11, p = 0.912; Std. beta = 0.02, 95% CI [-0.39, 0.44]

Outcome	Interaction with Age		Interaction with Gender	
	ANCOVA	Linear regression	ANCOVA	Linear regression
	Eta2 (partial) = 3.40e-03, 90% CI [0.00, 8.04e-03]	Interaction (bp med): beta = 0.44, 95% CI [0.08, 0.80], t(1706) = 2.38, p < .05; Std. beta = 0.28, 95% CI [0.05, 0.51] Interaction (statin): beta = -9.09e-03, 95% CI [-0.48, 0.46], t(1706) = -0.04, p = 0.970; Std. beta = -5.78e-03, 95% CI [-0.30, 0.29]	0.930; Eta2 (partial) = 5.06e-04, 90% CI [0.00, 4.64e-04]	Interaction (male, BP med): beta = -2.05, 95% CI [-10.57, 6.47], t(1705) = -0.47, p = 0.637; Std. beta = -0.09, 95% CI [-0.48, 0.29] Interaction (male, statin): beta = 3.85, 95% CI [-6.87, 14.56], t(1705) = 0.70, p = 0.481; Std. beta = 0.17, 95% CI [-0.31, 0.66]
Misses – Two back	Interaction (age and group): F(3, 1706) = 0.80, p = 0.496; Eta2 (partial) = 1.40e-03, 90% CI [0.00, 4.20e-03]	Interaction effect (both medications): beta = -0.05, 95% CI [-0.76, 0.65], t(1706) = -0.15, p = 0.879; Std. beta = -0.03, 95% CI [-0.42, 0.36] Interaction (bp med): beta = 0.32, 95% CI [-0.10, 0.73], t(1706) = 1.51, p = 0.132; Std. beta = 0.18, 95% CI [-0.05, 0.40] Interaction (statin): beta = 0.09, 95% CI [-0.45, 0.63], t(1706) = 0.32, p = 0.751; Std. beta = 0.05, 95% CI [-0.25, 0.35]	Interaction (gender and group): F(4, 1705) = 0.81, p = 0.517; Eta2 (partial) = 1.90e-03, 90% CI [0.00, 4.43e-03]	Interaction (male, both): beta = 3.42, 95% CI [-7.04, 13.89], t(1705) = 0.64, p = 0.521; Std. beta = 0.13, 95% CI [-0.28, 0.55] Interaction (male, BP med): beta = -4.97, 95% CI [-14.79, 4.85], t(1705) = -0.99, p = 0.321; Std. beta = -0.20, 95% CI [-0.58, 0.19] Interaction (male, statin): beta = 8.04, 95% CI [-4.30, 20.39], t(1705) = 1.28, p = 0.202; Std. beta = 0.32, 95% CI [-0.17, 0.80]
Misses – Three back	Interaction (age and group): F(3, 1706) = 1.08, p = 0.356; Eta2 (partial) = 1.90e-03, 90% CI [0.00, 5.26e-03]	Interaction effect (both medications): beta = 0.03, 95% CI [-0.70, 0.75], t(1706) = 0.07, p = 0.945; Std. beta = 0.01, 95% CI [-0.38, 0.40] Interaction (bp med): beta = 0.29, 95% CI [-0.14, 0.71], t(1706) = 1.33, p = 0.184; Std. beta = 0.16, 95% CI [-0.07, 0.38] Interaction (statin): beta = -0.33, 95% CI [-0.88, 0.23], t(1706) = -1.16, p = 0.248; Std. beta = -0.18, 95% CI [-0.47, 0.12]	Interaction (gender and group): F(4, 1705) = 2.14, p = 0.073; Eta2 (partial) = 5.00e-03, 90% CI [0.00, 9.95e-03]	Interaction (male, both): beta = 7.70, 95% CI [-3.01, 18.41], t(1705) = 1.41, p = 0.159; Std. beta = 0.30, 95% CI [-0.12, 0.71] Interaction (male, BP med): beta = -3.99, 95% CI [-14.04, 6.05], t(1705) = -0.78, p = 0.436; Std. beta = -0.15, 95% CI [-0.54, 0.23] Interaction (male, statin): beta = 15.63, 95% CI [3.00, 28.27], t(1705) = 2.43, p < .05; Std. beta = 0.60, 95% CI [0.12, 1.09]
D-prime	Interaction (age and group): F(3, 1706) = 1.22, p = 0.301; Eta2 (partial) = 2.14e-03, 90% CI [0.00, 5.76e-03]	Interaction effect (both medications): beta = -5.05e-03, 95% CI [-0.03, 0.02], t(1706) = -0.45, p = 0.653; Std. beta = -0.09, 95% CI [-0.48, 0.30] Interaction (bp med): beta = -0.01, 95% CI [-0.03, 5.50e-04], t(1706) = -1.88, p = 0.061; Std. beta = -0.22, 95% CI [-0.45, 9.73e-03] Interaction (statin): beta = -1.24e-03, 95% CI [-0.02, 0.02], t(1706) = -0.14, p = 0.885; Std. beta = -0.02, 95% CI [-0.32, 0.28]	Interaction (gender and group): F(4, 1705) = 1.05, p = 0.382; Eta2 (partial) = 2.45e-03, 90% CI [0.00, 5.53e-03]	Interaction (male, both): beta = -0.06, 95% CI [-0.39, 0.26], t(1705) = -0.38, p = 0.701; Std. beta = -0.08, 95% CI [-0.49, 0.33] Interaction (male, BP med): beta = 0.15, 95% CI [-0.16, 0.45], t(1705) = 0.93, p = 0.353; Std. beta = 0.18, 95% CI [-0.20, 0.57] Interaction (male, statin): beta = -0.32, 95% CI [-0.70, 0.07], t(1705) = -1.62, p = 0.106; Std. beta = -0.40, 95% CI [-0.89, 0.09]
Beta	Interaction (age and group): F(3, 1706) = 0.10, p = 0.959; Eta2 (partial) = 1.78e-04, 90% CI [0.00, 0.00]	Interaction effect (both medications): beta = 5.42e-03, 95% CI [-0.03, 0.04], t(1706) = 0.32, p = 0.749; Std. beta = 0.06, 95% CI [-0.33, 0.45] Interaction (bp med): beta = 1.26e-03, 95% CI [-0.02, 0.02], t(1706) = 0.13, p = 0.900; Std. beta = 0.01, 95% CI [-0.21, 0.24] Interaction (statin): beta = 5.78e-03, 95% CI [-0.02, 0.03], t(1706) = 0.45, p = 0.656; Std. beta = 0.07, 95% CI [-0.23, 0.37]	Interaction (gender and group): F(4, 1705) = 0.07, p = 0.992; Eta2 (partial) = 1.59e-04, 90% CI [0.00, 0.00]	Interaction (male, both): beta = 0.02, 95% CI [-0.47, 0.51], t(1705) = 0.08, p = 0.939; Std. beta = 0.02, 95% CI [-0.40, 0.43] Interaction (male, BP med): beta = 0.12, 95% CI [-0.35, 0.58], t(1705) = 0.49, p = 0.624; Std. beta = 0.10, 95% CI [-0.29, 0.48] Interaction (male, statin): beta = 0.03, 95% CI [-0.55, 0.61], t(1705) = 0.09, p = 0.927; Std. beta = 0.02, 95% CI [-0.46, 0.51]

Analysis of anti-hypertensive medication types

FERT

Outcome	Controlling for anti-hypertensive subtype		Controlling for calcium channel blocker		Antihypertensive subtype as predictor		Calcium channel blocker as predictor	
	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
All emotions - UBHR	Group: F(3) = 2.37, p = 0.068; Eta2 (partial) = 3.84e-03, 90% CI [0.00, 8.62e-03] Interaction: F(18) = 5.41, p < .001; Eta2 (partial) = 2.64e-03, 90% CI [1.41e-03, 3.09e-03]	N/A	Group: F(3) = 3.29, p = 0.020; Eta2 (partial) = 5.32e-03, 90% CI [4.54e-04, 0.01] Interaction: F(18) = 5.41, p < .001; Eta2 (partial) = 2.64e-03, 90% CI [1.41e-03, 3.09e-03]	N/A	Group: F(6) = 0.79, p = 0.581; Eta2 (partial) = 3.72e-03, 90% CI [0.00, 6.07e-03] Interaction: F(36) = 2.46, p < .001; Eta2 (partial) = 3.46e-03, 90% CI [1.12e-03, 3.28e-03]	N/A	Group: F(1) = 0.26, p = 0.610; Eta2 (partial) = 2.06e-04, 90% CI [0.00, 3.53e-03] Interaction: F(6) = 1.75, p = 0.106; Eta2 (partial) = 4.10e-04, 90% CI [0.00, 6.89e-04]	N/A
Angry - UBHR	Overall - F(3) = 3.26, p = 0.021; Eta2 (partial) = 5.21e-03, 90% CI [4.29e-04, 0.01] Statins - F(1) = 9.00, p = 0.003; Eta2 (partial) = 5.45e-03, 90% CI [1.11e-03, 0.01] BP med - F(1) = 0.68, p = 0.411; Eta2 (partial) = 3.93e-04, 90% CI [0.00, 3.51e-03] Both - F(1) = 0.01, p = 0.919; Eta2 (partial) = 6.33e-06, 90% CI [0.00, 5.92e-04]	Statin - beta = -0.05, 95% CI [-0.08, -0.02], t(5499) = -3.00, p < .01; Std. beta = -0.29, 95% CI [-0.48, -0.10] BP - beta = -1.90e-03, 95% CI [-0.07, 0.07], t(5499) = -0.05, p = 0.957; Std. beta = -0.01, 95% CI [-0.45, 0.42] Both - beta = -0.02, 95% CI [-0.09, 0.05], t(5499) = -0.52, p = 0.604; Std. beta = -0.12, 95% CI [-0.58, 0.34]	Overall - F(3) = 4.21, p = 0.006; Eta2 (partial) = 6.73e-03, 90% CI [1.16e-03, 0.01] BP - F(1) = 0.38, p = 0.537; Eta2 (partial) = 2.26e-04, 90% CI [0.00, 2.97e-03] Both - F(1) = 6.42, p = 0.011; Eta2 (partial) = 3.83e-03, 90% CI [4.67e-04, 0.01]	Statin - beta = -0.05, 95% CI [-0.08, -0.02], t(5504) = -3.00, p < .01; Std. beta = -0.29, 95% CI [-0.48, -0.10] BP – beta = -0.01, 95% CI [-0.04, 0.01], t(5504) = -1.05, p = 0.292; Std. beta = -0.09, 95% CI [-0.26, 0.08] Both - beta = -0.03, 95% CI [-0.06, -3.86e-03], t(5504) = -2.21, p < .05; Std. beta = -0.21, 95% CI [-0.40, -0.02]	F(6) = 1.04, p = 0.400; Eta2 (partial) = 4.85e-03, 90% CI [0.00, 8.19e-03]	Ace inhibitor: beta = -0.04, 95% CI [-0.08, -5.09e-03], t(3813) = -2.24, p < .05; Std. beta = -0.25, 95% CI [-0.47, -0.03] Angiotensin: beta = -7.68e-03, 95% CI [-0.07, 0.05], t(3813) = -0.24, p = 0.809; Std. beta = -0.05, 95% CI [-0.44, 0.35] Beta blocker: beta = 0.01, 95% CI [-0.04, 0.06], t(3813) = 0.41, p = 0.685; Std. beta = 0.06, 95% CI [-0.25, 0.37] Calcium channel blocker: beta = -0.02, 95% CI [-0.07, 0.03], t(3813) = -0.78, p = 0.437; Std. beta	N/A	N/A

Outcome	Controlling for anti-hypertensive subtype		Controlling for calcium channel blocker		Antihypertensive subtype as predictor		Calcium channel blocker as predictor	
	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
						= -0.12, 95% CI [-0.42, 0.18] Combination: beta = -7.39e-03, 95% CI [-0.04, 0.02], t(3813) = -0.47, p = 0.640; Std. beta = -0.05, 95% CI [-0.24, 0.15] Diuretic: beta = 0.03, 95% CI [-0.07, 0.13], t(3813) = 0.58, p = 0.564; Std. beta = 0.19, 95% CI [-0.46, 0.85]		
Disgust - UBHR	F(3) = 0.37, p = 0.773; Eta2 (partial) = 6.03e-04, 90% CI [0.00, 1.35e-03]	N/A	F(3) = 0.27, p = 0.850; Eta2 (partial) = 4.33e-04, 90% CI [0.00, 1.40e-03]	N/A	F(6) = 0.62, p = 0.712; Eta2 (partial) = 2.95e-03, 90% CI [0.00, 6.60e-03]	Ace inhibitor: beta = 7.08e-03, 95% CI [-0.02, 0.03], t(3813) = 0.51, p = 0.610; Std. beta = 0.05, 95% CI [-0.15, 0.25] Angiotensin: beta = 0.02, 95% CI [-0.02, 0.07], t(3813) = 0.97, p = 0.333; Std. beta = 0.18, 95% CI [-0.18, 0.54] Beta blocker: beta = 0.02, 95% CI [-0.02, 0.06], t(3813) = 0.90, p = 0.371; Std. beta = 0.13, 95% CI [-0.15, 0.41] Calcium channel blocker: beta = 0.02, 95% CI [-0.02, 0.06], t(3813) = 1.13, p =	N/A	N/A

Outcome	Controlling for anti-hypertensive subtype		Controlling for calcium channel blocker		Antihypertensive subtype as predictor		Calcium channel blocker as predictor	
	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
						0.258; Std. beta = 0.16, 95% CI [-0.11, 0.43] Combination: beta = -4.57e-03, 95% CI [-0.03, 0.02], t(3813) = -0.37, p = 0.710; Std. beta = -0.03, 95% CI [-0.21, 0.14] Diuretic: beta = 0.03, 95% CI [-0.05, 0.11], t(3813) = 0.70, p = 0.483; Std. beta = 0.21, 95% CI [-0.38, 0.81]		
Fear - UBHR	Overall: F(3) = 2.57, p = 0.053; Eta2 (partial) = 4.10e-03, 90% CI [0.00, 9.00e-03] Statin - F(1) = 6.80, p = 0.009; Eta2 (partial) = 4.11e-03, 90% CI [5.58e-04, 0.01] BP - F(1) = 0.75, p = 0.388; Eta2 (partial) = 4.34e-04, 90% CI [0.00, 3.64e-03] Both - F(1) = 0.10, p = 0.757; Eta2 (partial) = 5.80e-05, 90% CI [0.00, 1.97e-03]	Statin - beta = -0.05, 95% CI [-0.08, -0.02], t(5499) = -3.00, p < .01; Std. beta = -0.29, 95% CI [-0.48, -0.10] BP - beta = 0.03, 95% CI [-0.04, 0.09], t(5495) = 0.79, p = 0.432; Std. beta = 0.18, 95% CI [-0.27, 0.63] Both - beta = 0.01, 95% CI [-0.06, 0.08], t(5495) = 0.31, p = 0.754; Std. beta = 0.08, 95% CI [-0.40, 0.55]	Overall: F(3) = 3.93, p = 0.008; Eta2 (partial) = 6.27e-03, 90% CI [9.32e-04, 0.01] BP: F(1) = 0.55, p = 0.459; Eta2 (partial) = 3.23e-04, 90% CI [0.00, 3.32e-03] Both - F(1) = 8.84, p = 0.003; Eta2 (partial) = 5.24e-03, 90% CI [1.05e-03, 0.01]	Statin - beta = -0.04, 95% CI [-0.07, -9.57e-03], t(5500) = -2.62, p < .01; Std. beta = -0.26, 95% CI [-0.46, -0.07] BP: beta = -0.02, 95% CI [-0.04, 6.60e-03], t(5500) = -1.45, p = 0.147; Std. beta = -0.13, 95% CI [-0.31, 0.05] Both: beta = -0.03, 95% CI [-0.06, -6.33e-03], t(5500) = -2.40, p < .05; Std. beta = -0.24, 95% CI [-0.43, -0.04]	F(6) = 1.24, p = 0.284; Eta2 (partial) = 5.76e-03, 90% CI [0.00, 0.01]	Ace inhibitor: beta = -0.02, 95% CI [-0.05, 0.01], t(3813) = -1.34, p = 0.180; Std. beta = -0.15, 95% CI [-0.38, 0.07] Angiotensin: beta = -0.02, 95% CI [-0.07, 0.04], t(3813) = -0.52, p = 0.600; Std. beta = -0.11, 95% CI [-0.51, 0.29] Beta blocker: beta = -0.04, 95% CI [-0.09, 3.66e-03], t(3813) = -1.80, p = 0.072; Std. beta = -0.29, 95% CI [-0.61, 0.03] Calcium channel blocker: beta = -0.02, 95% CI [-0.06, 0.03], t(3813) = -0.68, p = 0.494; Std. beta	N/A	N/A

Outcome	Controlling for anti-hypertensive subtype		Controlling for calcium channel blocker		Antihypertensive subtype as predictor		Calcium channel blocker as predictor	
	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
						= -0.11, 95% CI [-0.41, 0.20] Combination: beta = -9.93e-03, 95% CI [-0.04, 0.02], t(3813) = -0.68, p = 0.497; Std. beta = -0.07, 95% CI [-0.27, 0.13] Diuretic: beta = -0.08, 95% CI [-0.17, 0.02], t(3813) = -1.58, p = 0.115; Std. beta = -0.54, 95% CI [-1.20, 0.13]		
Happiness - UBHR	F(3) = 1.28, p = 0.279; Eta2 (partial) = 2.08e-03, 90% CI [0.00, 5.52e-03]	N/A	F(3) = 1.26, p = 0.285; Eta2 (partial) = 2.06e-03, 90% CI [0.00, 5.48e-03]	N/A	F(6) = 1.38, p = 0.221; Eta2 (partial) = 6.49e-03, 90% CI [0.00, 0.01]	Ace inhibitor: beta = -7.78e-03, 95% CI [-0.03, 0.01], t(3813) = -0.69, p = 0.487; Std. beta = -0.07, 95% CI [-0.27, 0.13] Angiotensin: beta = -0.02, 95% CI [-0.06, 0.02], t(3813) = -1.11, p = 0.267; Std. beta = -0.20, 95% CI [-0.56, 0.15] Beta blocker: beta = 4.75e-03, 95% CI [-0.03, 0.04], t(3813) = 0.30, p = 0.762; Std. beta = 0.04, 95% CI [-0.24, 0.32] Calcium channel blocker: beta = -3.83e-03, 95% CI [-0.03, 0.03], t(3813) = -0.25, p	N/A	N/A

Outcome	Controlling for anti-hypertensive subtype		Controlling for calcium channel blocker		Antihypertensive subtype as predictor		Calcium channel blocker as predictor	
	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
						= 0.799; Std. beta = -0.03, 95% CI [-0.30, 0.23] Combination: beta = -0.02, 95% CI [-0.04, -5.51e-03], t(3813) = -2.52, p < .05; Std. beta = -0.23, 95% CI [-0.40, -0.05] Diuretic: beta = 0.02, 95% CI [-0.04, 0.09], t(3813) = 0.64, p = 0.521; Std. beta = 0.19, 95% CI [-0.40, 0.79]		
Sadness - UBHR	F(3) = 1.72, p = 0.160; Eta2 (partial) = 2.77e-03, 90% CI [0.00, 6.76e-03]	N/A	F(3) = 1.71, p = 0.164; Eta2 (partial) = 2.75e-03, 90% CI [0.00, 6.74e-03]	N/A	F(6) = 1.50, p = 0.175; Eta2 (partial) = 7.06e-03, 90% CI [0.00, 0.01]	Ace inhibitor: beta = -0.03, 95% CI [-0.05, 2.26e-04], t(3813) = -1.94, p = 0.052; Std. beta = -0.19, 95% CI [-0.38, 1.55e-03] Angiotensin: beta = -0.01, 95% CI [-0.06, 0.04], t(3813) = -0.50, p = 0.620; Std. beta = -0.09, 95% CI [-0.42, 0.25] Beta blocker: beta = -4.28e-03, 95% CI [-0.04, 0.03], t(3813) = -0.22, p = 0.828; Std. beta = -0.03, 95% CI [-0.30, 0.24] Calcium channel blocker: beta = -0.02, 95% CI [-0.05, 0.02], t(3813) = -0.89, p = 0.372; Std. beta	N/A	N/A

Outcome	Controlling for anti-hypertensive subtype		Controlling for calcium channel blocker		Antihypertensive subtype as predictor		Calcium channel blocker as predictor	
	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
						= -0.12, 95% CI [-0.37, 0.14] Combination: beta = 6.44e-03, 95% CI [-0.02, 0.03], t(3813) = 0.52, p = 0.605; Std. beta = 0.04, 95% CI [-0.12, 0.21] Diuretic: beta = 0.08, 95% CI [-3.81e-03, 0.16], t(3813) = 1.87, p = 0.062; Std. beta = 0.53, 95% CI [-0.03, 1.09]		
Surprise - UBHR	F(3) = 0.95, p = 0.414; Eta2 (partial) = 1.55e-03, 90% CI [0.00, 4.44e-03]	N/A	F(3) = 0.65, p = 0.583; Eta2 (partial) = 1.06e-03, 90% CI [0.00, 3.33e-03]	N/A	F(6) = 0.32, p = 0.928; Eta2 (partial) = 1.51e-03, 90% CI [0.00, 7.42e-04]	Ace inhibitor: beta = 1.13e-03, 95% CI [-0.02, 0.02], t(3813) = 0.09, p = 0.925; Std. beta = 9.54e-03, 95% CI [-0.19, 0.21] Angiotensin: beta = 0.02, 95% CI [-0.02, 0.06], t(3813) = 0.91, p = 0.364; Std. beta = 0.16, 95% CI [-0.19, 0.52] Beta blocker: beta = 1.84e-05, 95% CI [-0.03, 0.03], t(3813) = 1.10e-03, p > .999; Std. beta = 1.56e-04, 95% CI [-0.28, 0.28] Calcium channel blocker: beta = -6.44e-03, 95% CI [-0.04, 0.02], t(3813) = -0.40, p = 0.687; Std. beta	N/A	N/A

Outcome	Controlling for anti-hypertensive subtype		Controlling for calcium channel blocker		Antihypertensive subtype as predictor		Calcium channel blocker as predictor	
	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
						= -0.05, 95% CI [-0.32, 0.21] Combination: beta = 9.68e-03, 95% CI [-0.01, 0.03], t(3813) = 0.92, p = 0.358; Std. beta = 0.08, 95% CI [-0.09, 0.26] Diuretic: beta = -6.77e-03, 95% CI [-0.08, 0.06], t(3813) = -0.19, p = 0.847; Std. beta = -0.06, 95% CI [-0.64, 0.53]		

PILT

Outcome	Controlling for anti-hypertensive subtype		Controlling for calcium channel blocker		Antihypertensive subtype as predictor		Calcium channel blocker as predictor	
	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
Gain trials - choice of advantageous stimulus	F(3, 1100) = 0.25, p = 0.861; Eta2 (partial) = 6.81e-04, 90% CI [0.00, 1.53e-03]	Both: beta = 3.52, 95% CI [-7.68, 14.73], t(1100) = 0.62, p = 0.537; Std. beta = 0.19, 95% CI [-0.41, 0.79] BP: beta = 1.72, 95% CI [-8.74, 12.18], t(1100) = 0.32, p = 0.747; Std. beta = 0.09, 95% CI [-0.47, 0.66] Statin: beta = 0.59, 95% CI [-5.49, 6.66], t(1100) = 0.19, p = 0.850; Std. beta = 0.03, 95% CI [-0.30, 0.36]	F(3, 1105) = 0.25, p = 0.861; Eta2 (partial) = 6.79e-04, 90% CI [0.00, 1.52e-03]	Both: beta = 4.18, 95% CI [-0.78, 9.14], t(1105) = 1.66, p = 0.098; Std. beta = 0.23, 95% CI [-0.04, 0.49] BP: beta = 2.56, 95% CI [-1.79, 6.90], t(1105) = 1.15, p = 0.249; Std. beta = 0.14, 95% CI [-0.10, 0.37] Statin: beta = 0.41, 95% CI [-5.64, 6.47], t(1105) = 0.13, p = 0.894; Std. beta = 0.02, 95% CI [-0.30, 0.35]	F(6, 1103) = 1.16, p = 0.326; Eta2 (partial) = 6.26e-03, 90% CI [0.00, 0.01]	Ace inhibitor: beta = 1.92, 95% CI [-3.54, 7.37], t(1103) = 0.69, p = 0.491; Std. beta = 0.10, 95% CI [-0.19, 0.40] Angiotensin: beta = 8.53, 95% CI [-2.10, 19.17], t(1103) = 1.57, p = 0.116; Std. beta = 0.46, 95% CI [-0.11, 1.03] Beta blocker: beta = 5.25, 95% CI [-2.22, 12.73], t(1103) = 1.38, p = 0.168; Std. beta = 0.28, 95% CI [-0.12, 0.69] Calcium channel blocker: beta = -4.22, 95% CI [-11.26, 2.81], t(1103) = -1.18, p = 0.239; Std. beta = -0.23, 95% CI [-0.61, 0.15] Combination: beta = 0.74, 95% CI [-4.04, 5.52], t(1103) = 0.30, p = 0.762; Std. beta = 0.04, 95% CI [-0.22, 0.30]	F(1, 1108) = 1.84, p = 0.175; Eta2 (partial) = 1.66e-03, 90% CI [0.00, 8.08e-03]	beta = -2.40, 95% CI [-7.00, 2.20], t(1108) = -1.02, p = 0.307; Std. beta = -0.13, 95% CI [-0.38, 0.12]

Outcome	Controlling for anti-hypertensive subtype		Controlling for calcium channel blocker		Antihypertensive subtype as predictor		Calcium channel blocker as predictor	
	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
						Diuretic: beta = -5.89, 95% CI [-20.85, 9.07], t(1103) = -0.77, p = 0.440; Std. beta = -0.32, 95% CI [-1.12, 0.49]		
Loss trials - choice of advantageous stimulus	F(3, 1100) = 2.38, p = 0.068; Eta2 (partial) = 6.45e-03, 90% CI [0.00, 0.01]	Both: beta = 2.36, 95% CI [-6.30, 11.03], t(1100) = 0.54, p = 0.592; Std. beta = 0.16, 95% CI [-0.43, 0.76] BP: beta = 0.40, 95% CI [-7.69, 8.49], t(1100) = 0.10, p = 0.923; Std. beta = 0.03, 95% CI [-0.53, 0.59] Statin: beta = -1.80, 95% CI [-6.50, 2.90], t(1100) = -0.75, p = 0.452; Std. beta = -0.12, 95% CI [-0.45, 0.20]	F(3, 1105) = 2.39, p = 0.068; Eta2 (partial) = 6.44e-03, 90% CI [0.00, 0.01]	Both: beta = -0.67, 95% CI [-4.51, 3.16], t(1105) = -0.35, p = 0.730; Std. beta = -0.05, 95% CI [-0.31, 0.22] BP: beta = -2.40, 95% CI [-5.76, 0.96], t(1105) = -1.40, p = 0.161; Std. beta = -0.17, 95% CI [-0.40, 0.07] Statin: beta = -2.04, 95% CI [-6.72, 2.64], t(1105) = -0.85, p = 0.393; Std. beta = -0.14, 95% CI [-0.46, 0.18]	F(6, 1103) = 1.17, p = 0.319; Eta2 (partial) = 6.34e-03, 90% CI [0.00, 0.01]	Ace inhibitor: beta = 0.37, 95% CI [-3.85, 4.60], t(1103) = 0.17, p = 0.862; Std. beta = 0.03, 95% CI [-0.27, 0.32] Angiotensin: beta = 1.25, 95% CI [-6.97, 9.48], t(1103) = 0.30, p = 0.765; Std. beta = 0.09, 95% CI [-0.48, 0.65] Beta blocker: beta = -4.48, 95% CI [-10.26, 1.30], t(1103) = -1.52, p = 0.129; Std. beta = -0.31, 95% CI [-0.71, 0.09] Calcium channel blocker: beta = -0.37, 95% CI [-5.82, 5.07], t(1103) = -0.13, p = 0.893; Std. beta = -0.03, 95% CI [-0.40, 0.35] Combination: beta = 0.47, 95% CI [-3.23, 4.16], t(1103) = 0.25, p = 0.804; Std. beta = 0.03, 95% CI [-0.22, 0.29] Diuretic: beta = -7.05, 95% CI [-18.62, 4.52], t(1103) = -1.19, p = 0.232; Std. beta = -0.49, 95% CI [-1.29, 0.31]	F(1, 1108) = 0.03, p = 0.853; Eta2 (partial) = 3.10e-05, 90% CI [0.00, 1.97e-03]	beta = 2.07, 95% CI [-1.48, 5.62], t(1108) = 1.14, p = 0.253; Std. beta = 0.14, 95% CI [-0.10, 0.39]

N-back

Outcome	Controlling for anti-hypertensive subtype		Controlling for calcium channel blocker		Antihypertensive subtype as predictor		Calcium channel blocker as predictor	
	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
Hits– All test conditions	F(6) = 4.22, p < .001; Eta2 (partial) = 0.01, 90% CI [3.04e-03, 0.02]	N/A	F(6) = 4.22, p < .001; Eta2 (partial) = 0.01, 90% CI [3.04e-03, 0.02]	N/A	F(12) = 0.74, p = 0.714; Eta2 (partial) = 3.67e-03, 90% CI [0.00, 2.99e-03])	N/A	F(2) = 0.47, p = 0.623; Eta2 (partial) = 3.92e-04, 90% CI [0.00, 2.10e-03]	N/A
False alarms – All test conditions	F(6) = 1.75, p = 0.106; Eta2 (partial) = 4.33e-03, 90% CI [0.00, 7.26e-03]	N/A	F(6) = 1.75, p = 0.106; Eta2 (partial) = 4.33e-03, 90% CI [0.00, 7.26e-03]	N/A	F(12) = 1.49, p = 0.121; Eta2 (partial) = 7.37e-03, 90% CI [0.00, 8.80e-03]	N/A	F(2) = 3.02, p = 0.049; Eta2 (partial) = 2.50e-03, 90% CI [6.18e-06, 6.40e-03]	N/A
Correct rejections – All test conditions	F(6) = 0.74, p = 0.620; Eta2 (partial) = 1.83e-03, 90% CI [0.00, 2.94e-03]	N/A	F(6) = 0.74, p = 0.620; Eta2 (partial) = 1.83e-03, 90% CI [0.00, 2.94e-03]	N/A	F(12) = 0.60, p = 0.843; Eta2 (partial) = 2.99e-03, 90% CI [0.00, 1.73e-03]	N/A	F(2) = 0.54, p = 0.581; Eta2 (partial) = 4.49e-04, 90% CI [0.00, 2.27e-03]	N/A

Outcome	Controlling for anti-hypertensive subtype		Controlling for calcium channel blocker		Antihypertensive subtype as predictor		Calcium channel blocker as predictor	
	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression	ANCOVA	Linear regression
Misses – All test conditions	F(6) = 4.81, p < .001; Eta2 (partial) = 0.01, 90% CI [4.01e-03, 0.02]	N/A	F(6) = 4.81, p < .001; Eta2 (partial) = 0.01, 90% CI [4.01e-03, 0.02]	N/A	F(12) = 0.98, p = 0.462; Eta2 (partial) = 4.88e-03, 90% CI [0.00, 5.03e-03]	N/A	F(2) = 0.92, p = 0.398; Eta2 (partial) = 7.63e-04, 90% CI [0.00, 3.09e-03]	N/A